SEO

The search engine optimization services of a San Diego SEO Company will help your business attract more visitors to your website. The company offers SEO services that include keyword research, on-page optimization and overcoming platform limitations. The team also performs reputation management and paid search advertising to improve the visibility of your website. Its services will ensure that the pages of your website are indexed in search engines and easy to use.

A San Diego SEO Company specializing in organic search engine optimization. These SEO services target small and medium-sized businesses and help clients improve their visibility on the Internet. Whether you own a local business or have a national presence, the company can optimize your website to make it more visible to your target audience and increase profits. Among its clientele are real estate agencies, construction companies, HVAC providers, and law firms.

The services of the San Diego SEO Company are tailored to the needs of local businesses. The company offers a range of SEO services, from national level rankings to regional rankings. For small businesses, the company is the best choice for website optimization. If you are unsure whether or not SEO services are right for your business, contact a San Diego SEO Company representative today.

Ninthlink has been helping start-ups and global brands improve their online presence for over 10 years. The company’s SEO services include link structure development, keyword density, landing pages, manual submission to search engines, competitor analysis, and web analytics. His team is also revising meta tags.

San Diego SEO Company Golden Seller Inc. The process includes research and analysis, building SEO campaigns and monitoring performance. The company also manages social media for its clients. This SEO company also offers comprehensive web design, web hosting, and web security services.

The best digital marketing agency in San Diego offers customized solutions and does not offer cookie-cutter packages. It understands the target market, creates useful content and delivers it to your customers. It then promotes your business using various techniques, including email marketing, digital ads, social media, and website optimization.

The digital marketing experts at Digital Resource provide innovative digital marketing solutions for businesses. They partner with forward-thinking organizations and deliver results to their global clients. Her skills include social media marketing, website design, and Google advertising. They are also experts in video content creation.

SEO strategies can help your business grow, and it’s never too late to start. SEO services are a cost-effective investment for any business. And they boost the traffic and conversions of your business. With the help of an experienced SEO team, you can see incredible results. Your business will start generating more leads, more customers and a bigger bottom line.

& # xD;

& # xD;

& # xD;

& # xD;

& # xD;

July 19, 2022 7:37 PM ET

& # xD;

& # xD;

& # xD;

| Source: & # xD;

& # xD;

& # xD;

San Diego SEO Company & # xD;

& # xD;

I prefer to see Google rank original news stories first says Qamar Zaman. Many website creators use WP-automatic plugins and gaming the system.

?

?

?

?

?

Sep 3, 2022 6:16 PM ET

?

?

?

| Source:

?

?

KISS PR Digital Marketing

?

?

?

?

?

?

?

Dallas, Sept. 03, 2022 (GLOBE NEWSWIRE) — Eight days after Google began rolling out the helpful content update, Qamar Zaman and his team at KISS PR, a Texas-based website growth company, haven’t found any notably high SERPs ( search queries) viewed engine results pages) volatility figures, but excluding news websites. As of September 2, 2022, websites in the News category are the losers per SEM RUSH Sensor.

Social Cali Digital Marketing Agency is a leading digital marketing agency that offers San Diego business owners real solutions to help them grow their brands. An innovative digital marketing team emphasized the need to hire the best San Diego marketing agency for their business.

San Diego, CA – Social Cal Digital Marketing Agency shared the benefits of working with San Diego’s most reputable digital marketing company in a website post. The digital marketing team also shared their goal of helping brands grow so businesses can meet their goals and visions. Their experience and expertise in digital marketing has made them the most trusted digital marketing agency in San Diego and the surrounding area.

Social Cal digital marketing agency noted that they have customized solutions to meet the needs of any business. They also shared that their innovative team develops unique approaches that drive traffic to company websites and increase brand awareness among potential customers worldwide. The group shared that their commitment to helping San Diego-based brands grow has made them the most trusted digital marketing agency in San Diego.

Social Cal, a digital marketing agency, also noted that they use high technology to implement their plans. They particularly shared that in this digital era, digitized advertising and marketing is required to achieve outstanding results. This is because most people turn to online services for the products and services they need, hence the need for an attractive business website. Their digitized approaches have made them the go-to pick for the best digital marketing services in San Diego.

About Social Cal Digital Marketing Agency

Social Cali Digital Marketing Agency is a leading digital marketing agency dedicated to growing San Diego businesses and brands. The team is confident that their innovative and unique marketing methods make them a one-size-fits-all solution for corporate marketing services.

Media Contact Company Name: Social Cal Digital Marketing Agency Contact Person: Zandra Parker Email: Send Email Phone: (619) 393-6550 Address: 4407 Temecula St UNIT 6 City: San Diego State: CA 92107 Country: United States Website: https://www. social.com/ san-diego digital marketing agency

What are the 5 C’s of marketing?

"5 C" represents the company, customers, competitors, cooperation partners and climate. In short, the 5c analysis helps you evaluate the most important factors in your business.

What are the characteristics of digital marketing campaign process?

While every digital marketing campaign is different, the reality is that most are built on common fundamentals and core elements…5 Digital Marketing Characteristics of a Successful Startup…

• Quality website. …
• Strong social presence. …
• Organic SEO. …
• Timely and relevant content. …
• Engaging visuals.

What are the 5 characteristics of digital marketing?

The five most important elements of a digital campaign consist of mobile considerations, organic search, social media marketing, content marketing and lead nurturing. All these elements together form a single digital marketing strategy.

What are the 5 Ds of Digital Marketing? The 5 Ds of Digital Transformation Digital marketing revolves around these 5 Ds: Digital Devices, Digital Platforms, Digital Media, Digital Data and Digital Technology.

What are characteristics of digital marketing?

The audience is accurate, which avoids a lot of pointless information transmission and can also save costs. Digital marketing also has similarities and characteristics of multimedia, time and space, interactive, anthropomorphic, advanced, efficient and economical.

What are the characteristics of digital marketing explain its merits and demerits?

Advantages	Disadvantages
The right social media content management strategies help build customer loyalty with tailored and engaging messages.	Reaching a global audience also increases competition with global brands.

What are the four characteristics of digital self?

The digital self that teenagers acquire through interactions with disembodied people in an anonymous online world can be described as (1) inward-oriented, (2) narrative in nature, (3) retractile, and (4) multiplicative. These four characteristics of the digital self are explained in turn below.

Which is not a characteristic of digital marketing?

question. The correct answer is OPTION D: Time consuming. Digital marketers reach customers through the Internet, mobile devices, social media, search engines, and other platforms.

What is characteristic of digital marketing? The audience is accurate, which avoids a lot of pointless information transmission and can also save costs. Digital marketing also has similarities and characteristics of multimedia, time and space, interactive, anthropomorphic, advanced, efficient and economical.

Written by Adrian Ignacio, Journalist

Anyone in the field of digital marketing and communications knows that SEO is one of the most sustainable ways to attract traffic and potential business today. However, optimizing websites for organic searches is tricky because it comes with various technical issues that, if not identified or addressed properly, can also drastically reduce a website’s Google search performance. We recently interviewed a seasoned SEO expert, Mark, who shared with us one technical SEO challenge he’s dealt with in his career using an original method he invented and its implications.

Prior to joining Dotdash Meredith, America’s largest print and digital publisher, as Head of Growth for the organization’s travel, technology and sustainability sectors, Marco led SEO at The Company Store, a leading textile and home goods retailer with a successful online business. In 2017, the company was acquired by The Home Depot, looking to expand and improve its e-commerce and online platform.

During Marc’s venture at The Company Store, he created an original “no index and canonical” strategy to solve the problem of index bloat on the brand’s website. Index bloat occurs when hundreds of thousands of low-value pages, such as those with thin or duplicate content, are indexed, consuming Google’s allocated indexing budget that could be better spent indexing business-critical pages such as product pages or blog posts. Index bloat can be detrimental to search engine rankings because it lowers a website’s quality score in the eyes of Google’s algorithm. Google uses what is allowed to be indexed to assess the quality of any web page. As a result of this effort, the website’s organic traffic increased from 342,000 to over 411,000 in two months.

While Marco couldn’t share the details of the strategy with us, he hinted that it includes canonical and non-indexed tags, two HTML elements that mark Google’s main products and their relationship to color and size variations, which are pages that can be indexed. caused problems. This process is extremely complicated and involves months of planning and implementation. Also, the organic search potential of product variations should be measured through extensive keyword research to ensure that the site does not miss any opportunities by canonicalizing or not indexing. Companies like Adorama and J.Crew later used this strategy to improve their searchability and organic performance and find success.

Marc’s success at The Company Store wasn’t limited to solving a bloated website index. He also used tools such as Ahrefs and SEMRush to identify content gaps, mapped out the ideal structure of each by analyzing search engine results pages (SERPs), and collaborated with design and editing teams to make updates or produce new content. As a result, the brand’s organic traffic increased by nearly 4,000 sessions per month, with just three published pages. “It’s a very time-consuming and manual process, but the amount of traffic, in the end, makes it all worth it,” Marco said.

In addition to his corporate activities, Marco created and established his own website, MarcoFeng.com, which has become one of the top travel resources, with over 3 million annual readers in just a few years. He also created unique formats for his website, including grouping long-form content by geography, type and genre for greater readability, and used ratings and reviews from various local directories to create an editorially original overview. Although Marco no longer manages the site, his articles still attract massive attention. Awards? Marco has racked up a lot in the first half of the year alone, including dotCOMM, Hermes Creative Awards, CSS Design Awards, WebAwards 2022 for “Best Publishing Website” and more.

In 2021, the site also launched faceted navigation that allows readers to search destinations and guides using filters such as “best time to visit,” “located in,” “great for,” “price,” and “visa and vaccination requirements “, acting as a one-stop shop for travel planning. While such a feature is common in e-commerce, this is the first time it has been used in publishing, offering readers a whole new way to find and consume content. Another highlight of Marc’s site that we love is the use of children’s storybook-style illustrations, which make the site attractive and accessible.

Marko is a well-known SEO expert whose personal and professional work has won many awards and caused comments and coverage in large and small publications. If you have any SEO questions for him, below is his contact information.

Hailun (Marco) Fenghttps://www.marcofeng.com[email protected]

COMTEX_413907180/2776/2022-09-07T04:42:22

Summary

Background

Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analyzed results from the Global Burden of Disease, Injuries, and Risk Factors (GBD) Study 2019 to inform cancer control planning efforts worldwide.

Methods

The GBD 2019 comparative risk assessment was used to estimate cancer burden attributable to behavioral, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included based on the criteria of the World Cancer Research Fund. Estimated cancer deaths and disability-adjusted life years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented.

Findings

Globally, in 2019, the risk factors included in this analysis accounted for 4·45 million (95% uncertainty interval 4·01–4·94) deaths and 105 million (95·0–116) DALYs for both sexes combined, representing 44 .·4% (41·3–48·4) of all cancer deaths and 42·0% (39·1–45·6) of all DALYs. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males (50·6% [47·8–54·1] of all male cancer deaths) and 1·58 million (1·36–1 ·84) risk-attributable cancer deaths in females (36·3% [32·5-41·3] of all female cancer deaths). The main risk factors at the most detailed level worldwide for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex and alcohol use being the top three risk factors for risk-attributable cancer DALYs in low SDI areas in 2019, while DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), with the largest percentage increase in metabolic . risks (34·7% [27·9–42·8] and 33·3% [25·8–42·0]).

Interpretation

The main risk factors contributing to global cancer burden in 2019 were behavioral, while metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates globally, and policies should be adapted appropriately for local cancer risk factor burden.

Funding

Bill & Melinda Gates Foundation.

Introduction

Cancer is the second leading cause of death worldwide, and exposure to risk factors plays an important role in the biology and burden of many cancer types.

Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention.

Risk of overweight, obesity and cancer.

Environmental and hereditary factors in the causation of cancer – analyzes of twin cohorts from Sweden, Denmark and Finland.

Understanding the relative contribution of modifiable risk factors to cancer burden and their trends over time is crucial to informing cancer control efforts both locally and globally. In 2015, the UN published the Sustainable Development Goals (SDGs), with SDG target 3.4 focusing on reducing global premature mortality by a third for non-communicable diseases, including cancer, by 2030. Effectively addressing the growing burden of cancer worldwide will require a comprehensive. measures that include both curative and preventive interventions, especially in light of the anticipated challenges that the COVID-19 pandemic will bring to SDG target 3.4.

The impact of the COVID-19 pandemic on cancer care.

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modeling study.

Although some cancer cases are not preventable, governments can work at the population level to support an environment that minimizes exposure to known cancer risk factors. Primary prevention, or the prevention of cancer developing, is a particularly cost-effective strategy,

Cost-utility analysis of cancer prevention, treatment and control: a systematic review.

although it must be coupled with more comprehensive efforts to address cancer burden, including secondary prevention initiatives, such as screening programs, and ensure an effective capacity to diagnose and treat those with cancer. As part of cancer control strategies, prevention requires identification of causal risk factors, determination of contribution to local cancer burden, and development of effective strategies for their mitigation. Previous studies have quantified the burden of cancer attributable to individual risk factors worldwide or to multiple risk factors in selected countries and regions,

The causes of cancer: quantitative estimates of preventable risks of cancer in the United States today.

Estimates of global mortality attributable to particulate air pollution using satellite imagery.

Occupation and cancer – follow-up of 15 million people in five Nordic countries.

Elimination of occupational cancer.

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.

The current and future burden of cancer attributable to modifiable risk factors in Canada: summary of results.

16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010.

The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.

Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions.

Attributable causes of cancer in China.

Attributable causes of cancer in Japan in 2005 – a systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan.

providing decision locations and risk factor-specific information. However, comprehensive cancer risk factor estimates do not exist for many countries, leaving a major void as countries develop and update their cancer control plans. The International Agency for Research on Cancer’s Global Cancer Observatory provides estimates of global, regional, and national risk-attributable cancer burden for a subset of potentially modifiable risk factors (eg, obesity, alcohol consumption, infections, and ultraviolet radiation), but these assessments are not provided together in a comprehensive fashion over time, and some potentially modifiable risk factors are not assessed as part of that effort.

Global burden of cancer attributable to high body mass index in 2012: a population-based study.

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study.

Global burden of cancer attributable to infections in 2018: a global incidence analysis.

Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.

We identified previous work that primarily estimated the attributable cancer burden for single risk factors globally or multiple risk factors for individual countries. The Global Cancer Observatory also provides estimates of cancer attributable burden for selected risk factor categories separately. One previous comparative risk assessment project estimated risk-attributable cancer mortality for nine risk factors. We searched titles and abstracts in PubMed for English-language research articles that were published between January 1, 2010 and June 1, 2021, using the search terms “cancer or neoplasm or tumor or malignancy” and “risk factor or attributable risk or population”. attributable fraction” and “global or international or worldwide or world” and “burden or metric or incidence or mortality”, but did not identify additional informative studies. There is a gap in the literature on global estimates of risk-attributable cancer burden for a comprehensive list of risk factors that incorporate both cancer-related mortality and disability.

We report, for the first time, the global cancer burden attributable to a comprehensive list of behavioral, metabolic, and environmental and occupational risk factors using Global Burden of Disease, Injuries and Risk Factors 2019 results. By estimating risk-attributable cancer burden nationally and globally using both mortality and disability-adjusted life years (DALYs), this study provides a new perspective on attributable cancer burden. Globally, a large proportion of cancer deaths and DALYs were attributable to the modifiable risk factors included, with behavioral risks representing the greatest attributable burden. We identified large differences in attributable cancer mortality and DALY burden across Socio-demographic Index quintiles and between sexes. Risk-attributable cancer death and DALY burden increased globally from 2010 to 2019, with metabolic risk factors contributing to the largest percentage increases, particularly in low and low-middle Socio-demographic Index countries.

Implications of all available evidence

The burden of cancer remains a major public health challenge that is growing in magnitude worldwide. Modifiable risk factors are important contributors to cancer mortality and DALYs worldwide, with contribution varying by setting. The results of this study highlight the need for context-specific policies aimed at reducing exposure to risk factors as part of comprehensive cancer control efforts.

To our knowledge, the Global Burden of Disease, Injury and Risk Factor (GBD) Study is the only study to date that quantifies cancer burden attributable to a broad set of modifiable risk factors for each GBD round, for all countries around the world, across age groups, for both sexes, and over time. GBD 2019, the most recent iteration of the GBD study, provides an opportunity to estimate the global burden of cancer attributable to risk factors. A previous study used a similar comparative risk framework to estimate mortality from 12 cancer types and nine behavioral and environmental risk factors based on WHO cancer mortality data, but that analysis was limited to 2001 and has not been updated in a formal GBD analysis since.

Causes of cancer in the world: a comparative risk assessment of nine behavioral and environmental risk factors.

Here, we present estimates of 82 risk-outcome pairs, including cancer deaths and disability-adjusted life years (DALYs) attributable to risk factors at global, regional, and national levels in 2019, and estimate the temporal trends from 2010 to 2019 of cancer burden attributable to environmental and occupational, behavioral and metabolic risk factors to inform efforts to reduce exposure to cancer risk factors (appendix pp 157-60).

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

This manuscript was produced as part of the GBD Collaborator Network and in accordance with the GBD Protocol.

Methods

Overview of the GBD study

The GBD study was developed to provide global health estimates that are comprehensive and comparable for causes of death, disability, and their associated risk factors. GBD 2019 estimates mortality, incidence, prevalence, years of life lost (YLLs), years of life lived with disability (YLDs) and DALYs for 369 causes of death and disability and 87 risk factors, and groups of risk factors at the global level. , regionally, and for 204 countries and territories. The 2019 iteration of the GBD is the most up-to-date and supersedes all previous iterations. This Article reports estimates from 2010 to 2019, but extended years of estimates (1990–2019) are available online via the GBD Comparator and GBD Result Tool. Rates are reported per 100 000 person-years, and age-standardized rates were calculated using the GBD world population standard.

GBD 2019 Demographic Contributors Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.

Selected results in this Article are presented by Socio-demographic Index (SDI) to describe differences in cancer burden attributable to risk factors across the spectrum of socio-demographic development.

GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

SDI is a summary index calculated from the total fertility rate in women younger than 25 years, lagged-distributed income per capita, and average education for individuals aged 15 years and older (appendix p 55). The index ranges from 0 (low SDI) to 100 (high SDI), with quintiles used to describe low, low-medium, medium, high-medium and high SDI countries in 2019. Although both cancer deaths and DALYs attributable to risk factors are presented here, the majority of cancer DALYs worldwide are due to YLLs, reflecting cancer deaths weighted for age at death.

Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.

Thus, we do not present estimates of risk-attributable YLLs and YLDs here, but they are available in the online tools.

The GBD study complies with the Guidelines for Accurate and Transparent Health Assessments Reporting, and further details of this Article and the appendix are available in the GBD 2019 summary articles.

Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

GBD 2019 Demographic Contributors Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.

GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

Guidelines for accurate and transparent health assessment reporting: the GATHER statement.

Data sources for cancer burden estimates

Cancers included in the GBD study were those defined in chapter 2 (neoplasms) in the tenth revision of the International Classification of Diseases, with the exception of Kaposi’s sarcoma, for which most deaths are attributed to HIV/AIDS (appendix p 29).

WHO International statistical classification of diseases and related health problems.

Data sources used to inform the cancer estimates were obtained from vital registration systems, trial vital registration systems, verbal autopsy reports, and national and subnational population-based cancer registries. All data sources are provided with a unique identifier and compiled in the Global Health Data Exchange, which is publicly accessible.

Cancer burden estimation

Cancer registry, vital recording systems, and oral autopsy data are used to inform cancer mortality modeling in the GBD study, as one of these data sources might exist in a place where others do not. In some areas, cancer mortality data are scarce, but cancer incidence is reported through national or subnational population-based cancer registries. To maximize data informing mortality models, cancer incidence data were transformed into cancer mortality estimates with modeled mortality-to-incidence ratios (MIRs). MIRs specific to cancer causes (cancer types) were modeled with spatiotemporal Gaussian process regression (appendix pp 30-31).

Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

Death estimates from MIR-transformed incidence data were then pooled with mortality data from vital registration systems and verbal autopsies and used as inputs in cancer-specific Cause of Death Ensemble models.

Modeling causes of death: an integrated approach using CODEm.

These models use all available data and location-level covariates to test individual and ensemble models, and produce estimates of death for each cause, sex, age group, location and year estimated within GBD 2019, selecting models based on outliers. -example predictive validity. Finally, the predicted mortality estimates were adjusted to align with independently modeled all-cause mortality estimates for each age, group, sex, location, and year.

GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

Non-lethal cancer-specific computations began by generating incidence estimates from the modeled cancer death estimates using the MIRs corresponding to each cancer cause, age group, sex, location, and year. Cancer 10-year prevalence was modeled with incidence, background mortality, and estimated relative survival curves and their correlation with modeled MIRs (appendix pp 49–53). Cancer-specific prevalence for each outcome, age, group, sex, location, and year combination consists of four outcome stages: (1) diagnosis and treatment, (2) remission, (3) metastatic and disseminated, and (4) terminal. To generate YLDs, each consequence of prevalence was multiplied by its corresponding consequence-specific disability weight (appendix pp 53-54). Disability weights describe the severity of health loss associated with a consequence-specific condition and range from 0 (equivalent to full health) to 1 (equivalent to death).

GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

YLLs were calculated by multiplying the number of deaths in a specific age group for each cancer cause by the remaining standard life expectancy at the age of death.

GBD 2019 Demographic Contributors Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.

Finally, DALYs were calculated as the sum of YLDs and YLLs.

Risk-factor-attributable cancer burden estimation

GBD 2019 includes risk factors that are broadly categorized into three groups: (1) environmental and occupational, (2) behavioral, and (3) metabolic. This study includes 82 cancer risk-outcome pairs (23 cancer types and 34 risk factors), with risk factors identified using the World Cancer Fund criteria.

World Cancer Research FundAmerican Institute for Cancer ResearchFood, nutrition, and physical activity, and the prevention of cancer: a global perspective.

(appendix pp. 154–56). Risk-outcome pairs are organized into four mutually exclusive levels with increasing risk factor resolution (appendix pp 152-53). The general approach to risk factor estimation in the GBD study is described in this article, and details of the modeling approach for each risk factor are available in the 2019 GBD risk factor summary paper.

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

and the appendix (pp. 72–145). For percentages of risk-attributable cancer deaths or DALYs reported, the total cancer burden (risk and non-risk cancer burden) included non-melanoma skin cancers.

The GBD comparative risk assessment framework was used to compute the fraction of cancer-specific burden attributable to each risk factor. The framework is divided into six main steps that are followed for each risk-outcome pair. First, the World Cancer Research Fund criteria were used to identify risk factors with convincing or probable evidence for a causal association.

World Cancer Research FundAmerican Institute for Cancer ResearchFood, nutrition, and physical activity, and the prevention of cancer: a global perspective.

For GBD 2019, systematic reviews were updated to ensure appropriate inclusion of risk–outcome pairs.

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

Second, to estimate relative risks for each risk-outcome pair as a function of exposure, existing systematic reviews were updated and meta-analyses of relative risks were performed. In GBD 2019, the meta-analytic approach was updated for a selected set of continuous risk factors using GBD’s meta-regression-bayesian, regularized, tweaked tool (appendix pp 58–59). Third, risk factor exposure levels and distributions were modeled for each age, sex, location, and year combination with data available from published studies, household surveys, censuses, administrative data, ground monitoring data, or remote sensing data. To model risk factor exposure level, the GBD uses either Bayesian meta-regression modeling (DisMod-MR 2.1), a flexible approach that can incorporate sex-specific and age-specific data, or spatiotemporal Gaussian process regression, the preferred approach when exposure is. stable across age groups (appendix p 62). Fourth, for each risk factor, the theoretical minimum risk exposure level was identified, a counterfactual scenario in which a given population receives the optimal level of risk exposure (ie, no exposure for monotonically increasing risk functions such as smoking, the lowest point of the risk exposure). hazard function of exposure for J-shaped or U-shaped risks such as high BMI, and the 85th percentile of exposure in cohorts and trials for protective risks such as fruit consumption, weighted by the relative global magnitude of each outcome). Fifth, the population attributable fraction for each risk-outcome pair was calculated by age, sex, location and year, taking into account the risk function (ie relative risk), exposure level, and the theoretical minimum risk exposure level (appendix pp. 62–64). Sixth, for some risk factors it was necessary to estimate the population attributable fraction in combination with other risk factors considering mediation. For example, calculating the population attributable fraction for fruit consumption should account for the per ten ial mediating effect of fiber intake. Thus, a mediation matrix was used to correct for population attributable fractional overestimation that would occur if independence of specific risk factors were assumed.

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

Finally, to estimate the cancer burden attributable to each assessed risk factor, the YLLs, YLDs and deaths for a given cancer type were multiplied by the corresponding risk factor population attributable fraction. The sum of YLLs and YLDs was used to estimate the cancer DALYs attributable to risk factors.

Estimating uncertainty

To account for uncertainty in the attributable burden estimates, a total of 1000 draws were evaluated, from which the lower and upper limits of the 95% uncertainty interval (UI) were obtained from the 25th and 975th ranked values. Error was propagated through each estimation step, including the estimation of cancer deaths and DALYs, exposure, relative risk functions, and for associated risk factors the theoretical minimum risk exposure level.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

In 2019, the total number of cancer deaths worldwide attributable to all estimated risk factors was 4·45 million (95% UI 4·01–4·94) for both sexes combined, accounting for 44·4% (41·3–48). ·4) of all cancer deaths. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males and 1·58 million (1·36–1·84) in females, representing 50·6% (47·8–54). ·1) of all cancer deaths in males and 36·3% (32·5–41·3) in females (appendix pp 191–99). The total number of cancer DALYs globally attributable to all estimated risk factors in 2019 was 105 million (95·0–116) for both sexes combined, which accounted for 42·0% (39·1–45·6) of all cancer DALYs oh . Males were estimated to have 67·5 million (60·8–75·1) cancer DALYs attributable to risk factors, or 48·0% (45·3–51·5) of all cancer DALYs in males, while females were evaluated. to have 37·6 million (32·8–43·1) cancer DALYs attributable to risk factors, or 34·3% (30·9–38·7) of all cancer DALYs in females.

The leading Level 2 risk factor (appendix pp 152–53) in males in terms of attributable cancer DALYs was tobacco (figure 1), which accounted for 33·9% (32·3–35·4) of all cancer DALYs in males . in 2019 (appendix pp. 191–93). Alcohol use, dietary risks and air pollution were the next largest risk factors, accounting for 7·4% (6·7–8·2), 5·9% (4·4–8·3), and 4·4. % (3·4–5·5), respectively, of all male cancer DALYs in 2019. Tobacco was also the leading Tier 2 risk factor for females globally in terms of attributable cancer DALYs (figure 1) and accounted for 10·7 % (9·9–11·5) of all female cancer DALYs in 2019 (appendix pp 191–93). Unsafe sex was the second leading risk factor for females, accounting for 8·2% (7·0–8·8) of all female cancer DALYs in 2019, followed by dietary risks (5·1% [4·0–6· ) 7]), high BMI (4·7% [2·8–7·0]), and high fasting plasma glucose (3·6% [1·0–7·5]). A ranking of Level 2 risk factors by attributable cancer deaths worldwide in 2019 showed a similar ranking as by attributable cancer DALYs (appendix pp 181-87).

Figure 1 Cancer DALYs attributable to 11 Level 2 risk factors worldwide in 2019

(A) Absolute cancer DALYs for males. (B) Proportional cancer DALYs for males. (C) Absolute cancer DALYs for females. (D) Proportional cancer DALYs for females. Air pollution includes ambient particulate pollution and household air pollution from solid fuels. Other environmental risks include residential radon. Occupational risks include exposure to 13 specific carcinogens. Dietary risks include nine specific risk factors related to cancer. Tobacco includes smoking, chewing tobacco and secondhand smoke. See appendix (p 157–60) for details and definitions of each level 2 risk factor on the y-axis. See appendix (p 161) for more details on global absolute and proportional cancer deaths attributable to Level 2 risk factors. DALYs = disability-adjusted life years.

The leading cancer by risk-attributable deaths worldwide in 2019 for males and females was trachea, bronchus and lung cancer (36·9% [34·2–39·3] of all attributable cancer deaths), followed by colon. and rectal cancer, esophageal cancer and stomach cancer in males, and cervical cancer, colon and rectal cancer, and breast cancer in females (figure 2, appendix p 210). Deaths caused by cancer and risk-attributable deaths caused by cancer tended to be greater in males than females for leading causes of cancer death worldwide, with the exception of cancer types that occur predominantly in women (eg, breast) or are exclusively assessed in women. in the GBD study (eg, cervical, ovarian and uterine cancers; figure 2; for male-to-female ratios for risk-attributable cancer deaths see appendix pp 206-07). Excluding the sex-specific cancers with a risk-attributable burden (cervical, ovarian, uterine and prostate cancer) the male-to-female ratios for risk-attributable cancer deaths tended to be smaller in high SDI countries than in non-high SDI. countries (low, low-medium, medium, and high-medium SDI countries; appendix pp. 213-14, 217-18). Cancer deaths and risk-attributable cancer deaths worldwide for both sexes combined in 2019 occurred disproportionately often in high SDI countries, with 25·4% (24·0–26·7) of cancer deaths and 26·5% (24·9–28·1 ) of risk-attributable cancer deaths occurring in high SDI countries, although these countries had only 13·1% (12·5–13·8) of the global population (appendix p 221). The major cancers, gender analysis and SDI results remained largely the same when the cancers were ranked by risk-attributable DALYs instead of deaths (appendix p 162).

Figure 2 Global deaths from cancers attributable to risk factors in 2019 by gender and SDI

Non-high SDI countries include low, low-medium, medium and high-medium SDI countries. Cancer types are listed from left to right in order of greatest to least risk-attributable deaths. See appendix (pp. 213–14, 217–18) for estimates of risk-attributable cancer deaths in high and non-high SDI areas by sex. See appendix (p 162) for more details on DALYs from cancers attributable to risk factors in 2019 by gender and SDI. For additional versions of this figure showing age-standardized mortality and DALY rates see appendix (pp. 163-64). DALYs = disability-adjusted life years. SDI=Socio-demographic Index.

Geographic patterns for cancer age-standardized deaths and DALY rates attributable to environmental and occupational, behavioral and metabolic risks in 2019 differed around the world (figure 3, appendix pp 165-66), with generally higher age-standardized DALY rates within this Level. 1 risk factor categories (appendix pp. 152-53) notable in high-income North America, and central, western, and eastern Europe, and variably elevated rates by risk category in eastern and southeastern Asia, southern Latin America, and southern Africa. Globally in 2019, the top five regions in terms of risk-attributable cancer age-standardized mortality rates were central Europe (82·0 [71·0–94·9] per 100 000 person-years), eastern Asia (69·8). [58·0–83·0]), high-income North America (66·0 [60·5–72·1]), southern Latin America (64·2 [58·2–71·8]), and western Europe (63·8 [58·4–69·7]; appendix pp. 174, 234–39). Details of risk-attributable cancer age-standardized death and DALY rates at the country level are available in the appendix (pp. 234-239) and in the online GBD Compare and GBD Results.

Figure 3 Global map of age-standardized DALY quintiles for risk-attributable cancer burden, both sexes combined, 2019

(A) Environmental and occupational risks. (B) Behavioral risks. (C) Metabolic risks. Each map represents estimates at the national level. Quintiles are based on age-standardized DALY rates per 100 000 person-years. See appendix (pp. 165–68, 234–39) for more details on risk-attributable cancer deaths and DALYs for each country and territory. DALYs = disability-adjusted life years.

Figure 3 Global map of age-standardized DALY quintiles for risk-attributable cancer burden, both sexes combined, 2019

(A) Environmental and occupational risks. (B) Behavioral risks. (C) Metabolic risks. Each map represents estimates at the national level. Quintiles are based on age-standardized DALY rates per 100 000 person-years. See appendix (pp. 165–68, 234–39) for more details on risk-attributable cancer deaths and DALYs for each country and territory. DALYs = disability-adjusted life years.

Figure 4 shows age-specific attributable cancer DALY rates in 2019 by SDI quintiles. For the same age group, cancer DALY rates attributable to behavioral risks were generally greater than those attributable to environmental and occupational risks and metabolic risks, and attributable cancer DALY rates were generally greater with increasing SDI quintile. Attributable cancer DALY rates increased with age for each Level 1 risk category, before peaking at ages 70–74 years or ages 75–79 years, depending on the SDI quintile, with a later age peak generally on the higher end of the SDI spectrum

For all risk factors assessed for both sexes combined between 2010 and 2019, global attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), while the global age-standardized rates of attributable cancer deaths decreased by 6·9% (0·9–12·8) and cancer DALYs by 7·8% (1·4–14·0; appendix pp 240–42). The largest percentage increase in attributable cancer deaths and DALYs among the Level 1 risk factor categories was in metabolic risks, which increased by 34·7% (27·9–42·8) and 33·3% (25·8–42· ). 0), respectively, from 2010 to 2019, while behavioral risk-attributable cancer deaths and DALYs increased by 17·9% (10·4–26·0) and 14·4% (6·5–22·5), and environmental and occupational risk-attributable cancer deaths and DALYs increased by 16·7% (7·9–26·2) and 13·1% (3·9–23·1), respectively. Similarly, the largest percentage increase in global risk-attributable cancer age-standardized death and DALY rate was in metabolic risk factors, which increased by 2·8% (–2·2 to 8·8) and 3·8% ( –2.·0 to 10·5), respectively, while behavioral risk factors decreased by 8·7% (2·7–14·5) and 9·6% (3·2–15·8), respectively, and environmental and professional. risk factors decreased by 10·0% (2·8–16·7) and 11·4% (3·5–18·5), respectively.

In addition, the magnitude of change in risk-attributable cancer DALYs and deaths and age-standardized DALYs and death rates varied greatly between super-regions and SDI quintiles (figure 5, appendix pp. 148, 172, 223-25). The largest increases in age-standardized DALY rates due to metabolic risks were seen in southern Asia, northern Africa and the Middle East, and sub-Saharan African superregions, and in the low-middle and low SDI quintiles, while the largest declines were. in behavioral and environmental and occupational risks were seen in central Europe, eastern Europe and central Asia; high income; Latin American and Caribbean superregions; and in the high and high-middle SDI quintiles (appendix p 224). Overall, the superregions and SDI quintiles with the largest increase in age-standardized cancer DALY burden attributable to metabolic risks between 2010 and 2019 were those with the least improvement in cancer burden attributable to behavioral risks and environmental and occupational risks during the same period. time period (appendix p 224).

Figure 5 Percentage change in risk-attributable cancer DALY counts and age-standardized DALY rates for Level 1 risk factors by SDI quintile, both sexes combined, 2010–19

(A) Percent change in risk-attributable cancer DALY counts by SDI quintile. (B) Percent change in risk-attributable age-standardized cancer DALY rates by SDI quintile. See appendix (pp. 146–47) for more information on SDI quintiles. See appendix (p172) for more information on the percentage change in risk-attributable cancer DALYs and age-standardized DALY rates for risk factors by GBD world superregion. See appendix (p 173) for percentage change in risk-attributable cancer deaths and age-standardized mortality rates by SDI quintile and GBD world superregion. DALYs = disability-adjusted life years. GBD=Global Burden of Disease, Injury and Risk Factor Study. SDI=Socio-demographic Index. *95% uncertainty intervals that do not include zero.

Finally, different patterns in the main risk factors for attributable cancer age-standardized DALY rates were observed globally and across the SDI spectrum (figure 6, appendix pp 175-80). The top nine risk factors at the most detailed level contributing to global cancer burden defined by age-standardized DALY rates did not change between 2010 and 2019, and the top three risk factors (smoking, alcohol use and high BMI) were the same in the high SDI -quintile as worldwide. Smoking and alcohol use remained the two main risk factors in the average SDI quintile in 2010 and 2019, with unsafe sex decreasing from third to fifth position, high BMI rising from fourth to third position, and ambient particulate matter pollution increasing from fifth to fourth. position (appendix p 178). In the low SDI quintile, smoking remained the leading risk factor for risk-attributable cancer burden, with unsafe sex ranked second and alcohol use third in 2010 and 2019. Within the top five leading risk factors in the low SDI quintile, high BMI and high fasting plasma glucose both increased (fifth to fourth, and sixth to fifth, respectively), and household air pollution from solid fuels decreased (fourth to sixth) between 2010 and 2019 (appendix pp 175–80).

Figure 6 Leading risk factors at the most detailed level for risk-attributable cancer age-standardized DALY rates worldwide, both sexes combined, 2010–19

Top ten risk factors for age-standardized cancer DALY rates and risk factors moving into or out of the top ten between 2010 and 2019 are shown for the global level. Dotted lines indicate a decrease in rank. Solid lines indicate an increase or no change in rank. Data in parentheses are 95% uncertainty intervals. Risk factors at the most detailed level reflect the GBD hierarchy into which these categories of risks fall, ranging from Levels 2 to 4 (see appendix p 152 for more information on risk factor levels in the GBD hierarchy). See appendix (pp. 175–80) for an expanded version of this figure, which contains the top ten risk factors for risk-attributable cancer age-standardized DALY rates in males, females, and both sexes combined globally and by SDI quintile. See appendix (pp. 181–87) for more details on the top ten risk factors for risk-attributable cancer age-standardized mortality rates for males, females, and both sexes combined globally and by SDI quintile. DALYs = disability-adjusted life years. GBD=Global Burden of Disease, Injury and Risk Factor Study. SDI=Socio-demographic Index.

Discussion

Our analysis found that 44·4% (95% UI 41·3–48·4) of global cancer deaths and 42·0% (39·1–45·6) of global cancer DALYs were attributable to estimated risk factors in 2019. These findings highlight that a large proportion of cancer burden worldwide has potential for prevention through interventions aimed at reducing exposure to known cancer risk factors but also that a large proportion of cancer burden may not be preventable by controlling the risk factors currently assessed. Thus, cancer risk reduction efforts must be coupled with comprehensive cancer control strategies that include efforts to support early diagnosis and effective treatment. Most attributable cancer DALYs were accounted for by behavioral risk factors, such as tobacco, alcohol use, unsafe sex, and dietary risks, suggesting a need for concerted efforts to address behavioral risk factors to effectively reduce cancer burden worldwide. Attributable cancer DALYs from each Level 1 risk factor group generally increased with increasing SDI, and although there were similarities in the leading risk factors across the SDI spectrum for both sexes combined (ie, smoking and alcohol use), there were differences in risk factor patterns. following these leading risks, highlighting the need for cancer risk reduction efforts to be context-specific. Between 2010 and 2019, age-standardized cancer DALYs attributable to all risk factors decreased by 7·8% (1·4 to 14·0). Despite this decline, a global increase in age-standardized cancer DALYs (3·8% [–2·0 to 10.5]) attributable to metabolic risks was seen, largely driven by large increases in low and low-medium SDI countries. In addition, total risk-attributable cancer absolute DALY burden worldwide and in all SDI quintiles grew between 2010 and 2019, underscoring an expanding need for health systems around the world with the capacity to comprehensively care for individuals with cancer, while developing and implementing cancer control efforts. cons devise risk reduction strategies. These estimates could help inform cancer control planning by identifying key modifiable risk factors for cancer around the world, including for countries that may not have previous local research on cancer burden and cancer risk factor findings.

To our knowledge, this study represents the largest effort to date to determine the global burden of cancer attributable to risk factors, and it contributes to a growing body of evidence aimed at estimating the risk-attributable burden for specific cancers nationally,

The causes of cancer: quantitative estimates of preventable risks of cancer in the United States today.

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.

The current and future burden of cancer attributable to modifiable risk factors in Canada: summary of results.

16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010.

The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.

Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions.

Attributable causes of cancer in China.

Attributable causes of cancer in Japan in 2005 – a systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan.

Current perspective on the global and US cancer burden attributable to lifestyle and environmental risk factors.

The burden of cancer attributable to modifiable risk factors: the Australian cancer PAF cohort consortium.

The fractions of cancer attributable to modifiable factors: a global review.

Global burden of cancer attributable to high body mass index in 2012: a population-based study.

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study.

Global burden of cancer attributable to infections in 2018: a global incidence analysis.

Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.

Causes of cancer in the world: a comparative risk assessment of nine behavioral and environmental risk factors.

Our study builds on existing evidence by estimating both deaths and DALYs due to risk-attributable cancer burden, across a spectrum of cancer types and risk factors, for all countries, age groups and sexes, over time. Comparing the results of this study with studies reporting national-level population attributable fractions, GBD 2019 generally reported higher values ​​for all risk factors combined. These comparisons are between cases and deaths for a subset of countries and differences may be due to a larger number of risk factors assessed and larger estimates for selected risk factors, such as smoking, possibly due to differences in exposure definitions and risk-outcome pairs assessed. .

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.

The current and future burden of cancer attributable to modifiable risk factors in Canada: summary of results.

16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010.

The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.

Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions.

Attributable causes of cancer in China.

Attributable causes of cancer in Japan in 2005 – a systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan.

Compared with a previous effort to quantify the lethal burden of cancer attributable to risk factors worldwide, this study found a greater percentage of cancer deaths attributable to risk factors when assessing more risk factors (44·4% [95% UI 41·6–). 48·2] in 2001 in GBD 2019 compared to 35% in 2001 in the previous study), although both studies found major contributions of smoking and alcohol use worldwide and unsafe sex in lower incomes.

Causes of cancer in the world: a comparative risk assessment of nine behavioral and environmental risk factors.

Comparisons to a comprehensive global risk-attributable cancer burden in the Global Cancer Observatory are not possible, because incidence estimates are provided only for individual risk categories, but for alcohol consumption and elevated BMI, risk factors assessed by both studies, similar estimates of risk-attributable. cancer burden has been noted (4·1% of new cancer cases in 2020 attributable to alcohol consumption in the Global Cancer Observatory and 4·9% [4·4-5·5] of cancer deaths in 2019 attributable to alcohol use in the GBD. study ; 3·6% of new cancer cases in 2012 attributable to high BMI in the Global Cancer Observatory and 4·6% [2·7–7·1] of cancer deaths in 2019 attributable to high BMI in the GBD study).

Global burden of cancer attributable to high body mass index in 2012: a population-based study.

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study.

For cancer risk factors not included in this study, estimates from the Global Cancer Observatory suggest that an additional approximately 8·9% of cancer cases would be attributable to infections.

Global burden of cancer attributable to infections in 2018: a global incidence analysis.

(appendix p 67) and a further 1·2% of cancer cases would be attributable to ultraviolet radiation.

Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.

These estimates should be interpreted with some caution due to the different assessment approaches used, but could provide useful information for crucial remaining risk factors not yet included in the GBD study.

In GBD 2019, large all-age gender differences were seen in the global cancer burden attributable to all risk factors combined (48·0% [95% UI 45·3–51·5] of male cancer DALYs versus 34·3% [1 ] [1] 30·9–38·7] of female cancer DALYs). These gender differences are well documented, with several studies reporting a higher attributable cancer burden in males compared to females.

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.

The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.

Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions.

Attributable causes of cancer in China.

In this study, we identified gender differences across two main risk factor groups. For example, there were disparities in cancer DALYs attributable to behavioral risk factors, such as smoking (33·2% [31·7–34·7] for males versus 8·9% [8·3–9·6] for females. ) and alcohol use (7·4% [6·7-8·2] for males versus 2·3% [2·0-2·6] for females), which might be motivated by a higher exposure to these behavioral risk factors. among males than females. Similarly, for environmental and occupational risks, for example, the cancer DALYs attributable to occupational carcinogens were three times higher among males (3·9% [3·1–4·8]) than females (1·3% [1·0) –1·6]), which could reflect that males are more likely than females to be employed in workplaces with a higher risk of exposure to carcinogens. Between 2010 and 2019, the change in global age-standardized risk-attributable cancer DALY rates decreased slightly among females (–4·6% [–11·0 to 2·2]), while there was a more notable decrease among males (– 9·6% [–17·6 to –1·3]). This result could suggest disparities in our approach to cancer prevention by gender and a need for future sex-specific evaluations of effective cancer risk factor interventions.

Our results show a gradient across the sociodemographic spectrum in 2019, with the risk-attributable cancer age-standardized DALY rates generally increasing with higher SDI quintiles. However, from 2010 to 2019, age-standardized cancer DALY rates attributable to all risks combined decreased in high, high-medium and medium SDI countries, while these values ​​increased in low-medium SDI countries or were approximately stable in low SDI – countries This increase was largely due to metabolic risks, which include risk factors such as high BMI. The increase in metabolic risk-attributable cancer burden could be the result of these countries experiencing an epidemiological transition in which improvements in country-level development status are associated with increasing obesity levels.

Socioeconomic status and obesity in adult populations of developing countries: a review.

Transition of physical activity.

Globally, there has been great progress in reducing exposure to tobacco that can be linked to coordinated international and national prevention efforts.

The effects of tobacco control policies on global smoking prevalence.

GBD 2019 Tobacco Contributors Spatial, temporal and demographic patterns in smoking tobacco prevalence and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019.

Interventions through taxation and regulatory policies for tobacco smoking, including smoke-free policies, increased tobacco taxes, and advertising bans led by the WHO Framework Convention on Tobacco Control, have played an important role in these efforts.

The effects of tobacco control policies on global smoking prevalence.

Achievement of global tobacco control.

Similar efforts, including taxation and advertising bans, have been advocated to help reduce the harmful use of alcohol.

WHOTackling NCDs: “best buys” and other recommended interventions for the prevention and control of noncommunicable diseases.

WHO Global status report on alcohol and health 2018.

WHO The SAFER initiative: a world free from alcohol-related harm.

Behavioral risk factors are strongly influenced by the environment in which people live and individuals with cancer should not be blamed for their illness. Future research is needed to investigate the impact of public health approaches to cancer risk factor reduction that go beyond individual-oriented prevention and may be more effective long-term strategies than placing the onus on individuals to modify exposures to prevent cancer.

The public health approach in historical perspective.

Many risk factors for cancer have been well established for decades, but greater political commitment to implementing policies addressing cancer prevention is needed. Improving social determinants of health, such as access to education and poverty reduction, could be a viable approach to reduce exposure to certain risks across populations.

The social determinants of health: it is time to consider the causes of the causes.

WHO-European review of social determinants of health and the health divide.

Population-based approaches aimed at improving social determinants of health may provide an equitable cancer control approach to overcome the systemic barriers promoting disproportionate risk-attributable cancer burden growth in some regions, countries, and subpopulations within countries. For these reasons, future research should not overlook the importance of context-specific interventions that are led or led by those with an understanding of local cultural and behavioral patterns. Finally, cancers remain fundamentally linked to genetics and aging, and although addressing contributing risk factors is crucial to cancer prevention, this will never eliminate cancer burden. As a result, countries should continue to invest in comprehensive cancer control strategies beyond risk factor reduction, which include health systems capable of early diagnosis, detection through screening for selected cancers, and effective treatment options for those diagnosed with cancer.

Although GBD 2019 is the largest effort to date to estimate the global burden of cancer attributable to risk factors, opportunities for improvement remain. First, some limitations are inherent in the available data sources. For example, some countries do not have population-based cancer registries, which are an important data source for estimating cancer burden. As can be seen in the relative uncertainty of risk-attributable cancer burden estimated by GBD 2019 (appendix p 171), there is greater uncertainty relative to point estimates in many lower SDI countries compared to higher SDI countries. GBD study models depend on available data, and assessments should not replace but rather complement the ongoing decision-making work to expand and improve directly observed data around the world. Cancer registry development and support is integral to cancer control efforts and should be considered in broader cancer control planning initiatives. Delays are inherent with the publication of cancer registry and vital statistics reports, which result in more recent cancer death estimates often relying on historical data. The data used to estimate risk factor exposure are sometimes sparse and many data sources do not provide sufficient information to assess for potential measurement error or bias. Where there is information available, the GBD study plans to correct for systematic bias in risk exposure data by establishing a reference definition of each risk exposure and adjusting acceptable alternative exposure measurements based on studies with observed data pairs of the two different definitions. However, after these adjustments, residual measurement bias is likely to persist and may vary across the world, over time and by risk factor. Formal assessments of discovery model performance would be useful in future GBD iterations. Second, the risk factors included in this study are based on current knowledge of risk factors for cancer, but as knowledge increases there may be additional risk factors important to incorporate in future iterations of the GBD study. In addition, there are known risk factors for cancer, such as sunlight exposure (ie, ultraviolet radiation), and infectious agents, such as Helicobacter pylori, which are not included in the GBD study.

IARC monographs on the evaluation of carcinogenic risks to humans Solar and ultraviolet radiation.

Helicobacter pylori: stomach cancer and beyond.

Unsafe sex is assessed as a risk factor, but human papillomavirus, a known risk factor for several types of cancer, is not explicitly assessed; and although liver cancer burden due to hepatitis B and C is estimated within the GBD cause hierarchy, these viral infections are not assessed as risk factors, making their inclusion in a robust risk-attributable cancer burden estimate difficult. Infection-related cancers are more noticeable in lower SDI settings, so addressing these will be important to produce comprehensive global estimates of cancer-attributable risk and disparities. Third, second-order measures of cancer-related risk factors, including aspects such as income inequality and racism, would be difficult to comprehensively explain, but could add important context for future health policy work. Finally, the results of GBD 2019 were evaluated before the COVID-19 pandemic. Assessing the impact of the COVID-19 pandemic on risk-attributable cancer burden is an important area for future research. However, several key risk factors identified in this study are also linked to an increase in disease severity in individuals with COVID-19 and to a burden of other non-communicable diseases besides cancer. Thus, reducing exposure to these harmful risk factors may not only have a positive impact on cancer burden reduction efforts, but synergistically improve population health more broadly.

Globally, a large percentage of cancer deaths and DALYs were attributable to risk factors in 2019, and most were attributable to behavioral risks. Smoking continues to be the leading cancer risk factor worldwide, with other major contributors to cancer burden varying around the world. Targeting leading location-specific cancer risk factors could help countries make progress towards reducing non-communicable disease premature mortality by a third by 2030, as highlighted in SDG target 3.4. Although progress was seen in high and high-medium SDI countries for behavioral and environmental and occupational risk-attributable cancer age-standardized DALY rates between 2010 and 2019, in low and low-medium SDI countries, metabolic risk-attributable cancer- load increased. considerably. A considerable cancer burden is not preventable through the currently assessed risk factors, and, as such, countries should continue to simultaneously invest in risk reduction strategies while strengthening health systems to support early diagnosis and effective treatment of those with cancer. Given the growing burden of cancer worldwide, this study may help policymakers and researchers identify important modifiable risk factors that could be targeted in efforts to reduce cancer burden globally, regionally, and nationally.

GBD 2019 Cancer Risk Factors Collaborators

, Kelly Compton, Rixing Xu, Alistair R Acheson, Hannah Jacqueline Henrikson, Jonathan M Kocarnik, Louise Penberthy, Amirali Aali, Qamar Abbas, Behzad Abbasi, Mohsen Abbasi-Kangevari, Zeinab Abbasi-Kangevari, Hedayat Abbastabar, Michael Abdelmasseh-, Michael Abbasi Elsalam, Ahmed Abdelwahab Abdelwahab, Gholamreza Abdoli, Hanan Abdulkadir Abdulkadir, Aidin Abedi, Kedir Hussein Abegaz, Hassan Abidi, Richard Gyan Aboagye, Hassan Abolhassani, Abdorrahim Absalan, Yonas Derso Abtew, Hiwa Ebuhuba Abuchava, Hiwa Abu-Ghar Abuchava, Hiwa Ebuhuba Aboagye Manuel Acuna, Daniel Addison, Isaac Yeboah Addo, Oyelola A Adegboye, Miracle Ayomikun Adesina, Mohammad Adnan, Qorinah Estiningtyas Sakilah Adnani, Shailesh M Advani, Sumia Afrin, Muhammad Sohail Afzal, Manik Aggarwal, Bright Opoku Ahinzan Ahmad, Araz Rizwan Ahmad, Araz , Sajjad Ahmad, Sohail Ahmad, Sepideh Ahmadi, Haroon Ahmed, Luai A Ahmed, Muktar Beshir Ahmed, Tarik Ahmed Rashid, Wajeeha Aiman, Marjan Ajami, Gizachew Taddesse Akalu , Mostafa Akbarz adeh-Khiavi, Addis Aklilu, Maxwell Akonde, Chisom Joyqueenet Akunna, Hanadi Al Hamad, Fares Alahdab, Fahad Mashhour Alanezi, Turki M Alanzi, Saleh Ali Alessy, Abdelazeem M Algammal, Mohammed Khaled Al-Hanawi, Robert Kaba Beriwan Abdul , Robert Kaba Alhassan , Liaqat Ali, Syed Shujait Ali, Yousef Alimohamadi, Vahid Alipour, Syed Mohamed Aljunid, Motasem Alkhayyat, Sadeq Ali Ali Al-Maweri, Sami Almustanyir, Nivaldo Alonso, Shehabaldin Alqalyoobi, Rajaa M Al-Raddadi, Rami H Hani Al-Rifai, Salman Khalifah Al-Sabah, Ala’a B Al-Tammemi, Haya Altawalah, Nelson Alvis-Guzman, Firehiwot Amare, Edward Kwabena Ameyaw, Javad Javad Aminian Dehkordi, Mohammad Hosein Amirzade-Iranaq, Hubert Amu, Ganiyu Adeniyi Amusa , Robert Ancuce, Jason A Anderson, Yaregal Animut Animut, Amir Anoushiravani, Ali Arash Anoushirvani, Alireza Ansari-Moghaddam, Mustafa Geleto Ansha, Benny Antony, Maxwell Hubert Antwi, Sumadi Lukman Anwar, Razique Anwer, Anayochukwu Edward Anyasodor, Jalezaal Arabloo, Jalez aal Arabloo, Ola tunde Aremu, Ayele Mamo Argaw, Hany Ariffin, Timur Aripov, Muhammad Arshad, Al Artaman, Judie Arulappan, Raphael Taiwo Aruleba, Armin Aryannejad, Malke Asaad, Mulusew A Asemahagn, Zatollah Asemi, Mohammad Asxafadiraba, Rejafadiraba, Taiwo Aruleba , Mohammad Athar, Seyyed Shamsadin Athari, Maha Moh’d Wahbi Atout, Sameh Attia, Avinash Aujayeb, Marcel Ausloos, Leticia Avila-Burgos, Atalel Fentahun Awedew, Mamaru Ayenew Awoke, Tewachew Awoke, Beatriz Paulina Ayala Tejaye, Solomon Shilatu Ayen, Davood Azadi, Sina Azadnajafabad, Saber Azami-Aghdash, Melkalem Mamuye Azanaw, Mohammadreza Azangou-Khyavy, Amirhossein Azari Jafari, Hosein Azizi, Ahmed Y Y Azzam, Amirhesam Babajani, Muhammad Badar, Ashye D. Bagherieh, Saeed Bahadory, Atif Amin Baig, Jennifer L Baker, Ahad Bakhtiari, Ravleen Kaur Bakshi, Maciej Banach, Indrajit Banerjee, Mainak Bardhan, Francesco Barone-Adesi, Fabio Barra, Amadou Barrow, Nasir Z Bashir, Aza deh Bashiri, Saurav Basu, Abdul-Monim Mohamm ad Batiha, Aeysha Begum, Alehegn Bekele Bekele, Alemayehu Sayih Belay, Melaku Ashagrie Belete, Uzma Iqbal Belgaumi, Arielle Wilder Bell, Luis Belo, Habib Benzian, Alemshet C Bermudezga, Alemshet C. Eduardo Bernabe, Akshaya Srikanth Bhagavathula, Neeraj Bhala, Bharti Bhandari Bhandari, Nikha Bhardwaj, Pankaj Bhardwaj, Krittika Bhattacharyya, Vijayalakshmi S Bhojaraja, Soumitra S Bhuyan, Sadia Bibi, Awraris Hailu Bhandari, Birema Bhardwaj, Birema Bhattacharyya, Bagas Sur, Biremaw Bilchut, Bagas Sur Bhattacharyya Habitu Eshetu Birhan, Tone Bjørge, Oleg Blyuss, Belay Boda Abule Bodicha, Srinivasa Rao Bolla, Archith Boloor, Cristina Bosetti, Dejana Braithwaite, Michael Brauer, Hermann Brenner, Andrey Nikolaevich Briko, Nikolay Ivanovich Briko, Christina Maree Bulamuan,, Maria Teresa Bustamante-Teixeira, Muhammad Hammad Butt, Nadeem Shafique Butt, Zahid A Butt, Florentino Luciano Caetano dos Santos, Luis Alberto Cámera, Chao Cao, Yin Cao, Giu lia Carreras, Márcia Carvalho, Francieli Cembr anel, Ester Cerin, Promit Ananyo Chakraborty, Periklis Charalampous, Vijay Kumar Chattu, Odgerel Chimed-Ochir, Jesus Lorenzo Chirinos-Caceres, Daniel Youngwhan Cho, William C S Cho, Devasahayam J Chu Christopher, Dinh-Toi , Isaac Sunday Chukwu, Aaron J Cohen, Joao Conde, Sandra Cortés, Vera Marisa Costa, Natália Cruz-Martins, Garland T Culbreth, Omid Dadras, Fentaw Teshome Dagnaw, Saad M A Dahlawi, Xiaochen Dai, Lalit Dandona, Rakhi Dandona, Parnaz Daneshpajouh, Anna Danielewicz, An Thi Minh Dao, Reza Darvishi Cheshmeh Soltani, Aso Mohammad Darwesh, Saswati Das, Dragos Virgil Davitoiu, Elham Davtalab Esmaeili, Fernando Pio De la Hoz, Sisay Abebe Debela, Azizallah Dehghan, Biniyam Wo Demisse, Biniyam Wo Demisse Denova-Gutiérrez, Afshin Derakhshani, Meseret Derbew Molla, Diriba Dereje, Kalkidan Solomon Deribe, Rupak Desai, Markos Desalegn Desalegn, Fikadu Nugusu Dessalegn, Samuel Abebe A Dessalegni, Gashaw Dessie, Abebaw Alemayehu D esta , Syed Masudur Rahman Dewan , Samath Dhamminda Dh armaratne, Meghnath Dhimal, Mostafa Dianatinasab, Nancy Diao, Daniel Diaz, Lankamo Ena Digesa, Shilpi Gupta Dixit, Saeid Doaei, Linh Phuong Doan, Paul Narh Doku, Deepa Donbaque, Wendel Donbas, Mombawar Tim Robert Driscoll, Haneil Larson Dsouza, Oyewole Christopher Durojaiye, Sareh Edalati, Fatemeh Eghbalian, Elham Ehsani-Chimeh, Ebrahim Eini, Michael Ekholuenetale, Temitope Cyrus Ekundayo, Donatus U Ekwueme, Maha El Tantawi, El Ahmed Elbah, El Ahmed Elbah, Most , Muhammed Elhadi, Waseem El-Huneidi, Mohammad Hassan Emamian, Luchuo Engelbert Bain, Daniel Berhanie Enyew, Ryenchindorj Erkhembayar, Tegegne Eshetu, Babak Eshrati, Sharareh Eskandarieh, Juan Espinosa Montero, Farshid Taediman Eiyue, Ezzinean Taediman, Ezzinean Taediman Eyeu, Sayeh Ezzikouri, Adeniyi Francis Fagbamigbe, Saman Fahimi, Ildar Ravisovich Fakhradiyev, Emeritus Jose A Faraon, Jawad Fares, Abbas Farmany, Umar Farooque, Hossein Far rokhpour, Abidemi Omolara Fasanmi, Ali Fatehizadeh, Wafa Fatima, Hamed Fa ttahi, Ginenus Fekadu, Berhanu Elfu Feleke, Allegra Allegra Ferrari, Simone Ferrero, Lorenzo Ferro Desideri, Irina Filip, Florian Fischer, Roham Foroumadi, Masoud Foroutan, Takeshi Fukumoto Gaal, Mohamed M Gad, Muktar A Gadanya, Abduzhappar Gaipov, Nasrin Galehdar, Silvano Gallus, Tushar Garg, Mariana Gaspar Fonseca, Yosef Haile Gebremariam, Teferi Gebru Gebremeskel, Mathewos Alemu Gebremichael, Yohannes Fikadu Geda, Yibeltal Geismaw Ne Gelaete, Yibeltal Gebremariam, Melaku Getachew, Motuma Erena Getachew, Kazem Ghaffari, Mansour Ghafourifard, Seyyed-Hadi Ghamari, Mohammad Ghasemi Nour, Fariba Ghassemi, Ajnish Ghimire, Nermin Ghith, Maryam Gholamalizadeh, Jamshid Gholizadeh, Syyed-Gholizadeh, Sheri-Navashen Gilhoaq, Syyyed Paran Navashen Gilhoani Themba G Ginindza, Abraham Tamirat T Gizaw, James C Glasbey, Justyna Godos, Amit Goel, Mahaveer Golechha, Pouya Goleij, Davide Golinelli, Mohamad Golitaleb, Giusepp e Gorini, Bárbara Niegia Garcia Goulart, Giuseppe Grosso, Habtamu Alganeh Gua die, Mohammed Ibrahim Mohialdeen Gubari, Temesgen Worku Gudayu, Maximiliano Ribeiro Guerra, Damitha Asanga Gunawardane, Bhawna Gupta, Sapna Gupta, Veer Bala Gupta, Vivek, Me Kumar Gupdale, Vivek Alemu Guta, Parham Habibzadeh, Atlas Haddadi Avval, Nima Hafezi-Nejad , Adel Hajj Ali, Arvin Haj-Mirzaian, Esam S Halboub, Aram Halimi, Rabih Halwani, Randah R Hamadeh, Sajid Hameed, Samer Hamidi, Asif Hanif, Sanam Hariri, Netanya I Harlianto, Josep Maria Haro, Risky Kusuma Hartono, Ahmed I Hasaballah, S M Mahmudul Hasan, Hamidreza Hasani, Seyedeh Melika Hashemi, Abbas M Hassan, Soheil Hassanipour, Khezar Hayat, Golnaz Heidari, Mohammad Heidari, Zahraulbodi Heidary-nday Serna, Claudiu Herteliu, Kamal Hezam, Yuta Hiraike, Mbuzeleni Mbuzeleni Hlongwa, Ramesh Holla , Marianne Holm, Nobuyuki Horita, Mohammad Hoseini, Md Mahbub Hossain, Mohammad Bellal Hossain Hossain, Mohammad-Salar Hosseini, Ali Hosseinzadeh, Mehdi Hosseinzadeh, Mihaela Hostiuc, Sorin Hostiuc, Mowafa Househ, Junjie Huang, Fernando N Hugo, Ayesha Humayun, Salman Hussain, Nawfal R Hussein, Bing-Fang Hwang, Segun Emmanuel Ibitoye, Pulwasha Maria Ifkutahar, Kevin S. Stephen Ilesanmi, Irena M Ilic, Milena D Ilic, Mustapha Immurana, Kaire Innos, Pooya Iranpour, Lalu Muhammad Irham, Md Shariful Islam, Rakibul M Islam, Farhad Islami, Nahlah Elkudssiah Ismail, Gaetano Isola, Masao Iwagami, Linda Merin J, Abhishek Jaiswal, Mihajlo Jakovljevic, Mahsa Jalili, Shahram Jalilian, Elham Jamshidi, Sung-In Jang, Chinmay T Jani, Tahereh Javaheri, Umesh Umesh Jayarajah, Shubha Jayaram, Seyed Behzad Jazayeri, Rime Jebai, Bedru Jemal, Ravijeong Jemal, W, Har Ashish Jindal, Yetunde O John-Akinola, Jost B Jonas, Tamas Joo, Nitin Joseph, Farahnaz Joukar, Jacek Jerzy Jozwiak, Mikk Jürisson, Ali Kabir, Salah Eddine Oussama Kacimi, Vidya Kadashetti, Farima Kahe, Pradnya Vishal Kakodkar, Laleh Kalankesh, Leila R Kalankesh, Rohollah Kalhor, Vineet Kumar Kamal, Farin Kamangar, Ashwin Kamath, Tanuj Kanchan, Eswar Kandaswamy , Himal Kandel, HyeJ ung Kang, Girum Gebremeskel Kanno, Neeti Kapoor, Sitanshu Sekhar Kar, Shama D Karanth, Ibraheem Karaye M , Amirali Karimi, Bekalu Getnet Kassa, Patrick DMC Katoto, Joonas H Kauppila, Harkiran Kaur, Abinet Gebremickael Kebede, Leila Keikavoosi-Arani, Gemechu Gemechu Kejela, Phillip M Kemp Bohan, Maryam Keramati, Mohammad Keykhaei, Himanshu Khajurin, Abdul Khajuri, Aziz Khan Khan, Ejaz Ahmad Khan, Gulfaraz Khan, Md Nuruzzaman Khan, Moien AB Khan, Javad Khanali, Khaled Khatab, Moawiah Mohammad Khatatbeh, Mahalaqua Nazli Khatib, Maryam Khayamzadeh, Hamid Reza Khayat Kashani, Mohammad Xamin Khazei Khatabeh, Mahalaqua Nazli Khatib, Maryam Khayamzadeh, Hamid Reza Khayat Kashani, Mohammad Xamin A. Khodadost, Min Seo Kim, Yun Jin Kim, Adnan Kisa, Sezer Kisa, Miloslav Klugar , Jitka Klugarová, Ali-Asghar Kolahi, Pavel Kolkhir, Farzad Kompani, Parvaiz A Koul, Sindhura Lakshmi Koulmane Laxminarayana, Ai Koyanagi , Kewal Krishan, Yuvaraj Krishnamoorthy, Burcu Kucuk Bicer, Nuworza Kugbey, Mukhtar Kulimbet, Akshay Kumar, G Anil Kumar, Narinder Kumar, Om P Kurmi, Ambily Kuttikkattu, Carlo La Vecchia, Arista Lahiri, Dharmesh Kumar Lal, Q Judit Lám , Iván Landires, Bagher Larijani, Savita Lasrado, Jerrald Lau, Paolo Lauriola, Caterina Ledda, Sang-woong Lee, Shaun Wen Huey Lee, Wei-Chen Lee, Yeong Yeh Lee, Yo Han Lee, Samson Mideksa Legesse, James Leigh, Elvynna Leong, Ming-Chieh Li, Stephen S Lim, Gang Liu, Jue Liu, Chun-Han Lo, Ayush Lohiya, Platon D Lopukhov, László Lorenzovici, Mojgan Lotfi, Joana A Loureiro, Raimundas Lunevicius, Farzan Madadizadeh, Ahmad R Mafi, Sameh Magdeldin, Soleiman Mahjoub, Ata Mahmoodpoor, Morteza Mahmoudi, Marzieh Mahmoudimanesh, Rashidul Alam Mahumud, Azeem Majeed, Jamal Majidpoor, Alaa Makki, Konstantinos Christos Makris, Elaheh Malakan Rad, Mohammad-Reza Malekpour, Reza Malekzam Azem Malissa, Ahmadzam Malissa, Sneha Deepak Mallya, Mohammed A Mamun, Ana Laura Manda, Fariborz Mansour-Ghanaei, Borhan Mansouri, Mohamma d Ali Mansournia, Lorenzo Giovanni Mantovani, Santi Martini, Miquel Martorell, Sahar Masoudi, Seyedeh Zahra Masoumi, Clara N Matei, Elezebeth Mathews, Manu Raj Mathur, Vasundhara Mathur, Martin McK Mathur, Jitendra Kumar Meena, Khalid Mehmood, Entezar Mehrabi Nasab, Ravi Mehrotra, Addisu Melese, Walter Mendoza, Ritesh G Menezes, SIsay Derso Mengesha, Laverne G Mensah, Alexios-Fotios A Mentis, Andry Yasmid Mera Mera-Mamián, Tuomo J Mera-Mamián, Tuomo J. Mehari Woldemariam Merid , Amanual Getnet Mersha , Belsity Temesgen Meselu , Mahboobeh Meshkat , Tomislav Mestrovic , Junmei Miao Jonasson , Tomasz Miazgowski , Irmina Maria Michalek , Gelana Fekadu Worku Mijena , Ted R Miller , Shabir Ahmad Ahmad Mirmadeymad Kazem Mirmadeydham , Sermiadeymad Kazem , Sermiadeydham Mirza-Aghazadeh-Attari, Hamed Mirzaei, Hamid Reza Mirzaei, Abay Sisay Misganaw, Sanjeev Misra, Karzan Abdulmuhsin Mohammad, Esmaeil Mohammadi, Mokhtar Mohammadi, Abdollah Mohammadian-Ha fshejani , Reza Mohammadpourhodki , Arif Mohammed , Shafiu Mohammed , Syam Mohan , Mohammad Mohseni , Nagabhishek Moka , Ali H Mokdad , Alex Molassiotis , Mariam Molokhia , Kaveh Momenzadeh , Sara Momtazmanesh , Lorenzo Monasta , Fatemed Al Montasir Monasta , Fateme Utefoul Montasir Montero , Mohammad Amin Moosavi, Abdolvahab Moradi, Yousef Moradi, Mostafa Moradi Sarabi, Paula Moraga, Lidia Morawska, Shane Douglas Morrison, Jakub Morze, Abbas Mosapour, Ebrahim Mostafavi, Seyyed Meysam Mousavi, Haleh Mousavi Isfahani Khapun Khapun, Christophe Mousavi Khapun-hāmin. Kaambwa, Sumaira Mubarik, Francesk Mulita, Daniel Munblit, Sandra B Munro, Efrén Murillo-Zamora, Jonah Musa, Ashraf F Nabhan, Ahamarshan Jayaraman Nagarajan, Shankar Prasad Nagaraju, Gabriele Nagel, Mohammadreza Naghipour, Mukhammad Napas David Saimzada, Abbas Naqvi, Sreenivas Narasimha Swamy, Aparna Ichalangod Narayana, Hasan Nassereldine, Zuhair S Natto, Biswa Prakash Nayak, Rawlance Ndejjo, Sabina Onyinye Nduaguba, Wogene Wogene Negash, Seyed Aria Nejadghaderi, Kazem Nejati, Sandhya Neupane Kandel, Huy Van Nguyen Nguyen, Robina Khan Niazi, Nurulamin M Noor, Maryam Noori, Nafise Noroozi, Hasti Nouraei, Ali Nowroozi, Virginia Nuñez-Samudio, Chimezie Oputo Nguyen, Janchuzowmweg, Maryam Noori, Nafise Noroozi. Nzoputam, Bogdan Oancea, Oluwakemi Ololade Odukoya, Onome Bright Oghenetega, Ropo Ebenezer Ogunsakin, Ayodipupo Sikiru Oguntade, In-Hwan Oh, Hassan Okati-Aliabad, Akinkunmi Paul Okekunle, Andrew T Olagunju, Tinuke Babezer Ogunsakin, Isaac Okundemi, Isaac Okati-Aliabad , Akinkunmi Paul Okekunle, Andrew T. , Emad Omer, Abidemi E Emmanuel Omonisi, Sokking Ong, Obinna E Onwujekwe, Hans Orru, Stanislav S Otstavnov, Abderrahim Oulhaj, Bilcha Oumer, Oluwatomi Funbi Owopetu, Babatunji Emmanuel Oyinloye, Mahesh P A, Alicia Padudron -Mondish Rako, Alicia Padudron-Mondish, Rako Padudron Pakbin, Keyvan Pakshir, Reza Pakzad, Tamás Palicz, Adrian Pana, Anamika Pandey, Ashok Pandey, Suman Pant, S hahina Pardhan, Eun-Cheol Park, Eun-Kee Park, Seoyeon Park, Jay Patel, Siddhartha Pa ti, Rajan Paudel, Uttam Paudel, Mihaela Paun, Hamidreza Pazoki Toroudi, Minjin Peng, Jeevan Pereira, Renato B Pereira, Simone Perna, Navaraj Perumalsamy, Richard G Pestell, Raffaele Pezzani, Cristiano Piccinelli, Julian David Pillay, Zahra Zahid Piracha, Tobias Pischon, Maarten J Postma, Ashkan Pourabhari Langroudi, Akram Pourshams, Naeimeh Pourtaheri, Akila Prashant, Mirza Muhammad Fahd Qadir, Zahiruddin Quazi Syed, Mohammad Rabiee, Navid Rabiee, Amir Radfar, Raghu Anekal Rafieanan, Raghu Anekal Rafianan Rafianan, Radhakrish Rafieee, Zahiruddin Quazi Syed, Alireza Rafiei, Nasiru Raheem, Fakher Rahim, Md Obaidur Rahman, Mosiur Rahman, Muhammad Aziz Rahman, Amir Masoud Rahmani, Shayan Rahmani , Vahid Rahmanian , Nazanin Rajai , Aashish Rajesh , Pradhum Ram , Kiana Ramezanzadeh , Kamal Ranwela Ranabhaas , Kamal Ranwela Ranabhaas , Chythra R Rao, Sowmya J Rao, Sina Rashedi, Amirfarzan Rashidi, Mahs a Rashidi, Mohammad-Mahdi Rashidi, Zubair Ahmed Ratan, David Laith Rawaf, Salman Rawaf, Lal Rawal, Reza Rawassizadeh, Mohammad Sadegh Razeghinia , Ashfaq Ur Rehman , Inayat ur Rehman , Marissa B Reitsma , Andre M N Renzaho , Maryam Rezaei , Nazila Rezaei , Negar Rezaei , Nima Rezaei , Saeid Rezaei , Mohsen Rezaeian , Aziz Rezapour , Maria Riozakh Riad – Rezaei , Maria Riozakh Riad , Rezaei Blancas, Thomas J Roberts, Peter Rohloff, Esperanza Romero-Rodríguez, Gholamreza Roshandel, Godfrey M Rwegerera, Manjula S , Maha Mohamed Saber-Ayad, Bahar Saberzadeh-Ardestani, Siamak Sabour, Basema Saddik, Erfan Sadeghi, Mohammad Umar Saeb Saeb, , Mohsen Safaei, Azam Safary, Maryam Sahebazzamani, Amirhossein Sahebkar, Harihar Sahoo, Mirza Rizwan Sajid, Hedayat Salari, Sana Salehi, Marwa Rashad Salem, Hamideh Salimzadeh, Yoseph Leonardo Samodra, Abdallah M Samy, Senth, Francesco Sanabmar Sankara, Juan Sanabmar Milena M Santric-Milicevic, Muhammad Arif Nadeem Saqib, Arash Sarveazad, Fatemeh Sarvi, Br ijesh Sathian, Maheswar Satpathy, Nicolas Sayegh, Ione Jayce Ceola Schneider, Michaël Schwarzinger, Mario Šekerija, Subramani an Senthilkumaran, Sadaf G Sepanlou, Allen Seylani, Kenbon Seyoum, Feng Sha, Omid Shafaat, Pritik A Shah, Saeed Shahabi, Izza Shahid, Mohammad Amin Shahrbaf, Hamid R Shahsavari, Masood Ali Shaikh, Mohammed Feyisso Shaka, Elahemed Shaker, Elahemed Shaker, , Mequannent Melaku Sharew Sharew, Azam Sharifi, Javad Sharifi-Rad, Purva Sharma, Bereket Beyene Shashamo, Aziz Sheikh, Mahdi Sheikh, Sara Sheikhbahai, Rahim Ali Sheikhi, Ali Sheikhy, Peter Robin Shepherd, Adithi Shetty, Jeevan K Shetty, Ranjitha Shetty, Kenji Shibuya, Reza Shirkoohi, Hesamaddin Shirzad-Aski, K M Shivakumar, Siddharudha Shivalli, Velizar Shivarov, Parnian Shobeiri, Zahra Shokri Varniab, Seyed Afshin Shorofi, Sunil Shrestha, Migbar Mekonnen Sibhat, Sibhat Siddep, Sibhat, Sibhat, Sibhat, Sibhat, Sibhat, Sibhat, Sibhat, Sibhat, Sibhat. Augusto Santos Silva, Luís Manuel Lopes Rodrigues Silva, Guilherme Silva Julian, Nicola Silvestris, Wudneh Simegn, Achintya Dinesh Singh, Ambrish Singh, Garima Singh, Harpreet Singh, Jasvinder A Singh, Jitendra Kuma r Singh, Paramdeep Singh, Surjit Singh, Dhirendra Narain Sinha, Abiy H Sinke, Md Shahjahan Siraj, Freddy Sitas, Samarjeet Singh Siwal, Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, Bogdan Socea, Matthew J Soeberg, Ahmad Sofi-Matan Solomon, Yonatan , Mohammad Sadegh Soltani-Zangbar, Suhang Song, Yimeng Song, Reed J D Sorensen, Sergey Soshnikov, Houman Sotoudeh, Alieu Sowe, Mu’awiyyah Babale Sufiyan, Ryan Suk, Muhammad Suleman, Rizwan Suliankatchi Abdulkader, Saimaska ​​Sultanaklós, Daniel Surzóc , Seidamir Pasha Tabaeian, Rafael Tabarés-Seisdedos, Seyyed Mohammad Tabatabaei, Takahiro Tabuchi, Hooman Tadbiri, Ensiyeh Taheri, Majid Taheri, Muslem Taheri Soodejani, Ken Takahashi, Iman M Talaat, Ker YK Tampa, Mircea Tampa, Vivi, Y Tat, Ahmad Tavakoli, Arash Tavakoli , Arash Tehrani-Banihashemi, Yohannes Tekalegn, Fisa ha Haile Tesfay, Rekha Thapar, Aravind Thavamani, Viveksandeep Thoguluva Chandrasekar, Nihal Thomas, Nikhil Kenny Thomas, Jansje Henny Vera Ticoalu, Amir Tiyuri, Daniel Nigusse Tollosa, Roman Topor-Madry, Mathilde Touvier, Marcos Roberto Tovani-Palone, Eugenio Traini, Mai Thi Ngoc Tran, Jaya Prasad Tripathy, Gebresilasea Gendisha Ukke, Irfan Ullah, Saif Ullah, Sana Ullaskaran Unnikrish, Bíblish , Marco Vacante, Maryam Vaezi, Sahel Valadan Tahbaz, Pascual R Valdez, Constantine Vardavas, Shoban Babu Varthya, Siavash Vaziri, Diana Zuleika Velazquez, Massimiliano Veroux, Paul J Villeneuve, Francesco S Violante, Sergey Konstantinovitch Vladimirov, Vasily Vlassov, Bay Vo, Linh Gia Vu, Abdul Wadood Wadood, Yasir Waheed, Mandaras Tariku Walde, Richard G Wamai, Cong Wang, Fang Wang, Ning Wang, Yu Wang, Paul Ward, Abdul Waris, Ronny Westerman, Nuwan Darshana Wickramasinghe, Melat Woldemariam, Berhanu Woldu, Hong Xiao, Suowen Xu, Xiaoyue Xu, Lalit Yadav, Seyed Hossein Yahyazadeh Jabbari, Lin Yang . Zareshahrabadi, Armin Zarrintan, Mikhail Sergeevich Zastrozhin, Mohammad A Zeineddine, Dongyu Zhang, Jianquarong, Zhang Yunquarong Zhi-Jiang Zhang, Linghui Zhou, Sanjay Zodpey, Mohammad Zoladl, Theo Vos, Simon I Hay, Lisa M Force

Department of Molecular Medicine and Pathology (K B Tran MD, C M Buchanan PhD, Prof P R Shepherd PhD), University of Auckland, Auckland, New Zealand; Department of Clinical Hematology and Toxicology (K B Tran MD), Maurice Wilkins Centre, Auckland, New Zealand; Center for Surveillance and Applied Research (J J Lang PhD), Public Health Agency of Canada, Ottawa, ON, Canada; Institute for Health Metrics and Evaluation (K Compton BS, R Xu BS, A R Acheson BA, J M Kocarnik PhD, L Penberthy MS, J A Anderson BS, Prof M Brauer DSc, A J Cohen DSc, G T Culbreth PhD, X Dai PhD, Prof L Dandona MD, Prof R Dandona PhD, Prof S D Dharmaratne MD, H J Henrikson BA, K S Ikuta MD, Prof S S Lim PhD, T Mestrovic PhD, A H Mokdad PhD, H Nassereldine MD, M B Reitsma BS, R J D Sorensen PhD, Prof T Vos PhD , Prof S I Hay FMedSci, L M Force MD, Prof C J L Murray DPhil), Department of Health Metrics Sciences, School of Medicine (X Dai PhD, Prof R Dandona PhD, Prof S D Dharmaratne MD, Prof S S Lim PhD, A H Mokdad PhD, Prof T Vos PhD, Prof S I Hay FMedSci, L M Force MD, Prof C J L Murray DPhil), Division of Allergy and Infectious Diseases (K S Ikuta MD), Division of Plastic and Reconstructive Surgery (SD Morrison MD), Department of Global Health (R J D Sorensen) . PhD), Division of Pediatric Hematology-Oncology (L M Force MD), University of Washington, Seattle, WA, USA; Health Informatics Lab (T Javaheri PhD), Department of Computer Science (R Rawassizadeh PhD), Boston University, Boston, MA, USA; Department of Medicine (H J Henrikson BA), Brigham and Women’s Hospital, Boston, MA, USA; Faculty of Medicine (A Aali MD), Education Development Center (R Assadi PhD), E-Learning Center (M Ghasemi Nour MD), School of Medicine (A Haddadi Avval), Department of Nursing (R Mohammadpourhodki PhD), Applied Biomedical Research Center (A Sahebkar PhD), Biotechnology Research Center (A Sahebkar PhD), Department of Medical Informatics (S Tabatabaei PhD), Clinical Research Development Unit (S Tabatabaei PhD), Mashhad Un University of Medical Sciences, Mashhad, Iran (M Keramati MD); Health Policy Research Center (Aali MD, S Shahabi PhD), Health Information Management (A Bashiri PhD), Department of Epidemiology (M Dianatinasab MSc), Research Center for Health Sciences (P Habibzadeh MD, M Hoseini PhD), Department of Environmental Health (M Hoseini PhD) , Department of Radiology (P Iranpour MD), Non-communicable Disease Research Center (Prof R Malekzadeh MD, S G Sepanlou MD), Department of Medical Mycology and Parasitology (H Nouraei MSc, Prof K Pakshir PhD, Z Zareshahrabadi PhD), Shiraz University of Medical Sciences , Shiraz, Iran; Department of Biology (Q Abbas PhD), University of Bahrain, Manama, Bahrain; Uro-Oncology Research Center (B Abbasi MD), Non-communicable Disease Research Center (Z Abbasi-Kangevari BSc, A Aryannejad MD, S Azadnajafabad MD, M Azangou-Khyavy MD, S Ghamari MD, J Khanali MD, M Keykhaei MD, M Malekpour MD, S Momtazmanesh MD, F Montazeri MD, A Pourabhari Langroudi MD, S Rahmani MD, M Rashidi MD, N Rezaei MD, N Rezaei PhD, Z Shokri Varniab MD), Advanced Diagnostic and Interventional Radiology Research Center (H Abbastabar PhD) ) , Research Center for Immunodeficiencies (H Abolhassani PhD, Prof N Rezaei PhD), Department of Epidemiology and Biostatistics (Y Alimohamadi PhD, H Azizi PhD, M Mansournia PhD), Universal Scientific Education and Research Network (USERN) (M Amirzade-Iranaq) DDS ), Digestive Diseases Research Institute (A Anoushiravani MD, S Fahimi MD, xiri MD, Prof R Malekzadeh MD, S Masoudi MSc, Prof A Pourshams MD, H Salimzadeh PhD, S G Sepanlou MD, M Sheikh PhD), Experimental Medicine Research Center ( A Aryannejad MD), Department of Health Policy, Management, and Economics (A Bakhtiari PhD), National Institute for Health Research (E Ehsani-Chimeh PhD), Multiple Sclerosis Research Center (S Eskandarieh PhD), Department of Pathology (A Etemadimanesh MD), School of Medicine (H Farrokhpour MD, N Hafezi). -Nejad MD, S Hashemi MD, A Karimi MD, S Momtazmanesh MD, A N owroozi BMedSc), Endocrinology and Metabolism Research Institute (R Foroumadi MD, Prof B Larijani FACE , N Rezaei PhD), Department of Surgery (R Foroumadi MD), Ophthalmology Department (Prof F Ghassemi MD), Digestive Oncology Research Center (Prof F Kamangar) MD), Students’ Scientific Research Center (SSRC) (M Keykhaei MD) , Children’s Medical Center (F Kompani MD), Department of Pediatrics and Pediatric Cardiology (Prof E Malakan Rad MD), Tehran Heart Center (E Mehrabi Nasab MD), Department of Medical Immunology (H Mirzaei PhD), Faculty of Medicine (E Mohammadi MD , E Shaker MD, P Shobeiri MD), Department of Pharmacology (N Noroozi DVM, M Zahir MD), Metabolomics and Genomics Research Center (F Rahim PhD), Department of Cardiology (S Rashedi MD), Department of Gastroenterology (B Saberzadeh- Ardestani MD), Cancer Research Center (R Shirkoohi PhD), Cancer Biology Research Center (R Shirkoohi PhD), Department of Pediatric Allergy and Immunology (F Yazdanpanah MD) ), Department of Environmental Health (F Yousefian PhD), Tehran University of Medical Sciences, Tehran, Iran; Reproductive Biomedical Research Center (B Abbasi MD), Royan Institution, Isfahan, Iran; Social Determinants of Health Research Center (M Abbasi-Kangevari MD, Z Abbasi-Kangevari BSc, M Azangou-Khyavy MD, S Ghamari MD, J Khanali MD, A Kolahi MD, M Rashidi MD), School of Advanced Technologies in Medicine (S ) Ahmadi PhD), Department of Pharmacology (A Babajani MD, A Haj-Mirzaian MD, K Ramezanzadeh PharmD), Department of Community Nutrition (S Doaei PhD, S Edalati PhD), Cancer Research Center (M Gholamalizadeh PhD), Obesity Research Center ( A Haj-Mirzaian MD), Research Institute for Endocrine Sciences (A Halimi BSc), Functional Neurosurgery Research Center (E Jamshidi PharmD), Department of Neurosurgery (H Khayat Kashani MD), Department of Health & Community Medicine (A Kolahi MD), Department of Clinical Oncology (A R Mafi MD), School of Medicine (F Montazeri MD, S Nejadghaderi MD, M Zangiabadian MD), Stud ent Research Committee (S Rahmani MD), Department of Epidemiology (S Sabour PhD), Faculty of Medicine (M Shahrbaf MD), Medical Ethics and Legal Research ntro (M Taheri PhD), Shahid Beheshti University of Medical Sciences, Tehran, Iran (M Khayamzadeh MD); Department of Surgery (M Abdelmasseh MD, Prof J Sanabria MD), Marshall University, Huntington, WV, USA; Tropical Medicine Department (S Abd-Elsalam PhD), Tanta University, Tanta, Egypt; Department of Internal Medicine (A A Abdelwahab MD), Baylor College of Medicine, Houston, TX, USA; Department of Epidemiology (G Abdoli PhD), Social Development and Health Promotion Research Center (M Khezeli PhD), Substance Abuse Prevention Research Center (B Mansouri PhD), Advanced Dental Sciences Research Center (M Safaei PhD), Department of Infectious Disease (Prof .S Vaziri MD), Kermanshah University of Medical Sciences, Kermanshah, Iran; Department of Public Health (H A Abdulkadir MPH, Y H Gebremariam MPH), Department of Biomedical Science (Y D Abtew MSc, B B A Bodicha MSc), Department of Medical Laboratory Sciences (A Aklilu MSc), School of Nursing (TM Ayana MSc), Department of Medical Anatomy (A B Bekele MSc), Department of Nursing (B Demisse MSc, B B Shashamo MSc), Department of Midwifery (F W Demisse MSc, S A A Dessalegni MSc, B Oumer MPH, G G Ukke MSc), Department of Comprehensive Nursing (L E Digesa MSc). ), Department of Epidemiology and Biostatistics (MA Gebremichael MPH), School of Public Health (M K Gurara MPH, N B Sidemo MPH), Department of Anatomy (A G Kebede MA), Department of Medical Laboratory Science (M Woldemariam MSc), Arba Minch University , Arba Minch, Ethiopia; Department of Neurosurgery (A Abedi MD), Keck School of Medicine (A Abedi MD), Mark and Mary Stevens Neuroimaging and Informatics Institute (S Salehi MD), University of Southern California, Los Angeles, CA, USA; Department of Biostatistics (K H Abegaz MSc), Near East University, Nicosia, Cyprus; Department of Biostatistics and Health Informatics (K H Ab egaz MSc), Department of Public Health (Y Tekalegn MPH), Madda Walabu University, Bale Robe, Ethiopia; Laboratory Technology Sciences Department (H Abidi PhD), Department of Nursing (M Zoladl PhD), Yasu j University of Medical Sciences, Yasuj, Iran; Department of Family and Community Health (R G Aboagye MPH), Institute of Health Research (R K Alhassan PhD, M Immurana PhD), Department of Population and Behavioral Sciences (H Amu PhD), University of Health and Allied Sciences, Ho, Ghana; Department of Biosciences and Nutrition (H Abolhassani PhD), Karolinska University Hospital, Huddinge, Sweden; Medical Laboratory Sciences (A Absalan PhD), Department of Laboratory Sciences (K Ghaffari MSc), Khomein University of Medical Sciences, Khomein, Iran; Research and Development (A Absalan PhD), Satras Biotechnology Company, Tehran, Iran; University of Human Development (Prof H Abubaker Ali PhD), Department of Information Technology (A M Darwesh PhD), Department of Computer Science (M Hosseinzadeh PhD), University of Human Development, Sulaymaniyah, Iraq; Clinical Sciences Department (E Abu-Gharbieh PhD, Prof R Halwani PhD, Prof I M Talaat PhD), Department of Basic Medical Sciences (W El-Huneidi PhD), College of Medicine (Prof R Halwani PhD), Mass Communication Department (A Makki PhD), Department of Clinical Sciences (M M Saber-Ayad MD), Sharjah Institute for Medical Research (B Saddik PhD), University of Sharjah, Sharjah, United Arab Emirates; Department of Internal Medicine (B Achappa MD, A Boloor MD), Department of Forensic Medicine and Toxicology (H L Dsouza MD), Department of Community Medicine (N Joseph MD, R Thapar MD), Department of Obstetrics and Gynecology (A Shetty MS), Kasturba Medical College (Prof B Unnikrishnan MD), Manipal Academy of Higher Education, Mangalore, India; Department of Epidemiology and Population Health (Prof J M Acuna MD, A Oulhaj PhD), Khalifa University, Abu Dhabi, United Arab Emirates; Robert Stempel College of Public Health & Social Work k (Prof J M Acuna MD), Department of Epidemiology (R Jebai MPH), Florida International University, Miami, FL, USA; Department of Internal Medicine (D Addison MD), Ohio State University, Columbus, OH, USA; Center for Social Research in Health (I Y Addo PhD), C center for Primary Health Care and Equity (CPHCE) (F Sitas PhD), School of Population Health (X Xu PhD), University of New South Wales, Sydney, NSW, Australia; Quality and Systems Performance Unit (I Y Addo PhD), Cancer Institute NSW, Sydney, NSW, Australia; Public Health and Tropical Medicine (O A Adegboye PhD), James Cook University, Towsville, QLD, Australia; Slum and Rural Health Initiative Research Academy (M A Adesina BS, I I Olufadewa MHS), Slum and Rural Health Initiative, Ibadan, Nigeria; Department of Physiotherapy (M A Adesina BS), Department of Epidemiology and Medical Statistics (M Ekholuenetale MSc, A F Fagbamigbe PhD), Faculty of Public Health (M Ekholuenetale MSc, I I Olufadewa MHS), Department of Health Promotion and Education (S E Ibitoye MPH, Y O John-Akinola PhD), Department of Community Medicine (O S Ilesanmi PhD), Department of Obstetrics and Gynecology (O B Oghenetega MSc), College of Medicine (A P Okekunle PhD), University of Ibadan, Ibadan, Nigeria; Department of Neonatology (M Adnan MD), Indiana University Health Ball Memorial Hospital, Muncie, IN, USA; Faculty of Medicine (Q E S Adnani PhD), Universitas Padjadjaran (Padjadjaran University), Bandung, Indonesia; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, USA (S M Advani PhD); School of Medicine (S M Advani PhD), Department of Oncology (D Zhang PhD), Georgetown University, Washington, USA; Department of Conservative Dentistry (S Afrin DDS), Department of Population Sciences (Prof M B H Hossain PhD), University of Dhaka, Dhaka, Bangladesh; Department of Life Sciences (M S Afzal PhD, I Ullah PhD), School of Sciences (M N Saqib PhD), University of Management and Technology, Lahore, Pakistan; Department of Internal Medicine cine (M Aggarwal MD, M Alkhayyat MD, A D Singh MD), Department of Cardiovascular Medicine (M M Gad MD), Heart, Vascular, Thoracic Institute (A Hajj Ali MD), Cleveland Clinic, Cleveland, OH, USA ; The Australian Center for Public and Population Health Research (ACPPHR) (B O Ahinkorah MPH, E K Am eyaw MPhil), University of Technology Sydney, Sydney, NSW, Australia; College of Nursing (A R Ahmad PhD), International Relations & Diplomacy, Ranya, Iraq; International Relations & Diplomacy (A R Ahmad PhD), School of Pharmacy (B A Ali PhD), Tishk International University, Erbil, Iraq; Department of Natural Products and Alternative Medicine (R Ahmad PhD), Health Information Management and Technology Department (TM Alanzi PhD), Environmental Health Department (S M A Dahlawi PhD), Forensic Medicine Division (Prof R G Menezes MD), Imam Abdulrahman Bin Faisal University, Dammam, Saud -Arabia (F M Alanezi PhD); Department of Health and Biological Sciences (S Ahmad PhD), Abasyn University, Peshawar, Pakistan; Faculty of Pharmacy (S Ahmad MSc), MAHSA University, Kuala Langat, Malaysia; Department of Biosciences (H Ahmed PhD), COMSATS Institute of Information Technology, Islamabad, Pakistan; Institute of Public Health (L A Ahmed PhD, A S Bhagavathula PharmD, I Elbarazi DrPH), Department of Medical Microbiology & Immunology (Prof G Khan PhD), Family Medicine Department (M A Khan MSc), Computer Science and Software Engineering Big Data Analytics Center (Prof N Zaki PhD), United Arab Emirates University, Al Ain, United Arab Emirates; Department of Epidemiology (M B Ahmed MPH), Department of Biomedical Sciences (D Dereje MSc), Department of Public Health (M E Getachew MPH), Department of Health, Behavior and Society (AT T Gizaw MPH), Jimma University, Jimma, Ethiopia; Australian Center for Precision Health (M B Ahmed MPH), University of South Australia, Adelaide, SA, Australia; Department of Computer Science and Engineering (T Ahmed Rashid PhD), University of Kurdistan Hewle r, Erbil, Iraq; Department of Neurology (W Aiman ​​MD), Nishtar Medical University, Multan, Pakistan; Department of Food and Nutrition Policy and Planning Research (M Ajami PhD), National Institute of Nutrition, Tehran, Iran; National Nutrition and Food Technology Research Institute (M Ajami PhD), Shahid Beheshti University of Medical Sciences, Iran; Department of Microbial iology, Immunology and Parasitology (G T Akalu MSc), St Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia; Microbial, Cellular and Molecular Biology Department (G T Akalu MSc), Department of Surgery (A F Awedew MD), Immunology Research Center (A Derakhshani MSc), Department of Preventive Medicine (K S Deribe MPH), Department of Anatomy (A G Kebede MA), Medical Laboratory Sciences (AS Misganaw MSc), Microbial cellular and molecular biology (AS Misganaw MSc), Addis Ababa University, Addis Ababa, Ethiopia; Liver and Gastrointestinal Diseases Research Center (M Akbarzadeh-Khiavi PhD), Road Traffic Injury Research Center (Prof M Asghari-Jafarabadi PhD, E Davtalab Esmaeili PhD), Department of Health Policy & Administration (S Azami-Aghdash PhD), Research Center of Psychiatry and Behavioral Sciences (H Azizi PhD), Department of Medical Surgical Nursing (M Ghafourifard PhD, M Lotfi PhD), Student Research Committee (M Hosseini MD), School of Management and Medical Informatics (L R Kalankesh PhD), Medical Education Research Center (M Lotfi PhD), Anesthesiology and Critical Care (Prof A Mahmoodpoor ​​MD), Liver and Gastrointestinal Disease Research Center (S Mirinezhad PhD), Department of Radiology (M Mirza-Aghazadeh- ). Attari MD, A Zarrintan MD), Connective Tissue Diseases Research Center (A Safary PhD), Department of Immunology (M Soltani-Zangbar MSc), Alzahra Teaching Hospital (M Vaezi MD), Women’s Reproductive Health Research Center (M Vaezi MD) , Department of Pediatric Allergy and Immunology (F Yazdanpanah MD), Tabriz University of Medical Sciences, Tabriz, Iran; Department of Epidemiology and B iostatistics (M Akonde MLS), Department of Clinical Pharmacy and Outcomes Sciences (I Yunusa PhD), University of South Carolina, Columbia, SC, USA; Department of Public Health (C J Akunna DMD), The International Center for Oral Health (ICOH) for Africa, Jos, Nigeria; Department of Public Health (C J Akunna DMD), Federal Ministry of Health, Garki, Nigeria; Geriatric and Long Term Care Department (H Al Hamad MD, B Sathian PhD ), Rumailah Hospital (H Al Hamad MD), Hamad Medical Corporation, Doha, Qatar; Mayo Evidence-based Practice Center (F Alahdab MSc), Mayo Clinic Foundation for Medical Education and Research, Rochester, MN, USA; Department of Public Health (SA Alessy PhD), Saudi Electronic University, Riyadh, Saudi Arabia; Center for Cancer, Society & Public Health (S A Alessy PhD), Faculty of Dentistry, Oral & Craniofacial Sciences (E Bernabe PhD), Faculty of Life Sciences and Medicine (M Molokhia PhD), King’s College London, London, UK; Department of Bacteriology, Immunology, and Mycology (Prof A M Algammal PhD), Department of Physiology (Prof S Magdeldin PhD), Suez Canal University, Ismailia, Egypt; Department of Health Services and Hospital Administration (M K Al-Hanawi PhD), Health Economics Research Group (M K Al-Hanawi PhD), Department of Community Medicine (RM Al-Raddadi PhD), Department of Family and Community Medicine (N S Butt PhD), Rabigh Faculty of Medicine (A A Malik PhD), Department of Dental Public Health (Z S Natto DrPH), King Abdulaziz University, Jeddah, Saudi Arabia; Erbil Technical Health College (B A Ali PhD), Erbil Polytechnic University, Erbil, Iraq; Department of Biological Sciences (L Ali PhD), National University of Medical Sciences (NUMS), Rawalpindi, Pakistan; Center for Biotechnology and Microbiology (S S Ali PhD), University of Swat, Swat, Pakistan; Pars Advanced and Minimally Invasive Medical Manners Research Center (Y Alimohamadi PhD), Health Management and Economics Research Center (V Alipour PhD, J Arabloo PhD, A Rezapour PhD), Department of Health Economics (V Alipour PhD), Department of Internal Medicine (A Anoushirvani MD, S Tabaeian MD), Preventive Medicine and Public Health Research Center (B Eshrati PhD, A Tehrani-Banihashemi PhD), Minimally Invasive Surgery Research Center (A Kabir MD), Department of Health Care Management (H Mousavi Isfahani PhD), Student Research Committee (M Noori MD), Department of Physiology (H Pazoki Toroudi PhD), Physiology Research Center (H Pazoki Toroudi P hD), The Five Senses Health Institute (S Rezaei MD), Colorectal Research Center (A Sarveazad PhD), Trauma and Injury Research Center (M Taheri PhD), Pediatric Infectious Diseases Research Center (A Tavakoli PhD), Department of Medical Virology (A Tavakoli PhD), Department of Community and Family Medicine (A Tehrani-Banihashemi PhD), Department of Epidemiology and Biostatistics (A Tiyuri MSc), Iran University of Medical Sciences, Tehran, Iran; Department of Health Policy and Management (Prof S M Aljunid PhD), Department of Surgery (S K Al-Sabah MD), Department of Microbiology (H Altawalah FRCPath), Kuwait University, Kuwait, Kuwait; International Center for Casemix and Clinical Coding (Prof S M Aljunid PhD), National University of Malaysia, Bandar Tun Razak, Malaysia; College of Dental Medicine (S A A Al-Maweri PhD), Qatar University, Doha, Qatar; Faculty of Dentistry (S A A Al-Maweri PhD), Sana’a University, Sanaa, Yemen; College of Medicine (S Almustanyir MD), Alfaisal University, Riyadh, Saudi Arabia; Ministry of Health, Riyadh, Saudi Arabia (S Almustanyir MD); Department of Surgery (N Alonso MD), University of São Paulo, São Paulo, Brazil; Department of Internal Medicine (S Alqalyoobi MD), East Carolina University, Greenville, NC, USA; Independent Consultant, Greenville, NC, USA (S Alqalyoobi MD); Institute of Public Health (RH Al-Rifai PhD), United Arab Emirates University, Abu Dhabi, United Arab Emirates; Jaber Al Ahmad Al Sabah Hospital (S K Al-Sabah MD), Clinical Virology Unit (H A ltawalah FRCPath), Ministry of Health of Kuwait, Kuwait, Kuwait; Department of Family and Occupational Medicine (A Al-Tammemi MPH), University of Debrecen, Debrecen, Hungary; Research Group in Hospital Management and Health Policies (Prof N Alvis-Guzman PhD), Universidad de la Costa (University of the Coast), Barranquilla, Colombia; Health Economics Research Group (Prof. N Alvis-Guzman PhD), University of Cartagena, Cartagena, Colombia; School of Pharmacy (F Amare MSc), Department of Saninform adic (DB Enyew MSc), Department of Emergency and Critical Care Medicine (M Getachew MD), Department of Mental Health and Psychiatry (M T Walde MSc), Haramaya University, Harar, Ethiopia ; Applied Science and Technology (J J Aminian Dehkordi PhD), University of California Berkeley, Berkeley, CA, USA; Department of Chemical Engineering (J J Aminian Dehkordi PhD), Department of Parasitology (S Bahadory PhD), Department of Clinical Biochemistry (A Mosapour PhD), Tarbiat Modares University, Tehran, Iran; Department of Medicine (G A Amusa MD), Department of Obstetrics and Gynecology (J Musa MD), University of Jos, Jos, Nigeria; Department of Internal Medicine (G A Amusa MD), Jos University Teaching Hospital, Jos, Nigeria; Pharmacy Department (Prof R Ancuceanu PhD), Department of General Surgery (D V Davitoiu PhD, A Manda MD, B Socea PhD), Internal Medicine Department (M Hostiuc PhD), Department of Legal Medicine and Bioethics (S Hostiuc PhD), Department of Dermatology (C N Matei PhD, M Tampa PhD), Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Epidemiology and Biostatistics (Y A Animut MPH, Y Yeshaw MPH), Department of Health Education and Behavioral Sciences (H E Birhan MPH), Department of Biochemistry (M Derbew Molla MSc), Biochemistry Department (G Dessie MSc), Department of Surgical Nursing (A Desta MSc), Department of Medical Parasitology (T Eshetu MSc), Department of Human Physiology (Y Gela MSc), Department of Clinical Midwifery (T W Gudayu MPH), School of Medicine (A G Mersha MD), Institute of Public Health (M M S Sharew MPH ), Social and Administrative Pharmacy (W Simegn MSc), Department of Hematology and Immunohematology (B Woldu MSc), University of Gondar, Gondar, Ethiopia; Department of Epidemiology and Biostatistics (Prof A Ansari-Moghaddam PhD), Health Promotion Research Center (H Okati-Aliabad PhD), Zahedan University of Medical Sciences, Zahedan, Iran; Department of Public Health (M G Ansha MPH, A H Bilchut PhD), Debre Berhan University, Debre Berhan, Ethiopia; Menzies Institute for Medical Research (B Antony PhD, A Singh MTech), University of Tasmania, Hobart, TAS, Australia; Department of Medical Laboratory Science (M Antwi MPhil), Koforidua Technical University, Koforidua, Ghana; Department of Surgery (S Anwar PhD), Gadjah Mada University, Jogjakarta, Indonesia; Department of Pathology (R Anwer PhD), Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia; School of Community Health (A E Anyasodor PhD), Charles Sturt University, Orange, NSW, Australia; Social Determinants of Health Research Center (M Arab-Zozani PhD), Medical Toxicology & Drug Abuse Research Center (M Rezaei MD), Department of Epidemiology and Biostatistics (A Tiyuri MSc), Birjand University of Medical Sciences, Birjand, Iran; Department of Public Health (O Aremu PhD), Birmingham City University, Birmingham, UK; Clinical Pharmacy (A M Argaw MSc), Department of Nursing (W W Negash MSc), Madda Walabu University, Goba, Ethiopia; Department of Paediatrics (Prof H Ariffin MD), University of Malaya Medical Center (Prof H Ariffin MD), University of Malaya, Kuala Lumpur, Malaysia; Department of Public Health and Healthcare Management (T Aripov PhD), Tashkent Institute of Postgraduate Medical Education, Tashkent, Uzbekistan; Boston Children’s Hospital, Boston, MA, USA (T Aripov PhD); Center of Biotechnology and Microbiology (M Arshad PhD), University of Peshawar, Peshawar, Pakistan; Department of Health Sciences (A Artaman PhD), Zayed University, Dubai, United Arab Emirates; Department of Maternal and Child Health (J Arulappan DSc), Sultan Qaboos University, Muscat, Oman; Molecular and Cell Biology (R T Aruleba MSc), University of Cape Town, Cape Town, South Africa; Department of Plastic Surgery (M Asaad MD, A M Hassan MD), Health Sciences Center (D Dongarwar MS), Department of GI Medical Oncology (M A Zeineddine MD), University of Texas, Houston, TX, USA; School of Public Health (M A Asemahagn PhD), Department of Medical Laboratory Sciences (T Awoke MSc, A Melese MSc), School of Health Science (A Y Berhie MSc), Department of Epidemiology and Biostatistics (B E Felek e MPH), Department of Health Informatics (H A Guadie MPH), Department of Pharmacology (Y Yismaw MSc), Bahir Dar University, Bahir Dar, Ethiopia; Research Center for Biochemistry and Nutrition in Metabolic Diseases (Z Asemi PhD, H Mirzaei PhD), Department of Environmental Health (F Yousefian PhD), Kashan University of Medical Sciences, Kashan, Iran; Cabrini Research (Prof M Asghari-Jafarabadi PhD), Cabrini Institute, Melbourne, VIC, Australia; University Institute of Radiological Sciences and Medical Imaging Technology (T Ashraf MS), Department of Public Health (W Fatima PhD), Faculty of Allied Health Sciences (Prof S Gilani PhD), University Institute of Public Health (S Hameed MPH, A Hanif PhD) . , A Malik PhD), The University of Lahore, Lahore, Pakistan; Department of Medical Genetics (M Athar PhD), Science and Technology Unit (M Athar PhD), Umm Al-Qura University, Makkah, Saudi Arabia; Department of Immunology (S Athari PhD), Zanjan University of Medical Sciences, Zanjan, Iran; Faculty of Nursing (M M W Atout PhD, Prof A M Batiha PhD), Philadelphia University, Amman, Jordan; Department of Oral and Maxillofacial Surgery (S Attia MSc), Justus Liebig University of Giessen, Giessen, Germany; Northumbria HealthCare NHS Foundation Trust (A Aujayeb MBBS), National Health Service (NHS) Scotland, Newcastle-upon-Tyne, UK; S School of Business (Prof M Ausloos PhD), University of Leicester, Leicester, UK; Department of Statistics and Econometrics (Prof M Ausloos PhD, Prof C Herteliu PhD, A Pana MD), Bucharest University of Economic Studies, Bucharest, Romania; Center for Health Systems Research (L Avila-Burgos ScD), Center for Nutrition and Health Research (E Denova-Gutiérrez DSc), Center for Health System Research (M Rios-Blancas MPH), National Institute of Public Health, Cuernavaca, Mexico; Department of Epidemiology and Preventive Medicine (M A Awoke MPH), Department of General Practice (J Zhang MD), University of Melbourne, Melbourne, VIC, Australia; The Judith Lumley Center (B Ayala Quintanilla PhD), School of Nursing and Midwif ery (M Rahman PhD), La Trobe University, Melbourne, VIC, Australia; San Martin de Porres University, Lima, Peru (B Ayala Quintanilla PhD); Department of Midwifery (S S Ayen MSc, Y F Geda MSc), Wolkite University, Wolkite, Ethiopia; Department of Laboratory Sciences (D Azadi PhD), Arak University of Medical Sciences, Khomein, Iran; Department of Public Health (M M Azanaw MPH, F T Dagnaw MPH), Medical Laboratory Sciences (T Eyayu MSc), Department of Midwifery (B G Kassa MSc), Debre Tabor University, Debre Tabor, Ethiopia; School of Medicine (A Azari Jafari MD, S Mirmoeeni MD), Ophthalmic Epidemiology Research Center (M Emamian PhD), Department of Epidemiology (A Hosseinzadeh DrPH), Shahroud University of Medical Sciences, Shahroud, Iran (F Zare MSc); Department of Neurovascular Research (A Y Azzam MD), Nested Knowledge, Saint Paul, MN, USA; Faculty of Medicine (A Y Azzam MD), October 6 University, October 6 City, Egypt; Gomal Center of Biochemistry and Biotechnology (M Badar PhD), Gomal University, Dera Ismail Khan, Pakistan; Department of Forensic Science (AD Badiye MSc, N Kapoor MSc), Government Institute of Forensic Science, Nagpur, India; Department of Nursing (N Baghcheghi PhD), Saveh University of Medical Sciences, saveh, Iran; Basic Health Sciences Institute (N Bagheri PhD), Community-Oriented Nursing Midwifery Research Center (M Heidari PhD), Department of Epidemiology and Biostatistics (A Mohammadian-Hafshejani PhD), Shahrekord University of Medical Sciences, Shahrekord, Iran; School of Medicine (S Bagherieh BSc), Department of Pathology (P Daneshpajouhnejad MD), Department of Environmental Health Engineering (A Fatehizadeh PhD, E Taheri PhD), Research Institute for Primordial Prevention of Non-Communicable Disease (S Hariri MD), Department of Biology (M Meshkat MSc), Health Services Management (M Mohseni PhD), Biostatistics and Epidemiology (E Sadeghi PhD), Department of Radiology and Interventional Neuroradiology (O Shafaat MD), Isfahan University of Medical Sciences j, Isfahan, Iran; Department of Parasitology (S Bahadory PhD), Department of Healthcare Services Management (L Keikavoosi-Arani PhD), Alborz University of Medical Sciences, Karaj, Iran; Unit of Biochemistry (A A Baig PhD), Universiti Sultan Zainal Abidin (Sultan Zainal Abidin University), Kuala Terengganu, Malaysia; Center for Clinical Research and Prevention (J L Baker PhD), Bispebjerg University Hospital, Frederiksberg, Denmark; Division of RBMCH&N (R K Bakshi MD), Molecular Microbiology (M Bardhan MD), Biostatistics Department of (V K Kamal PhD), India Cancer Research Consortium (Prof. R Mehrotra DPhil), Indian Council of Medical Research, New Delhi, India ( Prof L Dandona MD); Department of Hypertension (Prof. M Banach PhD), Medical University of Lodz, Lodz, Poland; Memorial Hospital of Polish Mothers Research Institute, Lodz, Poland (Prof. M Banach PhD); Department of Pharmacology (I Banerjee MD), Sir Seewoosagur Ramgoolam Medical College, Belle Rive, Mauritius; Molecular Microbiology and Bacteriology (M Bardhan MD), National Institute of Cholera and Enteric Diseases, Kolkata, India; Department of Translational Medicine (F Barone-Adesi PhD), University of Eastern Piedmont, Novara, Italy; Academic Unit of Obstetrics and Gynecology (F Barra MD), Department of Health Sciences (DISAL) (A A Ferrari MD), Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) (Prof S Ferrero PhD), University Eye Clinic (L Ferro Desideri MD), University of Genoa, Genoa, Italy; Department of Public & Environmental Health (A Barrow MPH), University of The Gambia, Brikama, The Gambia; Epidemiology and Disease Control Unit (A Barrow MPH), Expanded Program on Immunization (A Sowe MSc), Ministry of Health, Kotu, The Gambia; School of Oral and Dental Sciences (N Z Bashir BDS), University of Bristol, Bristol, UK; Academics Department (S Basu MD), Indian Institute of Public Health, Gurgaon, India; Independent Consultant, Bogura, Bangladesh (A Begum MD); Nursing Department (AS Belay MSc), Secci o of Public Health (M G B Birega MPH), Mizan-Tepi University, Mizan Teferi, Ethiopia; Medical Laboratory Science (M A Belete MSc), Wollo University, Dessie, Ethiopia; Department of Oral Pathology and Microbiology (U I Belgaumi MD), Karad, India; Department of Global Health and Social Medicine (A W Bell MSW), Department of Environmental Health (N Diao DSc), Cardiovascular Department (F Kahe MD), Department of Orthopedic Surgery (K Momenzadeh MD), Department of Health Policy and Oral Epidemiology (Z S Natto DrPH), Department of Internal Medicine (N Rajai MD), Department of Global Health and Population (P Rohloff MD), Division of General Internal Medicine (Prof A Sheikh MD), Harvard University, Boston, MA, USA; Department of Social Services (A W Bell MSW), Tufts Medical Center, Boston, MA, USA; Biological Sciences Department (L Belo PhD), Applied Molecular Biosciences Research Unit (UCIBIO) (L Belo PhD, M Carvalho PhD, V M Costa PhD), Department of Medicine (Prof N Cruz-Martins PhD), Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE) (J Loureiro PhD), Department of Chemistry (R B Pereira PhD), University of Porto, Porto, Portugal; Department of Epidemiol ogy and Health Promotion (Prof. H Benzian PhD), New York University, New York, NY, USA; Department of Epidemiology and Biostatistics (AC Bermudez MD), Department of Health Policy and Administration (E A Faraon MD), University of the Philippines Manila, Manila, Philippines; Department of Epidemiology (A C Bermudez MD), Brown University, Providence, RI, USA; Department of Social and Clinical Pharmacy (AS Bhagavathula PharmD), Charles University, Hradec Kralova, Czech Republic; Institutes of Applied Health Research and Translational Medicine (N Bhala PhD), Queen Elizabeth Hospital Birmingham, Birmingham, UK; Institute of Applied Health Research (N Bhala PhD), NIHR Global Health Research Unit on Global Surgery (J C Glasbey MSc), University of Birmingham, Birmingham, UK; Physiology Department (B B Bhandari MD), Government Institute of Medical Sciences, Greater Noida, India; If Department of Anatomy (Prof N Bhardwaj MD, Prof S G Dixit MD), Department of Community Medicine and Family Medicine (P Bhardwaj MD), School of Public Health (P Bhardwaj MD), Department of Forensic Medicine and Toxicology (T Kanchan MD), Department of Surgical Oncology (Prof S Misra MCh), Department of Community Medicine (G Singh MD), Department of Pharmacology (S Singh DM, S B Varthya MD), All India Institute of Medical Sciences, Jodhpur, India; Department of Statistical and Computational Genomics (K Bhattacharyya MSc), National Institute of Biomedical Genomics, Kalyani, India; Department of Statistics (K Bhattacharyya MSc), University of Calcutta, Kolkata, India; Department of Anatomy (V S Bhojaraja MD), Department of Biochemistry (J K ​​​​Shetty MD), Royal College of Surgeons in Ireland Medical University of Bahrain, Busaiteen, Bahrain; Health Administration (S S Bhuyan PhD), Rutgers University, New Brunswick, NJ, USA; Institute of Soil and Environmental Sciences (S Bibi PhD, S Ullah PhD), University of Agriculture, Faisalabad, Faisalabad, Pakistan; Department of Health Behavior, Environment and Society l Medicine (B Bintoro MD), Center of Health and Behavior and Promotion (B Bintoro MD), Universitas Gadjah Mada (Gadjah Mada University), Sleman, Indonesia; Department of General Surgery and Medical-Surgical Specialties (Prof A Biondi PhD, M Vacante PhD), Department of Biomedical and Biotechnological Sciences (G Grosso PhD), Department of General Surgery and Surgical-Medical Specialties (Prof G Isola PhD), Clinical and Experimental Medicine (C Ledda PhD), Department of Medical and Surgical Sciences and Advanced Technologies (Prof M Veroux PhD), University of Catania, Catania, Italy; Department of Global Public Health and Primary Care (Prof T Bjørge PhD, O Dadras DrPH), University of Bergen, Bergen, Norway; Cancer Registry of Norway, Oslo, Norway (Prof. T Bjørge PhD); Wolfson Institute of Population Health (O Blyuss PhD), Queen Mary University of London, London, UK; Department of Biomedical Sciences (S Bolla PhD), Nazarba yev University, Nur-Sultan City, Kazakhstan; Department of Oncology (C Bosetti PhD), Department of Environmental Health Sciences (S Gallus DSc), Mario Negri Institute for Pharmacological Research, Milan, Italy; Department of Epidemiology (D Braithwaite PhD), UF Health Cancer Center (S D Karanth PhD), University of Florida, Gainesville, FL, USA; Cancer Population Sciences Program (D Braithwaite PhD), University of Florida Health Cancer Center, Gainesville, FL, USA; School of Population and Public Health (Prof M Brauer DSc, P A Chakraborty MPH), University of British Columbia, Vancouver, BC, Canada; Division of Clinical Epidemiology and Aging Research (Prof H Brenner MD), German Cancer Research Center, Heidelberg, Germany; Department of Biomedical Technologies (AN Briko MSc), Bauman Moscow State Technical University, Moscow, Russia; Department of Epidemiology and Evidence-Based Medicine (Prof N I Briko DSc, P D Lopukhov PhD), Department of Pediatrics and Pediatric Infectious Diseases (Prof D Munblit PhD), Digital Biodesign and Personalized Healthcar e Research Center (S K Vladimirov PhD), IM Sechenov First Moscow State Medical University, Moscow, Russia; Neurogenetics Research Clinic (C M Buchanan PhD), Auckland City Hospital, Auckland, New Zealand; Flinders Health and Medical Research Institute (N B Bulamu PhD), Health and Social Care Economics Group (C Mpundu-Kaambwa PhD), Nursing and Health Sciences (S Shorofi PhD), Southgate Institute for Health and Society (F H Tesfay PhD), Flinders University, Adelaide, SA, Australia; Department of Public Health (Prof M T Bustamante-Teixeira PhD, Prof M R Guerra PhD), Federal University of Juiz de Fora, Juiz de Fora, Brazil; Faculty of Pharmacy (M Butt MS), University of Central Punjab, Lahore, Pakistan; School of Public Health and Health Systems (Z A Butt PhD), University of Waterloo, Waterloo, ON, Canada; Al Shifa School of Public Health (Z A Butt PhD), Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan; Institute of Microengineering (F Caetano dos Santos PhD) , Federal Polytechnic School of Lausanne, Lausanne, Switzerland; Department of Internal Medicine (Prof. L A Cámera MD), Hospital Italiano de Buenos Aires (Italian Hospital of Buenos Aires), Buenos Aires, Argentina; Board of Directors (Prof L A Cámera MD), Argentine Society of Medicine, Buenos Aires, Argentina (Prof P R Valdez MEd); Program in Physical Therapy (C Cao MPH), Washington University in St Louis, St Louis, MO, USA; Department of Surgery (Y Cao DSc), Washington University in St Louis, Saint Louis, MO, USA; Oncology Network, Prevention and Research Institute (G Gorini MD), Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy (G Carreras PhD); Faculty of Health Sciences (M Carvalho PhD), Fernando Pessoa University, Porto, Portugal; Department of Nutrition (Prof F Cembranel DSc), Department of Physical Education (Prof D A S Silva PhD), Federal University of Santa Catarina, Florianópolis, Brazil; Mary MacKillop Institute for Health Research (Prof E Cerin PhD), Australian Catholic University, Melbourne, VIC, Australia; School of Public Health (Prof. E Cerin PhD), University of Hong Kong, Hong Kong, China; Department of Public Health (P Charalampous MSc), Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Community Medicine (V Chattu MD), Datta Meghe Institute of Medical Sciences, Sawangi, India; Saveetha Medical College (V Chattu MD), Saveetha University, Chennai, India; Department of Public Health and Health Policy (O Chimed-Ochir PhD), Hiroshima University, Hiroshima, Japan; Department of Public Health, Administration and Social Sciences (J L Chirinos-Caceres DrPH), Cayetano Heredia University, Lima, Peru; Division of Plastic Surgery (D Y Cho MD), Children’s Hospital of Philadelphia, Philadelphia, PA, USA; Department of Clinical Oncology (W C S Cho PhD), Queen Elizabeth Hospital, Hong Kong, China; Department of Pulmonary Medicine (Prof. D J Christopher MD), Department of Endocrinology, Diabetes and Metabolism (Prof N Thomas PhD), Christian Medical College and Hospital (CM C), Vellore, India; Center for Biomedicine and Community Health (D Chu PhD), VNU International School, Hanoi, Vietnam; Department of Surgery (I S Chukwu BMedSc), Federal Medical Centre, Umuahia, Nigeria; Health Effects Institute, Boston, MA, USA (A J Cohen DSc); Nova Medical School (J Conde PhD), Nova University of Lisbon, Lisbon, Portugal; Department of Public Health (S Cortés DrPH), Pontifical Catholic University of Chile, Santiago, Chile; Research Line in Environmental Exposures and Health Effects at Population Level (S Cortés DrPH), Centro de Desarrollo Urbano Sustentable (CEDEUS) (Advanced Center for Chronic Diseases [ACCDIS]), Santiago, Chile; Department of Health Sciences (Prof N Cruz-Martins PhD), Institute of Research and Advanced Training in Health Sciences and Technologies (CESPU), Famalicão, Portugal; School of Public Health (O Dadras DrPH), Walailak University, Thai Buri, Thailand; Research Department (H Kaur MPH), Health Policy Research (M R Mathur PhD), Department of Research (A Pandey PhD), Indian Institute of Public Health (Prof S Zodpey PhD), Public Health Foundation of India, Gurugram, India (Prof L Dandona MD , Professor R Dandona PhD, G Kumar PhD, D K Lal MD); Department of Pathology (P Daneshpajouhnejad MD), Department of Radiology and Radiological Science (N Hafezi-Nejad MD, O Shafaat MD, S Sheikhbahaei MD), Johns Hopkins University, Baltimore, MD, USA (H Tadbiri MD); Department of Human Nutrition (A Danielewicz PhD), Uniwersytet Warmińsko-Mazurski w Olsztynie (University of Warmia and Masuria in Olsztyn), Olsztyn, Poland; School of Public Health (A T Dao PhD), The University of Queensland, Brisbane, QLD, Australia; Department of Epidemiology (A T Dao PhD), Hanoi Medical University, Hanoi, Vietnam; Department Environmental Health (R Darvishi Cheshmeh Soltani PhD), Department of Nursing (M Golitaleb PhD), Arak University of Medical Sciences, Arak, Iran; Department of Biochemistry (S Das MD), Ministry of Health and Welfare, New Delhi, India; Department of Surgery (D V Davitoiu PhD), Clinica l Emergency Hospital Sf Pantelimon, Bucharest, Romania; Department of Public Health (Prof. F P De la Hoz PhD), National University of Colombia, Bogotá, Colombia; School of Public Health (S Debela MPH), Salale University, Fiche, Ethiopia; Department of Epidemiology and Community Medicine (A Dehghan PhD), Non-Communicable Diseases Research Center (NCDRC), Fasa, Iran; Division of Cardiology (R Desai MBBS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA; Department of Public Health (M D Desalegn MPH), Department of Pharmacy (G Fekadu MSc), Department of Public Health (M E Getachew MPH), Public Health Department (G G Kejela MPH), Wollega University, Nekemte, Ethiopia; Department of Public Health (F N Dessalegn MPH), Madda Walabu University, Bale Goba, Ethiopia; Department of Pharmacology (S Dewan PhD), Center for Life Sciences Research, Bangladesh, Dhaka, Bangladesh; Department of Life Sciences and Bioethics (S Dewan PhD), Tokyo Medical and Dental University, Tokyo, Japan; Department of Community Medicine (Prof S D Dharmaratne MD), University of Peradeniya, Peradeniya, Sri Lanka; Health Research Section (M Dhimal PhD), Research Section (A Ghimire BSc, U Paudel PhD), Research Section (A Pandey MPH), Clinical Research (S Pant MPH), Nepal Health Research Council, Kathmandu, Nepal; Department of Epidemiology (M Dianatinasab MSc), Maastricht University, Maastricht, The Netherlands; Center of Complexity Sciences (Prof D Diaz PhD), National Autonomous University of Mexico, Mexico City, Mexico; Faculty of Veterinary Medicine and Zootechnics (Prof D Diaz PhD, D Z Velazquez MSc), Autonomous University of Sinaloa, Culiacán Rosales, Mexico; School of Health (S Doaei PhD), Gastrointestinal and Liver Diseases Research Center (S Hassanipour PhD, F Joukar PhD, Prof F Mansour-Ghanaei MD, M Naghipour PhD), Caspian Digestive Disease Research Center (S Hassanipour PhD, F Joukar PhD, Prof F Mansour-Ghanaei MD), Caspian Digestive Diseases Research Center (M Naghipour PhD), Guilan University of Medical Sciences, Rasht, Iran; to urge completely off Global Health Innovations (L P Doan MSc, L G Vu MSc), Faculty of Medicine (L P Doan MSc, L G Vu MSc), Institute of Research and Development (M Hosseinzadeh PhD), Duy Tan University, Da Nang, Vietnam; School of Nursing and Midwifery (P N Doku PhD), University of Cape Coast, Cape Coast, Ghana; Responsabilidade Social (W M dos Santos PhD), Oswaldo Cruz German Hospital, São Paulo, Brazil; Brazilian Center for Evidence-based Health Care (W M dos Santos PhD), Joanna Briggs Institute, São Paulo, Brazil; Sydney School of Public Health (Prof T R Driscoll PhD), Save Sight Institute (H Kandel PhD), Asbestos Diseases Research Institute (J Leigh MD), NHMRC Clinical Trials Center (R A Mahumud PhD), Menzies Center for Health Policy (F Sitas PhD) ), University of Sydney, Sydney, NSW, Australia; Department of Forensic Medicine and Toxicology (H L Dsouza MD), Kasturba Medical Co llege Mangalore, Mangalore, India; Infection and Tropical Medicine (OC Durojaiye MPH), University of Sheffield, Sheffield, UK; Department of Medicine (Prof F Eghbalian MD), Department of Health Sciences (A Farmany PhD), Department of Microbiology (M Jalili MSc), Department of Midwifery (S Masoumi PhD), Hamadan University of Medical Sciences, Hamadan, Iran; Department of Orthodontics (E Eini DDS), Department of Medical Virology (S Jalilian PhD, S Jalilian PhD), Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Department of Biological Sciences (TC Ekundayo PhD), University of Medical Sciences, Ondo, Nigeria; Division of Cancer Prevention and Control (D U Ekwueme PhD), Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA; Pediatric Dentistry and Dental Public Health Department (Prof M El Tantawi PhD), Pathology Department (Prof I M Talaat PhD), Alexandria University, Alexandria, Egypt; Microbiology Department (M A Elbahnasawy PhD), Department of Zoology and Entomology (A I Hasaballah PhD), Al Azhar University, Cairo, Egypt; Department of Oncology (Prof H Elghazaly MD), Department of Obstetrics and G ynecology (Prof A F Nabhan PhD), Department of Entomology (AM Samy PhD), Ain Shams University, Cairo, Egypt; Department of Clinical Research (Prof H Elghazaly MD), Ain shams Research Institute (MASRI), Cairo, Egypt; Faculty of Medicine (M Elhadi MD), University of Tripoli, Tripoli, Libya; Lincoln International Institute for Rural Health (L Engelbert Bain PhD), University of Lincoln, Lincoln, UK; Department of International Cyber ​​Education (R Erkhbayar MD), Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia; Department of Obesity, Diabetes and Cardiovascular Risk (Prof J Espinosa-Montero PhD), National Institute of Public Health Mexico, Cuernavaca, Mexico; Department of Internal Medicine (F Etaee MD), Yale University, New Haven, CT, USA; Institute for Health Science Research Germans Trias i Pujol (I J Ezeonwumelu MSc), Autonomous University of Barcelona, ​​Badalona, ​​​​Spain; IrsiCaixa AIDS Research Institute, Badalona, ​​Spain (I J Ezeonwumelu MSc); Department of Virology (S Eztikouri PhD), Pasteur Institute of Morocco, Casablanca, Morocco; Population and Behavioral Sciences Division (A F Fagbamigbe PhD), University of St Andrews, St Andrews, UK; Laboratory of Experimental Medicine (I R Fakhradiyev PhD), Atchabarov Scientific Research Institute of Fundamental Medicine (M Kulimbet MSc), Kazakh National Medical University, Almaty, Kazakhstan; Department of Neurological Surgery (J Fares MD), Center for Global Health (J Musa MD), Northwestern University, Chicago, IL, USA; Department of Internal Medicine (U Farooque MD), Dow University of Health Sciences, Karachi, Pakistan; Endocrinology and Metabolism Research Institute (H Farrokhpour MD), Department of Epidemiology (S Nejadghaderi MD, S Rashedi MD, E Shaker MD), Research Department (A Sheikhy MD), Endocrinology and Metabolism Population Sciences Institute (A Sheikhy MD), Department of International Studies (P Shobeiri MD), Department of Oral Health (A Sofi-Mahmudi DDS), Non-Communicable Disease Research Center (NCDRC), Teher member, Iran (S Hashemi MD, E Mohammadi MD); Satcher Health Leadership Institute (A O Fasanmi PhD), Morehouse School of Medicine, Atlanta, GA, USA; School of Medicine (A O Fasanmi PhD), Department of Cardiology (P Ram MD), Emory University, Atlanta, GA, USA; Department of Public Health (W Fatima PhD), Afro-Asian Institute, Lahore, Pakistan (Prof S Gilani PhD); Center for Primary Health Care Network Management (H Fattahi PhD), Ministry of Health and Medical Education, Tehran, Iran; School of Pharmacy (G Fekadu MSc), Jockey Club School of Public Health and Primary Care (J Huang MD), The Chinese University of Hong Kong, Hong Kong, China; Department of Psychiatry (I Filip MD), Kaiser Permanente, Fontana, CA, USA; School of Health Sciences (I Filip MD), AT Still University, Mesa, AZ, USA; Institute of Public Health (F Fischer PhD), Charité Universitätsmedizin Berlin (Charité Medical University Berlin), Berlin, Germany; Department of Medical Parasitology (M Foroutan PhD), Faculty of Medicine (M Foroutan PhD), Abadan University of Medical Sciences, Abadan, Iran; Department of Dermatology (T Fukumoto PhD), Kobe University, Kobe, Japan; Health Services Management Training Center (P A Gaal PhD, T Joo MSc), Faculty of Health and Public Administration (J Lám PhD, T Palicz MD, M Szócska PhD), Semmelweis University, Budapest, Hungary; Department of Applied Social Sciences (P A Gaal PhD), Sapientia Hungarian University of Transylvania, Târgu-Mureş, Romania; Gillings School of Global Public Health (M M Gad MD), University of North Carolina Chapel Hill, Chapel Hill, NC, USA; Community Medicine Department (M A Gadanya FMCPH), Bayero University, Kano, Nigeria; Department of Community Medicine (M A Gadanya FMCPH), Aminu Kano Teaching Hospital, Kano, Nigeria; Department of Medicine (A Gaipov PhD), Nazarbayev University School of Medicine, Nur-Sultan, Kazakhstan; Surgical Technology (N Galehdar PhD), Department of Clinical Biochemistry and Department of Allied Medical Sciences (M Moradi Sar abi PhD), Lorestan University of Medical Sciences, Khorramabad, Iran; Department of Radiology (T Garg MBBS), King Edward Memorial Hospital, Mumbai, India; National Health Service, London, UK (M Gaspar Fonseca PhD); Reproductive and Family Health (T G Gebremeskel MPH), Aksum University, Aksum, Ethiopia; Department of Nursing (B N B Gemeda MSc), Debre Berhan University, Debre Birhan, Ethiopia; Research Group for Genomic Epidemiology (N Ghith PhD), Technical University of Denmark, Copenhagen, Denmark; Non-communicable Diseases Research Center (J Gholizadeh Navashenaq PhD), Non-communicable Diseases Research Center (N Pourtaheri PhD), Bam University of Medical Sciences, Bam, Iran; Department of Radiology (S Ghozy MD), Mayo Clinic, Rochester, MN, USA; Warwick Medical School (Professor P S Gill DM), University of Warwick, Coventr y, UK; Discipline of Public Health Medicine (T G Ginindza PhD, R E Ogunsakin PhD), School of Nursing and Public Health Medicine (M M Hlongwa PhD), University of KwaZulu-Natal, Durban, South Africa; Department of Laboratories (J Godos PhD), Oasi Research Institute, Troina, Italy; Department of Gastroenterology (Prof A Goel DM), Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; Health Systems and Policy Research (M Golechha PhD), Indian Institute of Public Health, Gandhinagar, India; Department of Genetics (P Goleij MSc), Health Institute of Higher Education, Sari, Iran; Department of Biomedical and Neuromotor Sciences (D Golinelli MD, F Sanmarchi MD), Department of Medical and Surgical Sciences (Prof F S Violante MD), University of Bologna, Bologna, Italy; Postgraduate Program in Epidemiology (Prof B N G Goulart DSc), Department of Preventive and Social Dentistry (F N Hugo PhD), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Department of Family and Community Medicine (M I M Gubari PhD), University Of Sulaimani, Sulaimani, Iraq; Department of Community Medicine (D A Gunawardane MD), University of Peradeniya, Kandy, Sri Lanka; Department of Public Health (B Gupta PhD), Torrens University Australia, Melbourne, VIC, Australia; Toxicology Department (S Gupta MSc), Shriram Institute for Industrial Research, Delhi, India; School of Medicine (V Gupta PhD), Deakin University, Geelong, VIC, Australia; Department of Clinical Medicine (Prof V K Gupta PhD), School of Engineering (N Rabiee PhD), Macquarie University, Sydney, NSW, Australia; Faculty of Social Sciences (M K Gurara MPH), Katholieke Universiteit Leuven, Leuven, Belgium; Department of Midwifery (A Guta MSc), Department of Nursing (Y Solomon MSc), Dire Dawa University, Dire Dawa, Ethiopia; College of Dentistry (E S Halboub PhD), Substance Abuse and Toxicology Research Center (S Mohan PhD), Jazan University, Jazan, Saudi Arabia; School of Dentistry (E S Halboub PhD), Sana’a Univer site, Sana’a, Yemen; Department of Family and Community Medicine (Prof R R Hamadeh PhD), Arabian Gulf University, Manama, Bahrain; School of Health and Environmental Studies (Prof S Hamidi DrPH), Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates; Faculty of Medicine (N I Harlianto BSc), Institute for Risk Assessment Sciences (IRAS) (E Traini MSc), Utrecht University, Utrecht, The Netherlands; Department of Radiology (N I Harlianto BSc), University Medical Center Utrecht, Utrecht, The Netherlands; Research Unit (J M Haro MD), University of Barcelona, ​​Barcelona, ​​Spain; Biomedical Research Networking Center for Mental Health Network (CiberSAM), Barcelona, ​​Spain (J M Haro MD); Sekolah Tinggi Ilmu Kesehatan Indonesia Maju (Indonesian College of Health Sciences) (R K Hartono MPH), Institution of Public Health Sciences, Jakarta, Indonesia; Department of Public Health (S Hasan PhD), German University Bangladesh, Dhaka, Bangladesh; Daffodil International University, Dhaka, Bangladesh (S Hasan PhD); Ophthalmology (H Hasani MD), IUMS, Karaj, Iran; Institute of Pharmaceutical Sciences (K Hayat MS), University of Veterinary and Animal Science, Lahore, Pakistan; Department of Pharmacy Administration and Clinic a Pharmacy (K Hayat MS), Xian Jiaotong University, Xian, China; Independent Consultant, Santa Clara, CA, USA (G Heidari MD); Research Center (Z Heidarymeybodi MD), Department of Biostatistics and Epidemiology (M Taheri Soodejani PhD), Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Departamento de Salud Oral (Department of Oral Health) (B Y Herrera-Serna PhD), Universidad Autónoma de Manizales (Autonomous University of Manizales), Manizales, Colombia; School of Business (Prof C Herteliu PhD), London South Bank University, London, UK; Department of Applied Microbiology (K Hezam PhD), Taiz University, Taiz, Yemen; Department of Microbiology (K Hezam PhD), Nankai University, Tianjin, China; Division for Health Care Promotion (Y Hiraike PhD), University of Tokyo, Tokyo, Japan; Kasturba Medical College, Mangalore (R Holla MD, A Kamath MD), Department of Community Medicine (S D Mallya MD, C R Rao MD, R S Shetty MD), Department of Nephrology (Prof S Nagaraju DM), Manipal College of Dental Sciences, Manipal (Prof A I Narayana PhD), Manipal College of Dental Sciences (Prof R A Radhakrishnan PhD), Manipal Academy of Higher Education, Manipal, India (A Kamath MD); Epidemiology & Public Health Research Dept (M Holm PhD), International Vaccine Institute, Seoul, South Korea; Department of Pulmonology (N Horita PhD), Yokohama City University, Yokohama, Japan; National Human Genome Research Institute (NHGRI) (N Horita PhD), National Institutes of Health, Bethesda, MD, USA; Social and Environmental Health Research Department (M Hossain MPH), Nature Study Society of Bangladesh, Khulna, Bangladesh; Department of Health Promotion and Community Health Sciences (M Hossain MPH), Texas A&M University, College Station, TX, USA; Clinical Legal Medicine Department (S Hostiuc PhD), National Institute of Legal Medicine Mina Minovici, Bucharest, Romania; College of Science and Engineering (Prof M Househ PhD), Hamad Bin Khalifa University, Doha, Qatar; Department of Public Health and Community Medicine (Pro f A Humayun PhD), Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan; Czech National Center for Evid-Based Healthcare and Knowledge Translation (S Hussain PhD, M Klugar PhD, J Klugarová PhD), Institute of Biostatistics and Analyzes (S Hussain PhD), Department of Public Health (A Riad DDS), Czech National Center for Evidence-based Healthcare and Knowledge Translation (A Riad DDS), Masaryk University, Brno, Czech Republic; Department of Biomolecular Sciences (N R Hussein PhD), University of Zakho, Zakho, Iraq; Department of Occupational Safety and Health (Prof B Hwang PhD), China Medical University, Taichung, Taiwan; Department of Health Policy and Management (P M Iftikhar MD), City University of Ne w York, New York, NY, USA; Department of Community Medicine (O S Ilesanmi PhD), Department of Medicine (AS Oguntade MSc), Department of Total Quality Management (O F Owopetu MSc), University College Hospital, Ibadan, Ibadan, Nigeria; Faculty of Medicine (I M Ilic PhD, Prof M M Santric-Milicevic PhD), School of Public Health and Health Management (Prof M M Santric-Milicevic PhD), University of Belgrade, Belgrade, Serbia; Department of Epidemiology (Prof M D Ilic PhD), University of Kragujevac, Kragujevac, Serbia; Department of Epidemiology and Biostatistics (K Innos PhD), National Institute for Health Development, Tallinn, Estonia; Faculty of Pharmacy (L M Irham BPharm), University of Ahmad Dahlan, Yogyakarta, Indonesia; Department of Nutrition Research (M Islam MSc), Institute of Public Health Nutrition, Dhaka, Bangladesh; Department of Epidemiology and Preventive Medicine (RM Islam PhD), Monash University, Melbourne, VIC, Australia; Surveillance and Health Services Research (F Islami PhD), American Cancer Society, Atlanta, GA, USA; Department of Clinical Pharmacy (Prof N Ismail PhD), MAHSA University, Bandar Saujana Putra, Malaysia; Department of Health Services Research (M Iwagami PhD), University of Tsukuba, Tsukuba, Japan; Department of Noncommunicable Disease Epidemiology (M Iwagami PhD), Department of Health Care Research and Policy (Prof M McKee DSc), Medical Statistics Department (S Shivalli MD), London School of Hygiene & Tropical Medicine, London, UK; Department of Orthodontics & Dentofacial Orthopedics (L J BDS), Dr D Y Patil University, Pune, India; Center for Community Medicine (A Jaiswal MD), Department of Preventive Oncology (J K ​​Meena MD), All India Institute of Medical Sciences, New Delhi, India; Institute of Advanced Manufacturing Technologies (Professor M Jakovljevic PhD), Peter the Great St Petersburg Polytechnic University, St Petersburg, Russia; Institute of Comparative Economic Studies (Prof M Jakovljevic PhD), Hosei University, Toky o, Japan; Department of Microbiology (M Jalili MSc), Hamadan University of Medical Sciences, hamadan, Iran; Division of Pulmonary Medicine (E Jamshidi PharmD), Lausanne University Hospital (CHUV), Lausanne, Switzerland; Department of Preventive Medicine (Prof S Jang PhD), Yonsei University College of Medicine (S Park BEng), Yonsei University, Seodaemun-gu, South Korea; Department of Internal Medicine (C T Jani MD), Harvard University, Cambridge, MA, USA; Postgraduate Institute of Medicine (U U Jayarajah MD), Department of Pharmacology (P Ranasinghe PhD), University of Colombo, Colombo, Sri Lanka; Department of Surgery (U U Jayarajah MD), National Hospital, Colombo, Sri Lanka; Department of Biochemistry (Prof S Jayaram MD), Government Medical College, Mysuru, India; Department of Urology (S Jazayeri MD), University of Florida, Jacksonville, FL, USA; Department of Anesthesiology (B Jemal MSc), School of Public Health (G G Kanno MSc, M F Shaka MPH), Paediatrics and Child Health Nursing (M M Sibhat MSc), Dilla University, Dilla, Ethiopia; Department of Public Health (W Jeong PhD), Graduate School of Public Health (H Kang BPharm), Department of Preventive Medicine (Prof E Park PhD), Institute of Health Care Research (Prof E Park PhD), Yonsei University, Seoul, South Korea; Department of Community Medicine (R P Jha MSc), Dr Baba Saheb Ambedkar Medical College & Hospital, Delhi, Bara that; Department of Community Medicine (R P Jha MSc), Banaras Hindu University, Varanasi, India; National Health System Resource Center (H Jindal MD), Ministry of Health & Family Welfare, New Delhi, India; Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland (Prof J B Jonas MD); Department of Ophthalmology (Prof J B Jonas MD), Heidelberg University, Mannheim, Germany; Department of Family Medicine and Public Health (J J Jozwiak PhD), University of Opole, Opole, Poland; Institute of Family Medicine and Public Health (M Jürisson PhD, H Orru PhD), University of Tartu, Tartu, Estonia; Department of Medicine (S Kacimi MD), University of Tlemcen, Tlemcen, Algeria; Department of Oral Pathology and Microbiology, Forensic Odontology (V Kadashetti MDS), Krishna Institute of Medical Sciences deemed-to-be-university, Karad, India; Independent Consultant, Pune, India (P V Kakodkar MDS); Social Determinants of Health Research Center (L R Kalankesh PhD), Department of Anatomy (J Majidpoor ​​PhD), Gonabad University of Medical Sciences, Gonabad, Iran; Institute for Prevention of Noncommunicable Diseases (R Kalhor PhD), Health Services Management Department (R Kalhor PhD), Qazvin University of Medical Sciences, Qazvin, Iran; Division of Epidemiology and Biostatistics (V K Kamal PhD), National Institute of Epidemiology, Chennai, India, India; Department of Biology (Prof. F Kamangar MD), Morgan State University, Baltimore, MD, USA; Department of Periodontology (E Kandaswamy MS), Louisiana State University Health Sciences Center, New Orleans, LA, USA; Sydney Eye Hospital (H Kandel PhD), South East Sydney Local Health District, Sydney, NSW, Australia; Department of Preventive & Social Medicine (Prof S S Kar MD), Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India; School of Health Professions and Human Services (I M Karaye MD), Hofstra University, Hempstead, NY, USA; Institute for Epidemiology and Social Medicine (A Karch MD) , University of Münster, Münster, Germany; Center for Tropical Diseases and Global Health (P D Katoto PhD), Catholic University of Bukavu, Bukavu, Democratic Republic of Congo; Department of Global Health (P D Katoto PhD), Stellenbosch University, Cape Town, South Africa; Surgery Research Unit (J H Kauppila MD), University of Oulu, Oulu, Finland; Department of Molecular Medicine and Surgery (J H Kauppila MD), Karolinska Institute, Stockholm, Sweden; Department of Surgery (P M Kemp Bohan MD), Brooke Army Medical Center, San Antonio, TX, USA; Amity Institute of Forensic Sciences (H K hajuria PhD, B P Nayak PhD), Amity University, Noida, India; Bioinformatics and Biostatistics (A Khan PhD), Bio-X Institute (A K Khan MS), Department of Bioinformatics and Biostatistics (A U Rehman PhD), Shanghai Jiao Tong University, Shanghai, China; Department of Animal Sciences (A K Khan MS), Quaid-i-Azam University, Islamabad, Islamabad, Pakistan; Department of Epidemiology and Biostatistics (E A Khan MPH), Department of Public Health (Z Z Piracha PhD), Health Services Academy, Islamabad, Pakistan; Department of Population Science (M Khan PhD), Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh; Primary Care Department (M A Khan MSc), NHS North West London, London, UK; Faculty of Health and Wellbeing (K Khatab PhD), Sheffield Hallam University, Sheffield, UK; College of Arts and Sciences (K Khatab PhD), Ohio University, Zanesville, OH, USA; Basic Medical Sciences (M M Khatatbeh PhD), Yarmouk University, Irbid, Jordan; Global Evidence Synthesis Initiative (Prof M Khatib PhD), Department of Community Medicine (Prof Z Quazi Syed PhD), Datta Meghe Institute of Medical Sciences, Wardha, India; The Iranian Academy of Medical Sciences, Tehran, Iran (M Khayamzadeh MD); Department of Medicine (M Khazeei Tabari MD), Department of Immunology (Prof A Rafiei PhD), Molecular and Cell Biology Research Center (Prof A Rafiei PhD), Department of Medical-Surgical Nursing (S Shorofi PhD), Department d e Environmental Health (Prof Z Yousefi PhD), Mazandaran University of Medical Sciences, Sari, Iran; MAZUMS Office (M Khazeei Tabari MD), Universal Scientific Education and Research Network, Tehran, Iran; Department of Epidemiology (M Khodadost PhD, M Khodadost PhD), Department of Public Health (F Sarvi PhD), Larestan University of Medical Sciences, Larestan, Iran; Department of Genomics and Digital Health (M Kim MD), Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, South Korea; Public Health Center (M Kim MD), Ministry of Health and Welfare, Wando, South Korea; School of Traditional Chinese Medicine (Y Kim PhD), Xiamen University Malaysia, Sepang, Malaysia; School of Health Sciences (Prof A Kisa PhD), Kristiania University College, Oslo, Norway; Department of Global Community Health and Behavioral Sciences (Prof A Kisa PhD), Department of Medicine (M F Qadir PhD), Tulane University, New Orleans, LA, USA; Department of Nursing and Health Promotion (S Kisa PhD), Oslo Metropolitan University, Oslo, Norway; Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic (M Klugar PhD); Faculty of Health and Medical Sciences (J Klugarová PhD), Adelaide Medical School (L Yadav PhD), University of Adelaide, Adelaide, SA, Australia; Institute for Allergology (P Kolkhir MD), Charité Medical University Berlin, Berlin, Germany (Prof T Pischon MD); Division of Immune-mediated Skin Diseases (P Kolkhir MD), First Moscow State Medical University (Sechenov University), Moscow, Russia; Department of Internal and Pulmonary Medicine (Prof P A Koul MD), Sheri Kashmir Institute of Medical Sciences, Srinagar, India; Kasturba Medical College, Udupi, India (S Koulmane Laxminarayana MD); Biomedical Research Networking Center for Mental Health Network (CIBERSAM) (A Koyanagi MD), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, ​​Spain (A Koyanagi MD); Department of Anthropology (Prof K Krishan PhD), Panjab University, Chandigarh, India; Community Medicine (Y Krishnamoorthy MD), Employees’ State Insurance Model Hospital, Chennai, India; Faculty of Medicine (B Kucuk Bicer PhD), Gazi University, Ankara, Turkey; University of Environment and Sustainability, Somanya, Ghana (N Kugbey PhD); Health Research Institute (M Kulimbet MSc), Al Farabi Kazakh National University, Almaty, Kazakhstan; Cardiothoracic Surgery (A Kumar MD), UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, India; Department of Cardiothoracic Surgery (A Kumar MD), Medanta Hospital, Gurugram, India; Department of Orthopedics (Prof N Kumar MS), Medanta Hospital, Lucknow, India; Faculty of Health and Life Sciences (O P Kurmi PhD), Coventry University, Coventry, UK; Department of Medicine (O P Kurmi PhD), Department of Psychiatry and Behavioral Neurosciences (A T Olagunju MD), Department of Pathology and Molecular Medicine (T O Olagunju MD), McMaster University, Hamilton, ON, Canada; Department of Nephrology (A Kuttikkattu MD), Usha Hospital, Chengannur, India; Department of Clinical Sciences and Community Health (Prof C La Vecchia MD), University of Milan, Milan, Italy; Dr B C Roy Multi Specialty Medical Research Center (A Lahiri MD), Indian Institute of Technology Kharagpur, Kharagpur, India; NEVES Society for Patient Safety, Budapest, Hungary (J Lám PhD); Division of Cancer Epidemiology and Genetics (Q Lan PhD), National Cancer Institute, Rockville, MD, USA; Unit of Genetics and Public Health (Prof I Landires MD), Unit of Microbiology and Public Health (V Nuñez-Samudio PhD), Institute of Medical Sciences, Las Tablas, Panama; Department of Public Health (V Nuñez-Samudio PhD), Ministry of Health, Herrera, Panama (Prof I Landires MD); Department of Otolaryngology (S Lasrado MS), Father Muller Medical College, Mangalore, India; Department of Surgery (J Lau MPH, K Tan PhD), National University of Singapore, Singapore, Singapore; International Society Doctors for the Environment, Arezzo, Italy (P Lauriola MD); Pat ern Recognition and Machine Learning Lab (Prof S Lee PhD), Gachon University, Seongnam, South Korea; School of Pharmacy (S W H Lee PhD), Monash University, Bandar Sunway, Malaysia; School of Pharmacy (S W H Lee PhD), Taylor’s University Lakeside Campus, Subang Jaya, Malaysia; The Office of Health Policy & Legislative Affairs (W Lee PhD), Department of Pathology (V Y Tat BS), University of Texas, Galveston, TX, USA; Department of Medicine (Prof Y Lee PhD), School of Advanced Sciences (Prof Y Lee PhD), University of Science Malaysia, Kota Bharu, Malaysia; Department of Preventive Medicine (Y Lee PhD), Korea University, Suwon-si, South Korea; Knowledge Translation Directorate (S M Legesse PhD), Environmental Health and Noninfectious Disease Research team (SD Mengesha MSc), Ethiopian Public Health Institute, Addis Ababa, Ethiopia; Faculty of Science (E Leong PhD), Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei; Department of Health Promotion and Health Education (M Li PhD), National Taiwan Normal University, Taipei, Taiwan; School of Life Sciences (G Liu PhD), University of Technology Sydney, Ultimo, NSW, Australia; Center for Inflammation (G Liu PhD), Centenary Institute, Camperdown, NSW, Australia; Department of Epidemiology and Biostatistics (Prof J Liu PhD), Peking University, Beijing, China; Department of Internal Medicine (C Lo MD), Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA; Department of Public Health (A Lohiya MD), Kalyan Singh Super Specialty Cancer Institute, Lucknow, India; Department of Health Economics (L Lorenzovici MSc), Syreon Research Romania, Targu Mures, Romania; Department of Doctoral Studies (L Lorenzovici MSc), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Tirgu Mures, Tirgu Mures, Romania; School of Health (J Loureiro PhD), Polytechnic Institute of Porto, Portugal; Department of General Surgery (Prof R Lunevicius DSc), Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; Sec Department of Surgery (Prof R Lunevicius DSc), Institute of Population Health Sciences (MR Mathur PhD), University of Liverpool, Liverpool, UK; Department of Biostatistics and Epidemiology (F Madadizadeh PhD), Yazd University of Medical Sciences, Yazd, Iran; Proteomics and Metabolomics Unit (Prof S Magdeldin PhD), Children’s Cancer Hospital Egypt, Cairo, Egypt; Cell and Molecular Biology Research Center (Prof S Mahjoub PhD), D epartment of Clinical Biochemistry (Prof S Mahjoub PhD, A Mosapour PhD), Babol University of Medical Sciences, Babol, Iran; Radiology and Precision Health Program (M Mahmoudi PhD), Michigan State University, East Lansing, MI, USA; Department of Biostatistics and Epidemiology (M Mahmoudimanesh PhD), Management and Leadership in Medical Education Research Center (S Mousavi PhD), Department of Immunology (M Razeghinia MSc), Kerman University of Medical Sciences, Kerman, Iran; Department of Primary Care and Public Health (Prof A Majeed MD, Prof S Rawaf MD), National Heart & Lung Institute (Prof D Munblit PhD), WHO Collaborating Center for Public Health Education and Training (D L Rawaf MD), Imperial College London, London, UK; Cyprus International Institute for Environmental and Public Health (K C Makris PhD), Cyprus University of Technology, Limassol, Cyprus; Clinical Pharmacy Department (T Mallhi PhD), Jouf University, Sakaka, Saudi Arabia; Department of Epidemiology (MA Mamun HSC), CHINTA Research Bangladesh, Dhaka, Bangladesh; Department of Public Health and Informatics (MA Mamun HSC), Jahangirnagar University, Dhaka, Bangladesh; General Surgery Department I (A Manda MD), Emergency University Hospital Bucharest, Bucharest, Romania; School of Medicine and Surgery (Prof. L G Mantovani DSc), University of Milan Bicocca, Monza, Italy; Value-Based Healthcare Unit (Prof L G Mantovani DSc), IRCCS MultiMedica, Sesto San Giovanni, Italy; Faculty of Public Health (S Martini PhD), Universitas Airlangga (Airlangga University), Surabaya, Indonesia; Indonesian Public Health Ass ociation, Surabaya, Indonesia (S Martini PhD); Department of Nutrition and Dietetics (M Martorell PhD), University of Concepcion, Concepción, Chile; Center for Healthy Living (M Martorell PhD), University of Concepción, Concepción, Chile; Board of Directors (C N Matei PhD), Association of Resident Physicians, Bucharest, Romania; Department of Public Health and Community Medicine (E Mathews PhD), Cen tral University of Kerala, Kasaragod, India; Department of Orthopedic Surgery (V Mathur MD), Massachusetts General Hospital, Boston, MA, USA; School of Atmospheric Physics (K Mehmood PhD), Nanjing University of Information Science and Technology, Nanjing, China; Peru Country Office (W Mendoza MD), United Nations Population Fund (UNFPA), Lima, Peru; Eunice Kennedy Shriver National Institute of Child Health and Human Development (L G Mensah MD), National Institutes of Health, Bethesda, MD, USA; University Research Institute (A A Mentis MD), National and Kapodistrian University of Athens, Athens, Greece; CES University, Medellin, Colombia (A Y M Mera-Mamián MSc); Cauca University, Popayan, Colombia (A Y M Mera-Mamián MSc); Breast Surgery Unit (T J Meretoja MD), Helsinki University Hospital, Helsinki, Finland; University of Helsinki, Helsinki, Finland (T J Meretoja MD); Department of Epidemiology and Biostatistics (M W Merid MPH), University of Gondar, Addis Ababa, Ethiopia; School of Medicine and Public Health (A G Mersha MD), Department of Public Health and Medicine (D N Tollosa PhD), University of Newcastle, Newcastle, NSW, Australia; Midwifery Department (Prof B T Meselu MSc), Debre Markos University, Debre Markos, Ethiopia; University Center Varazdin (T Mestrovic PhD), University North, Varazdin, Croatia; School of Public Health and Community Medicine (J Miao Jonasson PhD), University of Gothenburg, Gothenburg, Sweden; Department of Propedeutics of Internal Diseases & Arterial Hypertension (Prof. T Miazgowski MD), Pomeranian Medical University, Szczecin, Poland; Section Woman-P atrino-Child (I Michalek PhD), Lausanne University Hospital, Lausanne, Switzerland; Department of Nursing (G F W Mijena MSc), Haramaya University, Harar, Ethiopia; Pacific Institute for Research & Evaluation, Calverton, MD, USA (T R Miller PhD); School of Public Health (T R Miller PhD), Curtin University, Perth, WA, Australia; College of Applied Medical Sciences (S A Mir PhD), Majma ah University, Riyadh, Saudi Arabia; Social Determinants of Health Center (M Mirza-Aghazadeh-Attari MD), Urmia University of Medical Science, Urmia, Iran; Department of Biology (K A Mohammad PhD), Salahaddin University-Erbil, Erbil, Iraq; Department of Information Technology (M Mohammadi PhD), Lebanese French University, Erbil, Iraq; Department of Biology (A Mohammed PhD), University of Jeddah, Jeddah, Saudi Arabia; Health Systems and Policy Research Unit (S Mohammed PhD), Department of Community Medicine (M B Sufiyan MD), Ahmadu Bello University, Zaria, Nigeria; Department of Health Care Management (S Mohammed PhD), Technical University of Berlin, Berlin, Germany; School of Helath Sciences (S Mohan PhD), University of Petroleum and Energy Studies, Dehradun, India; Health Services Management (M Mohseni PhD), Iran University of Medical Sciences, Iran, Iran; Oncology Department (N Moka MD), Appalachian Regional Healthcare, Hazard, KY, USA; Department of Internal Medicine (N Moka MD), University of Kentucky, Lexington, KY, USA; School of Nursing (Prof A Molassiotis PhD), Department of Land Surveying and Geo-Informatics (Y Song PhD), Hong Kong Polytechnic University, Hong Kong, China; Clinical Epidemiology and Public Health Research Unit (L Monasta DSc, E Traini MSc), Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; Faculty of Medicine and University Hospital of Cologne (Prof U Mons PhD), University of Cologne, Cologne, Germany; Department of Medicine (A A Montasir FMD), TMSS Medical College, Bogura, Bangladesh; Department of Medicine (A A Montasir FMD), Sofia Ismail Memorial Medical Centre, Bogura, Bangladesh; Faculty of Veterinary Medicine and Zootechnics (Prof A Montero PhD), Autonomous University of Sinaloa, Culiacan, Mexico; Department of Molecular Medicine (M Moosavi PhD), National Institute of Genetic Engineering and Biotechnology, Tehran, Iran; School of Medicine (Prof A Moradi PhD), Department of Nutrition (M Raeisi PhD), Golestan Research C enter of Gastroenterology and Hepatology (G Roshandel PhD), Infectious Diseases Research Center (H Shirzad-Aski PhD), Golestan University of Medical Sciences , Gorgan, Iran; Social Determinants of Health Research Center (Y Moradi PhD), Kurdistan University of Medical Sciences, Kurdistan, Iran; Computer, Electrical, and Mathematical Sciences and Engineering Division (P Moraga PhD), King Abdullah University of Science and Technology, Thuwal, Saudi Arabia; International Laboratory for Air Quality and Health (Prof. L Morawska PhD), School of Public Health and Social Work (M T N Tran PhD, N Wang PhD), Queensland University of Technology, Brisbane, QLD, Australia; Department of Cardiology and Cardiac Surgery (J Morze PhD), University of Warmia and Mazury, Olsztyn, Poland; Department of Medicine (E Mostafavi PhD), Stanford Cardiovascular Institute (E Mostafavi PhD), Stanford University, Palo Alto, CA, USA; Department of Fruit and Vegetable Product Technology (Prof. A Mousavi Khaneghah PhD), Professor Wacław Dąbrowski Institute of Agricultural and Food Biotechnology State Research Institute, Warsaw, Poland; Department of Epidemiology and Biostatistics (S Mubarik MS, Prof C Yu PhD), School of Medicine (Z Zhang PhD), Wuhan University, Wuhan, China; Department of Surgery (F Mulita MD), General University Hospital of Patras, Patras, Greece; Faculty of Medicine (F Mulita MD), University of Thessaly, Larissa, Greece; Science Communication Department (S B Munro PhD), Invitae, Boulder, CO, USA; Family Medicine Unit 19 (E Murillo-Zamora PhD), Mexican Institute of Social Security, Colima, Mexico; after degree in Medical Sciences (E Murillo-Zamora PhD), Universidad de Colima, Colima, Mexico; Knowledge Translation and Utilization (Prof A F Nabhan PhD), Egyptian Center for Evidence Based Medicine, Cairo, Egypt; Research and Analytics Department (A J Nagarajan MTech), Initiative for Financing Health and Human Development, Chennai, India; Department of Research and Analysis (A J Nagarajan MTech ), Bioinsilico Technologies, Chennai, India; Institute of Epidemiology and Medical Biometrics (Prof G Nagel PhD), Ulm University, Ulm, Germany; Laboratory of Analysis of Public Health Indicators and Health Digitization (M Naimzada MD, S S Otstavnov PhD), Department of Information Technologies and Management (S K Vladimirov PhD), Moscow Institute of Physics and Technology, Dolgoprudny, Russia; Experimental Surgical and Oncology Laboratory (M Naimzada MD), Kursk State Medical University, Kursk, Russia; Health Workforce Department (TS Nair MD), World Health Organization, Geneva, Switzerland; School of Pharmacy (A Naqvi PhD), University of Reading, Reading, UK; Mysore Medical College and Research Institute (Prof S Narasimha Swamy MD), Government Medical College, Mysore, India; Department of Disease Control and Environmental Health (R Ndejjo MSc), Makerere University, Kampala, Uganda; School of Pharmacy (S O Nduaguba PhD), West Virginia University, Morgantown, WV, USA; Department of Nursing (W W Negash MSc), Madda Walabu University, Ginnir, Ethiopia; Pharmaceutical Sciences Research Center (K ​​Nejati PhD), Ardabil University of Medical Science, Ardabil, Iran; Estia Health Blakehurst (S Neupane Kandel BSN), Estia Health, Sydney, NSW, Australia; Health Innovation and Transformation Center (H V N Nguyen PhD), Federation University Australia, Brisbane, QLD, Australia; Department of Population and Quantitative Health Sciences (H V N Nguyen PhD), University of Massachusetts Medical School, Worcester, MA, USA; International Islamic University Islamabad, Islamabad, Pakistan (R K Niazi PhD); Medical Research Council Clinical Trials Unit (N M Noor MRCP), Institute of Cardiovascular Science (AS Oguntade MSc), University College London, London, UK; Department of Gastroenterology (N M Noor MRCP), Cambridge University Hospitals, Cambridge, UK; Center of Excellence in Reproductive Health Innovation (CERHI) (C I Nzoputam MPH), University of Benin, Benin City, Nigeria; Department of Physiol ogy (O J Nzoputam PhD), University of Benin, Edo, Nigeria; Department of Physiology (O J Nzoputam PhD), Benson Idahosa University, Benin City, Nigeria; Department of Management and Economic Sciences (Prof B Oancea PhD), Department of Statistics and Cybernetics (Prof M Paun PhD), University of Bucharest, Bucharest, Romania; Department of Community Health and Primary Care (O O Odukoya MSc), University of Lagos, Idi Araba, Nigeria; Department of Family and Preventive Medicine (O O Odukoya MSc), Department of Medical Oncology (N Sayegh MD), University of Utah, Salt Lake City, UT, USA; Department of Preventive Medicine (I Oh PhD), Kyung Hee University, Dongdaemun-gu, South Korea; Department of Food and Nutrition (A P Okekunle PhD), Seoul National University, Seoul, South Korea; Department of Psychiatry (A T Olagunju MD), University of Lagos, Lagos, Nigeria; Community Prevention and Care Services (B O Olakunde PhD), National AIDS Control Committee, Abuja, Nigeria; Mass Communication Department (E Omer PhD), Ajman University, Dubai, United Arab Emirates; Department of Anatomical Pathology (A E E Omonisi FWACP), Ekiti State University, Ado- Ekiti, Nigeria; Department of Anatomical Pathology (A E E Omonisi FWACP), Ekiti State University Teaching Hospital, Ado- Ekiti, Nigeria; Noncommunicable Disease Prevention Unit (S Ong FAMS), Ministry of Health, Bandar Seri Begawan, Brunei; Early Detection & Cancer Prevention Services (S Ong FAMS), Pantai Jerudong Specialist Centre, Bandar Seri Begawan, Brunei; Department of Pharmacology and Therapeutics (Prof. O E Onwujekwe PhD), University of Nigeria Nsukka, Enugu, Nigeria; Department of Sustainability va Health (H Orru PhD), Umeå University, Umea, Sweden; Department of Project Management (S S Otstavnov PhD), Department of Health Care Administration and Economics (Prof V Vlassov MD), National Research University Higher School of Economics, Moscow, Russia; Department of Biochemistry (B E Oyinloye PhD), Afe Babalola University, Ado Ekiti, Nigeria a; Department of Biochemistry and Microbiology (B E Oyinloye PhD), University of Zululand, Kwadlangezwa, South Africa; Department of Respiratory Medicine (Prof M P A DNB), Jagadguru Sri Shivarathreeswara Academy of Health Education and Research, Mysore, India; National School of Public Health (A Padrón-Monedero PhD), Institute of Health Carlos III, Madrid, Spain; Department of Forensic Medicine and Toxicology (J Padubidri MD), Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India, Mangalore, India; Department of Food Safety (B Pakbin PhD), Qazvin University of Medical Sciences, Medical Microbiology Research Center, Iran; Department of Epidemiology (R Pakzad PhD), Ilam University of Medical Sciences, Ilam, Iran; Hungarian Health Management Association (T Palicz MD), Hungarian Health Management Association, Budapest, Hungary; Department of Health Metrics (A Pana MD), Center for Health Outcomes & Evaluation, Bucharest, Romania; Research Department (A Pandey MPH), Public Health Research Society Nepal, Kathmandu, Nepal; Vision and Eye Research Institute (Prof S Pardhan PhD), Anglia Ruskin University, Cambridge, UK; Department of Medical Humanities and Social Medicine (Prof E Park PhD), Kosin University, Busan, South Korea; Global Health Governance Program (J Patel), Center for Medical Informatics (Prof A Sheikh MD), University of Edinburgh, Edinburgh, UK; School of Dentistry (J Patel), University of Leeds, Leeds, UK; Skills Innovation and Academic Network (SIAN) Institute (S Pati PhD), Association for Biodiversity Conservation and Research (ABC), Odisha, India; Central Department of Public Health (R Paudel MPH), Faculty of Humanities and Social Sciences (U Paudel PhD), Tribhuvan University, Kathmandu, Nepal; Department of Bioinformatics and Biostatistics (Prof M Paun PhD), National Institute of Research and Development for Biological Sciences, Bucharest, Romania; Department of Infection Control (M Peng MPH), Taihe Hospital, Shiyan , China; The First Clinical College (M Peng MPH), School of Public Health and Management (Y Yu MS), Hubei University of Medicine, Shiyan, China; Department of Orthopedics (J Pereira MS), Yenepoya Medical College, Mangalore, India; Department of Biology (Prof S Perna PhD), University of Bahrain, Sakir, Bahrain; Department of Zoology (Prof N Perumalsamy PhD), Yadava College, Madurai, India; Department of Zoology (Prof N Perumalsamy PhD), Annai Fathima College, Madurai, India; Pennsylvania Cancer and Regenerative Medicine Center (R G Pestell MD), Baruch S Blumberg Institute, Doylestown, PA, USA; Department of Medicine (RG Pestell MD), Xavier University School of Medicine, Woodbury, NY, USA; Department of Medicine (R Pezzani PhD), University of Padova, Padova, Italy; Associazione Italiana Ricerca Oncologica di Base AIROB (Italian Association of Basic Research Oncology), Padova, Italy (R Pezzani PhD); SSD Epidemiology Screening (C Piccinelli MS), City of Health and Science University Hospital of Turin, Turin, Italy; Basic Medical Sciences Department (J D Pillay PhD), Durban University of Technology, Durban, South Africa; Molecular Epidemiology Research Group (Prof. T Pischon MD), Max Delbrueck Center for Molecular Medicine, Berlin, Germany; University Medical Center Groningen (Prof. M J Postma PhD), School of Economics and Business (Prof M J Postma PhD), University of Groningen, Groningen, The Netherlands; Department of Biochemistry (Prof A Prashant PhD), Jagadguru Sri Shivarathreeswara University, Mysuru, India; Biomedical Engineering Department (Prof M Rabiee PhD), Amirkabir University of Technology, Tehran, Iran; Pohang University of Science and Technology, South Korea (N Rabiee PhD); College of Medicine (A Radfar M D), University of Central Florida, Orlando, FL, USA; Department of Medical Oncology (Prof V Radhakrishnan MD), Cancer Institute (WIA), Chennai, India; Department of Medicine (A Rafiee MSc), University of Alberta, Edmonton, AB, Canada; Department of Pathology (N Rah eem FMCPath), Federal Medical Centre, Yola, Nigeria; Center for Surveillance, Immunization, and Epidemiological Research (M Rahman PhD), National Institute of Infectious Diseases, Tokyo, Japan; Global Health Nursing (M Rahman PhD), St Luke’s International University, Tokyo, Japan; Department of Population Science and Human Resource Development (M Rahman DrPH), University of Rajshahi, Rajshahi, Bangladesh; School of Nursing and Healthcare Professions (M Rahman PhD), Federation University Australia, Berwick, VIC, Australia; Future Technology Research Center (A Rahmani PhD), National Yunlin University of Science and Technology, Yunlin, Taiwan; Department of Community Medicine (V Rahmanian PhD), Jahrom University of Medical Sciences, Jahrom, Iran; Department of Surgery (A Rajesh MD), University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; Department of Epidemiology, Biostatistics and Occupational Health (J Rana MPH), McGill University, Montreal, QC, Canada; Research and Innovation Division (J Rana MPH), South Asian Institute for Social Transformation (SAIST), Dhaka, Bangladesh; Health Emergency Operations Center (K ​​Ranabhat MPH), Ministry of Health & Population, Kathmandu, Nepal; Central Department of Public Health (K Ranabhat MPH), Institute of Medicine, Kathmandu, Nepal; Department of Oral Pathology (S Rao MDS), Sharavathi Dental College and Hospital, Shimogga, India; Department of Epidemiology and Biostatistics (Prof M Rezaeian PhD), Department of Medical Biochemistry (M Sahebazzamani MSc), Rafsanjan University of Medical Sciences, Rafsanjan, Iran (A Rashidi MD); Department of Clinical Science (M Rashidi DVM), Islamic Azad University, Garmsar, Iran; Department of Biomedical Engineering (Z Ratan MSc), Khulna University of Eng Hieristics and Technology, Khulna, Bangladesh; School of Health and Society (Z Ratan MSc), University of Wollongong, Wollongong, NSW, Australia; University College London Hospitals, London, UK (D L Rawaf MD); Academic Public Health England (Prof S Rawaf MD), Public Health England, London, UK; School of Health, Medical and Applied Sciences (L Rawal PhD), CQ University, Sydney, NSW, Australia; Department of Immunology and Laboratory Sciences (M Razeghinia MSc), Medical Laboratory Sciences (M Sahebazzamani MSc), Sirjan School of Medical Sciences, Sirjan, Iran; Molecular Biology and Biochemistry (A U Rehman PhD), University of California Irvine, Irvine, CA, USA; Department of Pharmacy (I Rehman PhD), Biochemistry (Prof A W Wadood PhD), Abdul Wali Khan University Mardan, Mardan, Pakistan; School of Medicine (Prof A M N Renzaho PhD), Translational Health Research Institute (Prof A M N Renzaho PhD), Western Sydney University, Campbelltown, NSW, Australia; Immunity in Infection, Malignancy and Autoimmunity Network (NIIMA) (Prof N Rezaei PhD), Universal Science Education and Research Network (USERN), Tehran, Iran; Eye and Skull Base Research Centers (S Rezaei MD), Rassoul Akram Hospital, Tehran, Iran; Institute of Diagnostic and Interventional Radiology and Neuroradiology (R Rikhtegar MD), Essen University Hospital, Essen, Germany; Dana-Farber Cancer Institute, Boston, MA, USA (T J Roberts MD); Center for Indigenous Health Research (P Rohloff MD), Wuqu’ Kawoq Maya Health Alliance, Tecpan, Guatemala; Clinical and Epidemiological Research in Primary Care (GICEAP) (E Romero-Rodríguez PhD), Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain; Department of Internal Medicine (G M Rwegerera MD), University of Botswana, Gaborone, Botswana; Department of Oral and Maxillofacial Surgery (M S MDS), Jagadguru Sri Shivarathreeswara University, Mysore, India; Department of Medical Pharmacology (MM Saber-Ayad MD), Public Health and Community Medicine Department (MR Salem MD), Cairo University, Giza, Egypt; Independent Consultant, Gdansk, Poland (Prof. M R Saeb PhD); Research and Development (Prof U Saeed PhD), Islamabad Diagnostic Center Pakistan, Islamabad, Pakistan; Biolog ical Production Division (Prof U Saeed PhD), National Institute of Health, Islamabad, Pakistan; Department of Development Studies (H Sahoo PhD), International Institute for Population Sciences, Mumbai, India; Department of Statistics (MR Sajid PhD), University of Gujrat, Pakistan, Gujrat, Pakistan; Department of Health Policy and Management (H Salari PhD), Bushehr University of Medical Sciences, Bushehr, Iran; School of Public Health (Y L Samodra MPH), Taipei Medical University, Taipei, Taiwan; Department of Nutrition and Preventive Medicine (Prof J Sanabria MD), Department of Pediatrics (S Sankararaman MD), Division of Pediatric Gastroenterology (A Thavamani MD), Case Western Reserve University, Cleveland, OH, USA; Department of Paediatrics (S Sankararaman MD, A Thavamani MD), University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH, USA; Research Development Coordination Section (M N Saqib PhD), Pakistan Health Research Council, Islamabad, Pakistan; Faculty of Health & Social Sciences (B Sathian PhD), Bournemouth University, Bournemouth, UK; UGC Center of Advanced Study in Psychology (M Satpathy PhD), Utkal University, Bhubaneswar, India; Udyam-Global Association for Sustainable Development, Bhubaneswar, India (M Satpathy PhD); Department of Health Sciences (I J C Schneider PhD), Federal University of Santa Catarina, Araranguá, Brazil; Department of Methodology and Innovation in Prevention (M Schwarzinger MD), University Hospital of Bordeaux, Bordeaux, France; University of Bordeaux (M Schwarzinger MD), Inserm, Bordeaux, France; Department of Medical Statistics (M Šekerija PhD), University of Zagreb, Zagreb, Croatia; Department of Epidemiology and Prevention of Chronic Noncommunicable Diseases (M Šekerija PhD), Croatian Institute of Public Health, Zagreb, Croatia; Emergency Department (S Senthilkumaran MD), Manian Medical Centre, Erode, India; National Heart, Lung, and Blood Institute (A Seylani BS), National Institutes of Health, Rockvil le, MD, USA; Department of Midwifery (K Seyoum MSc), Madda Walabu University, Robe, Ethiopia; Center for Biomedical Information Technology (F Sha PhD), Shenzhen Institutes of Advanced Technology, Shenzhen, China; Infectious Diseases and Microbiology (P A Shah MBBS), Rajiv Gandhi University of Health Sciences, Bangalore, India; HepatoPancreatoBiliary Surgery and Liver Transplantation (P A Shah MBBS), HealthCare Global Limited Cancer Care Hospital, Bangalore, India; Department of Internal Medicine (I Shahid MBBS), Ziauddin University, Karachi, Pakistan; Regenerative Medicine (M Shahrbaf MD), Royan Institution, Tehran, Iran; Department of Chemistry (H Shahsavari PhD), Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran; Independent Consultant, Karachi, Pakistan (M A Shaikh MD); Symbiosis Medical College for Women (M Shannawaz PhD), Symbiosis International University, Pune, India; Nahavand School of Allied Medical Sciences (A Sharifi PhD), Hamadan University of Medical Sciences, Hamadan, Nahavand, Iran; Facultad de Medicina (Faculty of Medicine) (J Sharifi-Rad PhD), Universidad del Azuay (University of Azuay), Cuenca, Ecuador; Department of Medical Oncology (P Sharma MD), Kent Hospital, Warwick, RI, USA; Genomic Epidemiology Branch (M Sheikh PhD), International Agency for Research on Cancer, Lyon, France; Health in Disasters and Emergencies (R Sheikhi BHlthSci), Iran University of Medical Sciences, Shahrekord, Iran; Maurice Wilkins Center for Biodiscovery, Auckland, New Zealand (Prof P R Shepherd PhD); Tokyo Foundation for Policy Research, Tokyo, Japan (Prof. K Shibuya MD); Public Health Dentistry Department (Professor K M Shivakumar PhD), Krishna Institute of Medical Sciences deemed-to-be-university, Karad, India; Clinical Immunology and Hematology (V Shivarov PhD), Sofi amed University Hospital, Sofia, Bulgaria; Department of Genetics (V Shivarov PhD), Sofia University “St Kliment Ohridiski”, Sofia, Bulgaria; School of Pharmacy (S Shrestha PharmD), Monash U university, Selangor Darul Ehsan, Malaysia; Department of Hematology-Oncology (S K Siddappa Malleshappa MD), Baystate Medical Center, Springfield, MA, USA; Department of Health Science (Prof. L M R Silva PhD), Polytechnic of Guarda, Guarda, Portugal; Department of Health Science (Prof L M R Silva PhD), University of Beira Interior, Covilhã, Portugal; Real World Insights (G Silva Julian MSc), IQVIA, São Paulo, Brazil; Department of Medical Oncology (N Silvestris MD), IRCCS Cancer Institute “Giovanni Paolo II”, Bari, Italy; DIMO (N Silvestris MD), University of Bari, Bari, Italy; Department of Community Medicine (G Singh MD), Lady Hardinge Medical College, New Delhi, India; Department of Pulmonary and Critical Care Medicine (H Singh MD), Medical College of Wisconsin, Milwaukee, WI, USA; School of Medicine (Prof J A Singh MD), Department of Radiology (H Sotoudeh MD), University of Alabama at Birmingham, Birmingham, AL, USA; Medicine Service (Prof J A Singh MD), US Department of Veterans Affairs (VA), Birmingham, AL, USA; Department of Community Medicine & Public Health (J Singh PhD), Tribhuvan University, Janakpur, Nepal; Department of Radiodiagnosis (P Singh MD), All India Institute of Medical Sciences, Bathinda, India; Department of Epidemiology (D N Sinha PhD), School of Preventive Oncology, Patna, India; Department of Epidemiology (D N Sinha PhD), Healis Sekhsaria Institute for Public Health, Mumbai, India; Program Services Unit (A H Sinke MD), Pathfinder International, Addis Ababa, Ethiopia; Maternal and Child Health Division (M Siraj MSc), International Center for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh; Department of Chemistry (S S Siwal PhD), Maharishi Markandeshwar (deemed-to-be-university), Mullana- Ambala, India, Mullana, India; Department No16 (V Y Skryabin MD) , Moscow Research and Practice Center on Addictions, Moscow, Russia; Department of Infectious Diseases and Epidemiology (A A Skryabina MD), Pirogov Russian National Research h Medical University, Moscow, Russia; Surgery (B Socea PhD), “Sf Pantelimon” Emergency Clinical Hospital Bucharest, Bucharest, Romania; Asbestos Diseases Research Institute, Sydney, NSW, Australia (M J Soeberg PhD); Cochrane Iran Associate Center (A Sofi-Mahmudi DDS), Iranian Ministry of Health and Medical Education, Tehran, Iran; Department of Health Policy and Management (S Song PhD), University System of Georgia, Athens, GA, USA; Public Health Department (S Soshnikov PhD), Bukhara State Medical Institute, Bukhara, Uzbekistan; Laboratory of Analysis of Public Health Indicators and Digitization of Health (S Soshnikov PhD), Moscow Institute of Physics and Technology, Moscow, Russia; Department of Epidemiology and Global Health (A Sowe MSc), Umeå University, Umeå, Sweden; Department of Management, Policy, and Community Health (R Suk PhD), The University of Texas Health Science Center at Houston, Houston, TX, USA; Center for Biotechnology and Microbiology (M Suleman PhD), University of Swat, Mingora, Swat, Pakistan; School of Life Sciences (M Suleman PhD), Xiamen University, Xiamen, China; National Institute of Epidemiology (R Suliankatchi Abdulkader MD), Indian Council of Medical Research, Chennai, India; Department of Maternal and Child Health (S Sultana MPH), Projahnmo Research Foundation, Dhaka, Bangladesh; Department of Medical Oncology (D Sur PhD), The Oncology Institute “Prof Dr Ion Chiricuţă” Cluj-Napoca, Cluj-Napoca, Romania; Department of Medical Oncology (D Sur PhD), Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Medicine (Prof. R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain; Carlos III Health Institute (Prof R Tabarés-Seisdedos PhD), Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain; Cancer Con trol Center (T Tabuchi MD), Osaka International Cancer Institute, Osaka, Japan; University of Western Australia, Sydney, NSW, Australia (Prof. K Takahashi PhD ); University of Occupational and Environmental Health, Japan (Prof. K Takahashi PhD); Department of Dermato-Venereology (M Tampa PhD), Dr Victor Babes Clinical Hospital of Infectious Diseases and Tropical Diseases, Bucharest, Romania; Department of Economics (N Y Tat MS), Rice University, Houston, TX, USA; Research and Innovation (N Y Tat MS), Enventure Medical Innovation, Houston, TX, USA; Engineering Systems and Environment (A Tavakoli PhD), University of Virginia, Charlottesville, VA, USA; School of Public Health (F H Tesfay PhD), Mekelle University, Mekelle, Ethiopia; Department of Gastroenterology and Hepatology (V Thoguluva Chandrasekar MD), Mayo Clinic, Scottsdale, AZ, USA; Department of Gastroenterology (N K Thomas MD), PSG Institute of Medical Sciences and Research, Coimbatore, India; Faculty of Public Health (J H V Ticoalu MPH), Universitas Sam Ratulangi, Manado, Indonesia; Institute of Public Health (R Topor-Madry PhD), Jagiellonian University Medical College, Krakow, Poland; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland (R Topor-Madry PhD); Nutritional Epidemiology Research Team EREN (M Touvier PhD), National Institute for Health and Medical Research INSERM, Paris, France; Department of Health, Medicine and Human Biology (M Touvier PhD), Sorbonne Paris Nord University, Bobigny, France; Department of Pathology and Forensic Medicine (M R Tovani-Palone PhD), University of São Paulo, Ribeirão Preto, Brazil; Modestum, London, UK (M R Tovani-Palone PhD); Department of Health Informatics (M T N Tran PhD), Hanoi Medical University, Hanoi, Vietnam; Department of Community Medicine (J P Tripathy MD), All India Institute of Medical Sciences, Nagpur, India; Department of Zoology (S Ullah PhD), Division of Science and Technology (S Ullah PhD), University of Education, Lahore, Lahore, Pakistan; Clinical Cancer r Research Center (S Valadan Tahbaz PhD, S Yahyazadeh Jabbari MD), Milad General Hospital, Tehran, Iran; Department of Microbiology (S V aladan Tahbaz PhD), Faculty of Medicine (M Zahir MD), Islamic Azad University, Tehran, Iran; Velez Sarsfield Hospital, Buenos Aires, Argentina (Prof P R Valdez MEd); Laboratory of Toxicology (C Vardavas PhD), University of Crete, Heraklion, Greece; School of Mathematics and Statistics (Prof P J Villeneuve PhD), Carleton University, Ottawa, ON, Canada; Occupational Health Unit (Prof. F S Violante MD), Sant’Orsola Malpighi Hospital, Bologna, Italy; Faculty of Information Technology (B Vo PhD), HUTECH University, Ho Chi Minh City, Vietnam; Foundation University Medical College (Prof Y Waheed PhD), Foundation University Islamabad, Islamabad, Pakistan; Department of Cultures, Societies and Global Studies (R G Wamai PhD), Northeastern University, Boston, MA, USA; School of Public Health (R G Wamai PhD), University of Nairobi, Nairobi, Kenya; Department of Medicine (C Wang MPH), Vanderbilt University, Nashville, TN, USA; School of Public Health (F Wang PhD), Xuzhou Medical University, Xuzhou, China; National Center for Chronic and Noncommunicable Disease Control and Prevention (N Wang PhD), Chinese Center for Disease Control and Prevention, Beijing, China; Department of Otorhinolaryngology (Y Wang MD), Third Hospital of Peking University, Beijing, China; Center for Health Policy Research (Prof P Ward PhD), Torrens University Australia, Adelaide, SA, Australia; Department of Biomedical Sciences (A Waris MS), City University of Hong Kong, Hong Kong, China; Competence Center of Mortality Follow-up of the German National Cohort (R Westerman DSc), Federal Institute for Population Research, Wiesbaden, Germany; Department of Community Medicine (ND Wickramasinghe MD), Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka; School of Public Health (H Xiao PhD), Zhejiang University, Zhejiang, China; Department of Public Health Science (H Xiao P hD), Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Endocrinology (Prof S Xu PhD), University of Science and Technolog y of China, Hefei, China; Department of Medicine (Prof S Xu PhD), University of Rochester, Rochester, NY, USA; Cardiovascular Program (X Xu PhD), The George Institute for Global Health, Sydney, NSW, Australia; Research and Development Division (L Yadav PhD), The George Institute for Global Health, New Delhi, India; Cancer Epidemiology and Prevention Research (L Yang PhD), Alberta Health Services, Calgary, BC, Canada; Department of Oncology (L Yang PhD), University of Calgary, Calgary, AB, Canada; Department of Pharmacy (Y Yismaw MSc), Alkan Health Science, Business and Technology College, Bahir Dar, Ethiopia; Department of Neuropsychopharmacology (N Yonemoto PhD), National Center of Neurology and Psychiatry, Kodaira, Japan; Department of Public Health (N Yonemoto PhD), Juntendo University, Tokyo, Japan; Department of Health Policy and Management (Prof M Z Younis PhD), Jackson State University, Jackson, MS, USA; School of Business & Economics (Prof M Z Younis PhD), Putra Maylisia University, Kuala Lumpur, Malaysia; Department of Pharmacology (B A Zaman MSc), University of Duhok, Duhok, Iraq; Research and Development (I Zare BSc), Sina Medical Biochemistry Technologies, Shiraz, Iran; Department of Bioengineering and Therapeutic Sciences (Prof M S Zastrozhin PhD), University of California San Francisco, San Francisco, CA, USA; Addictology Department (Prof M S Zastrozhin PhD), Russian Medical Academy of Continuing Professional Education, Moscow, Russia; Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia (J Zhang MD); School of Public Health (Y Zhang PhD), Hubei Province Key Laboratory of Occupational Hazard Identification and Control (Y Zhang PhD), Wuhan University of Science and Technology, Wuhan, China; Bone Marrow Transplantation Center (L Zhou MD), Zhejiang University, Hangzhou, China.

See appendix (pp. 260–69) for detailed information on individual author contributions to the research, divided into the following categories: managing the overall research enterprise; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for searching, cataloging, extracting or cleaning data; draw or code figures and tables; providing data or critical feedback on data sources; development methods or computer machinery; providing critical feedback on methods or results; edit the manuscript or revise it critically for important intellectual content; and manage the evaluation or publication process. Members of the core research team for this topic had full access to the underlying data used to generate estimates presented in this Article. All other authors had access to and reviewed assessments as part of the research appraisal process, which includes additional stages of formal review. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.

Data sharing

Declaration of interests

R Ancuceanu reports consulting fees from AbbVie; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events by AbbVie, Sandoz, B Braun, and Laropharm; everything outside the presented work. J Conde reports grants or contracts from a European Research Council Starting Grant (ERC-StG-2019-848325; €1·5 million funding); patents planned, issued, or pending for functionalized nanoparticles and compounds for cancer treatment and methods (US application number 62/334538), and TRPV2 antagonists (US patent application 17/590,061); everything outside the presented work. S Das reports grants or contracts from Department of Science and Technology Grant for research on COVID-19; support for attending meetings or traveling through the American Society of Clinical Pathology Travel Grant (US$1500); leadership or fiduciary role in another board, society, committee or advocacy group, paid or unpaid, with the American Association of Clinical Chemistry CME Committee, Personalized Division Committee, and as an HEA Committee; everything outside the presented work. TR Driscoll reports a leadership or fiduciary role in another board, society, commission or advocacy group, unpaid, such as Chair of the Occupational and Environmental Cancer Committee of Cancer Council Australia, Chair of the Australian Mesothelioma Registry Expert Advisory Group for the Australian Institute of Health and Welfare , and a member of the Research and Evaluation Committee of the Australian Security and Eradication Agency, all outside the submitted work. H Elghazaly reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Roche, BMS, Lilly, Pfizer, AstraZeneca, Janssen, MSD, Novartis, and Sandoz, all as personal payments; fee for Roche expert testimony as personal fees; participation in data safety monitoring board or advisory board for Roche, BMS, Lilly, Pfizer, AstraZeneca, Janssen, MSD, Novartis, Sandoz, incl. ive of personal payments; everything outside the presented work. L M Force reports support for the current script of the Bill & Melinda Gates Foundation; grants or contracts from St Baldrick’s Foundation, St Jude Children’s Research Hospital, and National Institutes of Health (NIH) Loan Repayment Program; a leadership or fiduciary role in another board, society, committee or advocacy group, unpaid, with The Lancet Oncology International Advisory Board; everything outside the presented work. N Ghith reports that their salary is covered by a grant from Novo Nordisk Foundation (NNF16OC0021856), outside of the submitted work. C Herteliu reports grants from the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (PN-III-P4-ID-PCCF-2016-0084, October 2018, until September 2022; and PN-III-P2-2.1). -SOL-2020-2-0351, June–October, 2020), outside the presented work. K Innos reports support for the present manuscript from Estonian Research Council, grant number PRG722 as payment to their institution. N E Ismail reports a leadership or fiduciary role in another board, society, committee or advocacy group, unpaid, such as a Council Member for the Malaysian Academy of Pharmacy, outside of the submitted work. J J Jozwiak reports payment or honoraria for lectures, presentations, speakers, manuscript writing, or educational events from Teva, Amgen, Synexus, Boehringer Ingelheim, ALAB Laboratories, Zentiva, all as personal payments outside of the submitted work. M Klugar reports grants Czech-Norwegian Collaboration on Meta-Research and Critical Thinking Education in Healthcare (EHP-CZ-ICP-2-009), Evidence Implementation in Clinical Practice (2020-1-DE01-KA203-005669), To International Network for Evidence-based Research in Clinical Health Research in the Czech Republic (LTC20031), and Strategic Partnership in Innovation and Development of Evidence-Based Management (2019-1-CZ01-KA202-061350), all as payments to their institution; participation on a data safety monitoring board or advisory board as an unpaid member of a Cochrane advisory board mission for Evidence Advocacy; other non-financial interest as Director of Cochrane, JBI and GRADE Centers of the Czech Republic; everything outside the presented work. K Krishan reports non-financial support from UGC Center of Advanced Study, CAS II, Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. J A Loureiro reports support for the current manuscript from Scientific Employment Stimulus (FCT; CEECINST/00049/2018) as support to his salary and from UIDB/00511/2020 from the LEPABE, financed by national funds through the FCT/MCTES (PIDDAC) as research support M Mahmoudi reports other financial and non-financial interest with Academic Parity Movement, a non-profit organization dedicated to addressing academic discrimination, violence and incivility as a co-founder and director, Partners in Global Wound Care as a founding partner, and receiving royalties or honoraria for his published books, plenary lectures, and a licensed patent, all outside the submitted work. A-F A Mentis reports grants or contracts from “MilkSafe: a new pipeline to enrich formula milk using omics technologies”, research co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call to RESEARCH—CREATE—INNOVATE (project code T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860); shares or stock options in a family winery; other financial or non-financial interests as scientific officer with BGI group; everything outside the presented work. S Mohammed reports support for the current manuscript from the Gates Foundation; fellowship grant from Alexander von Humboldt Foundation, outside the presented work. N Moka reports a leadership or fiduciary role in another board, society, commission or advocacy group, unpaid, with the Kentucky Society of Clinical Oncology as treasurer, outside of the submitted work. S B Munro reports stocks or stock selection jn in Invitae, and other financial or non-financial interests as an employee of Invitae, a genetic testing company. O O Odukoya reports support for the current manuscript from the Fogarty International Center of the National Institutes of Health under award number K43TW010704. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. R G Pestell reports support for the current manuscript from W81XWH1810605 Breast Cancer Research Breakthrough Grant and R21 CA235139-01. NIH grant; patents issued and pending in the area of ​​cancer diagnosis and therapy; participation in a data security monitoring committee or advisory board as a member of the VGI Health Technology Scientific Advisory Board, Chair Scientific Advisory Board for MD Anderson, and Cancer Center Breast Cancer SPORE Program; a leadership or fiduciary role in another board, society, committee or advocacy group, paid or unpaid, such as Founder and CEO of biotech companies LightSeed, EcoGenome and StromaGenesis; stock or stock options in CytoDyn and VGI Health Technology; everything outside the presented work. M J Postma reports shares or share options in Health-Ecore (25%) and Pharmacoeconomics Advice Groningen (100%) outside the presented work. Radfar and I Filip report other financial or non-financial interest with Avicenna Medical and Clinical Research Institute, outside the presented work. T J Roberts reports support for attending Conquer Cancer Foundation meetings or trips; a leadership or fiduciary role in another board, society, committee or advocacy group, paid or unpaid, with Biocon Biologics; everything outside the presented work. S Shrestha reports other financial or non-financial interests in the School of Pharmacy, Monash University Malaysia in receipt of a Graduate Research Merit Scholarship. L M L R Silva reports grants or contracts with the project code CENTRO-04-3559-FSE-000162, Fundo Social Europeu (FSE), outside the presented work. J A Singh reports consulting fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam partners, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life , UBM, Trio Health, Medscape, WebMD, and Practice Point communications, and the National Institutes of Health and the American College of Rheumatology; payment or honorarium for participation in the speakers bureau for Simply Speaking; support to attend meetings or travel of the OMERACT steering committee, to attend their meeting every 2 years; participation in a data safety monitoring committee or advisory committee as an unpaid member of the FDA Arthritis Advisory Committee; leadership or fiduciary role in another board, society, committee or advocacy group, paid or unpaid, as a member of the steering committee of OMERACT, an international organization that develops initiatives for clinical trials and receives arms-length funding from 12 pharmaceutical companies, with the Veterans Affairs Rheumatology Field Advisory Committee as Chair, and with the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis as director and editor; stock or stock options in TPT Global Tech, Vaxart pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Series Therapeutics, Tonix Pharmaceuticals, and Charlotte’s Web Holdings and previously owned stock options in Amarin, Viking, and Moderna pharmaceutical; everything outside the presented work.

We are grateful to the surveillance systems, including cancer registries, that have generated and shared data on observed cancer burdens. S M Aljunid acknowledges the Department of Health Policy and Management, College of Public Health, Kuwait University for the approval and support to participate in this research project. H Ariffin acknowledges support from the Ministry of Higher Education, Malaysia (grant FRGS/1/2021/SKK0/UM/01/1). F Barra acknowledges support from Lega Italiana through the Lotta contro i Tumori – LILT – Bando 5 x 1000 anno 2019. L Belo and M Carvalho acknowledge the support of FCT in the context of the project UIDP/04378/2020 and UIDB/04378/2020 . by UCIBIO and the project LA/P/0140/2020 by i4HB. A J Cohen was supported by the Health Effects Institute, Boston, MA, USA. J Conde acknowledges financial support from the European Research Council – ERC Starting Grant 848325. V M Costa acknowledges her grant (SFRH/BHD/110001/2015), received from Portuguese national funds through Fundação para a Ciência e Tecnologia (FCT), IP, under the Transitory Standard DL57/2016/CP1334/CT0006. T C Ekundayo was supported by the African-German Network of Excellence in Science (AGNES), the Federal Ministry of Education and Research (BMBF) and the Alexander von Humboldt Foundation (AvH). N Ghith acknowledges grant support from Novo Nordisk Foundation (NNF16OC0021856). J C Glasbey is supported by a Doctoral Research Fellowship from the National Institute for Health Research (NIHR300175). V K Gupta and V B Gupta acknowledge financial support from National Health and Medical Research Council (NHMRC), Australia. C Herteliu, A Pana, and M Ausloos acknowledge partial support through a grant from the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. C Herteliu is also partially supported by a grant from the Romanian Ministry of Research Innovation and Digitization, MCID, project number ID-585-CTR-42-PFE-2021. S Hussain wa s supported by Operational Program Research, Development and Education–Project, Pos tdoc2MUNI (number CZ.02.2.69/0.0/0.0/18_053/0016952). M Jakovljevic acknowledges partial support through the grant OI 175 014 from the Ministry of Educational Science and Technological Development of the Republic of Serbia. J H Kauppila acknowledges research grants from Sigrid Jusélius Foundation and the Finnish Cancer Foundation. M N Khatib acknowledges support from Datta Meghe Institute of Medical Sciences (regarded as a university). Y J Kim was supported by the Research Management Center, Xiamen University Malaysia [XMUMRF/2020-C6/ITCM/0004]. S L Koulmane Laxminarayana acknowledges institutional assistance from Manipal Academy of Higher Education, Manipal. K Krishan is supported by the UGC Center of Advanced Study (Phase II), awarded to the Department of Anthropology, Panjab University, Chandigarh, India. I Landires is a member of the Sistema Nacional de Investigación (SNI), which is supported by the Secretaría Nacional de Ciencia, Tecnología e Innovación de Panama (SENACYT). M-C Li was supported by the Ministry of Science and Technology, Taiwan (MOST 110-2314-B-003-001). G Liu acknowledges support from Lung Foundation Australia’s CREATE Hope scientific fellowship. J Liu acknowledges support from the National Natural Science Foundation (72122001). J A Loureiro was supported by a Scientific Employment Incentive (FCT; CEECINST/00049/2018). E Mathews is supported by a Clinical and Public Health Early Career Fellowship (grant number IA/CPHE/17/1/503345) from the DBT India Alliance/Wellcome Trust Department of Biotechnology, India Alliance (2018-2023). T J Meretoja was supported by an unrestricted grant from Cancer Foundation Finland sr. S Mohammed acknowledges a fellowship from the Alexander von Humboldt Foundation, outside of the presented work. M Molokhia is supported by the National Institute for Health Research Biomedical Research Center at Guy’s and St Thomas’ National Health. h Service Foundation Trust and King’s College London. L Monasta received support from the Italian Ministry of Health at the Maternal and I Institute nfana Sano IRCCS Burlo Garofolo, Trieste – Italy (RC 34/2017). U Mons is supported by the Marga and Walter Boll Foundation, Kerpen, Germany. M A Moosavi acknowledges the financial support of National Institute of Genetics Engineering and Biotechnology (NIGEB). J Musa acknowledges support from the NIH/FIC K43TW011416 for research-protected time for cervical cancer research and career development at University of Jos. V Nuñez-Samudio is a member of the Sistema Nacional de Investigación (SNI), which is supported by the Secretariat of Panama. National Institute of Science, Technology and Innovation (SENACYT). O O Odukoya acknowledges support from the Fogarty International Center of the National Institutes of Health under award number K43TW010704 for research-protected time. The content is solely the responsibility of all authors and does not necessarily represent the official views of the National Institutes of Health. A S Oguntade acknowledges funding through a doctoral scholarship from the Nuffield Department of Population Health, University of Oxford (Oxford Population Health). J R Padubidri acknowledges Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal for their constant support in research collaborations. R G Pestell acknowledges support from NIH grant W81XWH1810605 Breast Cancer Research, Breakthrough Grant R21 CA235139-01. Z Z Piracha acknowledges the International Center for Medical Sciences Research (ICMSR), Islamabad (44000), Pakistan. R A Radhakrishnan acknowledges support from Wellcome Trust/DBT India Alliance – IA/CPHI/18/1/503927. U Saeed acknowledges the International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan. A M Samy acknowledges the support of Ain Shams University and the Egyptian Fulbright Mission Program. F Sha was supported by Shenzhen Science and Techn ology Program (grant number KQTD20190929172835662). H R Shahsavari acknowledges the Research Council of Institute for Advanced Studies in Basic Sciences (IASBS). Shetty acknowledges Kasturba Medical College, Mangalore, Manipal Ac ademy of Higher Education, Manipal for all the academic support. D A S Silva acknowledges funding in part from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES)—Finance Code 001 and D A S Silva is supported in part by CNPq-Brazil (309589/2021-5). L M L R Silva was supported by project CENTRO-04-3559-FSE-000162, Fundo Social Europeu (FSE). Am Singh is supported by the International Graduate Research Scholarship, University of Tasmania. R Suliankatchi Abdulkader acknowledges support from ICMR—National Institute of Epidemiology. B Unnikrishnan acknowledges Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal. H Xiao acknowledges support from the Division of Public Health Sciences of the Fred Hutchinson Cancer Research Center. X Xu is supported by the Scientia Program of the University of New South Wales (Australia). C Yu was supported by the National Natural Science Foundation of China (grant number 82173626) and Wuhan Medical Research Program of Joint Fund of Hubei Health Committee (grant number WJ2019H304).

Editorial note: The Lancet Group takes a neutral position regarding territorial claims in published maps and institutional affiliations.

Supplementary Material

References

Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention.

Risk of overweight, obesity and cancer.

Environmental and hereditary factors in the causation of cancer – analyzes of twin cohorts from Sweden, Denmark and Finland.

The impact of the COVID-19 pandemic on cancer care.

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modeling study.

Cost-utility analysis of cancer prevention, treatment and control: a systematic review.

The causes of cancer: quantitative estimates of preventable risks of cancer in the United States today.

Estimates of global mortality attributable to particulate air pollution using satellite imagery.

Occupation and cancer – follow-up of 15 million people in five Nordic countries.

Elimination of occupational cancer.

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.

The current and future burden of cancer attributable to modifiable risk factors in Canada: summary of results.

16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010.

The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.

Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions.

Attributable causes of cancer in China.

Attributable causes of cancer in Japan in 2005 – a systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan.

Global burden of cancer attributable to high body mass index in 2012: a population-based study.

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study.

Global burden of cancer attributable to infections in 2018: a global incidence analysis.

Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.

Causes of cancer in the world: a comparative risk assessment of nine behavioral and environmental risk factors.

Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

Guidelines for accurate and transparent health assessment reporting: the GATHER statement.

International statistical classification of diseases and related health problems.

Modeling causes of death: an integrated approach using CODEm.

Food, nutrition, and physical activity, and the prevention of cancer: a global perspective.

Current perspective on the global and US cancer burden attributable to lifestyle and environmental risk factors.

The burden of cancer attributable to modifiable risk factors: the Australian cancer PAF cohort consortium.

The fractions of cancer attributable to modifiable factors: a global review.

Socioeconomic status and obesity in adult populations of developing countries: a review.

Transition of physical activity.

The effects of tobacco control policies on global smoking prevalence.

Spatial, temporal and demographic patterns in smoking tobacco prevalence and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019.

Achievement of global tobacco control.

Addressing NCDs: “best buys” and other recommended interventions for prevention and control of noncommunicable diseases.

Global status report on alcohol and health 2018.

The SAFER initiative: a world free from alcohol-related harm.

The public health approach in historical perspective.

The social determinants of health: it is time to consider the causes of the causes.

WHO-European review of social determinants of health and the health divide.

Solar and ultraviolet radiation.

Helicobacter pylori: stomach cancer and beyond.

Article Info

Publication History

Identification

DOI: https://doi.org/10.1016/S0140-6736(22)01438-6

Copyright

© 2022 The Author(s). Published by Elsevier Ltd.

User License

ScienceDirect

Linked Articles

The growing global burden of cancer is rapidly outstripping current cancer control capacity. More than 19 million new cancers were diagnosed in 2020 worldwide, and 10 million people died from cancer.1 By 2040, this burden is expected to increase to about 30 million new cancers each year and 16 million deaths from cancer according to the Global Cancer . Lookout

London, Sept. 05, 2022 (GLOBE NEWSWIRE) — Ignite SEO offers qualified search engine optimization services for businesses that want to increase their online credibility, rank higher and be more easily found on Google, increase their brand awareness and achieve a higher percentage of sustainable traffic.

Their industry-leading SEO consulting services, provided by Ignite SEO founder and CEO, Adam Collins – who has over 12 years of experience and an impressive portfolio of successful SEO campaigns for a range of businesses across industries – have proven to help deliver tailored strategies, instructions and techniques to increase your online presence.

Widely recognized by industry experts as an SEO expert, Adam Collins runs several SEO training courses and SEO business seminars across the UK and is now using his experience to step up and offer specialist search engine optimization services from Ignite SEO in London.

Adam Collins’ SEO services at Ignite SEO are different from other SEO companies because he doesn’t keep his expert techniques a secret.

Instead, he regularly attends and hosts SEO training and business seminars to not only acquire the latest techniques in the industry currently available, but also share them with you and help you understand keyword research, technical SEO, link building and other important aspects searches. engine ranking – so you’ll have the knowledge to implement an effective SEO strategy yourself.

Ignite SEO pinpoints four key areas that businesses need to prioritize if they want to increase their organic traffic and in turn generate an increase in genuine sales, all of which are included in their SEO consulting services. These are:

Ignite SEO is now offering its professional SEO services in London.

Whether you are a large, small or start-up, Ignite SEO London has the skills and experience to improve your search engine rankings, help you break into your local market and stand out from your competition.

Their SEO London services offer a variety of strategies to improve your business’ online presence and include:

To find out more about Ignite SEO London and see their full list of SEO services, visit their website at https://www.igniteseo.co.uk/services/seo-consultant/.

Source: https://thenewsfront.com/after-running-successful-seo-training-sessions-across-the-uk-ignite-seo-are-now-offering-their-expert-seo-services-in-london/

What are the two types of SEO in digital marketing?

6 types of SEO you need to increase your website traffic

• On-page SEO. This is a type of SEO that you are probably familiar with. …
• Off-page SEO. Defining off-page SEO is a bit more difficult. …
• Technical SEO. …
• Local SEO. …
• App store optimization. …
• YouTube SEO.

How many types of SEO marketing are there? There are about 12 different types of SEO that help websites rank better on search engine results pages.

What are the types of SEO?

The three types of SEO are: On-page SEO – Everything on your web pages – Blogs, Product text, Web text. Off Page SEO – Anything that happens outside of your website that helps your SEO strategy – backlinks. Technical SEO â All technical things done to improve search rankings â indexing a website to help robots crawl.

What are 3 main areas of SEO?

This is a complete guide to the three components of SEO. These are technical SEO, on-page SEO and off-page SEO.

How does SEO work in simple words?

How does SEO work? SEO works by making certain changes to your website’s design and content that make your website more attractive to search engines. You do this in hopes that the search engine will show your website as the first result on the search engine results page.

What is SEO in plain English? Search Engine Optimization (SEO) is the practice of getting targeted traffic to a website from organic search engine rankings.

How does SEO work in simple terms?

SEO works by optimizing website pages, conducting keyword research and earning inbound links. Generally, you can see the results of your SEO efforts when a search engine crawls a website and indexes it. Taking a deeper look: there are tons of ways to improve your website’s on-page SEO.

What is SEO and how it works?

Search Engine Optimization (SEO) is the art and science of achieving higher page rankings in search engines like Google. Since search is one of the main ways people discover content online, a higher search engine ranking can lead to an increase in website traffic.

What is keyword volume quizlet?

what is keyword range? Number of people searching for a search term.

What is keyword scope? As the term suggests, keyword search volume refers to the volume (or number) of searches for a particular keyword in a given time frame. Keyword search volume is usually averaged over a specific time frame to give marketers a general idea of ​​the search term’s competitiveness and overall volume.

How do I find keyword volume?

To find out about search volume, simply type a keyword into the box on the Google Trends home page and you’ll be taken to a results page that looks something like this. The higher the interest (on a 100-point scale), the higher the search volume.

How can I get keyword volume for free?

Go to StoryBase.com and enter your gross ist in the search box. StoryBase works as a “reverse search engine” and provides you with all the long search terms associated with the words in your gross list. Perform a search volume analysis. Copy and paste your keyword list into a keyword volume checker like SearchVolume.io (Free).

What is a good keyword volume?

• The keyword golden ratio must be less than 0.25. The ratio is… the number of Google results that have the keyword phrase in the title divided by the local monthly search volume where the LMS is less than 250. If the KGR is less than 0.25, you should be in the top 100. when your page is indexed.â

What is a keyword quizlet?

Keywords are words or phrases used to associate your ads with terms people are searching for.

Which is an example of a keyword quizlet?

A specific job title would be an example of a keyword. Employers search resumes by keyword both manually and electronically.

What is a keyword and example?

Keywords are words and phrases that people type into search engines to find what they are looking for. For example, if you wanted to buy a new jacket, you could type something like “men’s leather jacket” into Google. Although this phrase is made up of more than one word, it is still a keyword.

Does Longtailpro cover all the following keyword relevance keyword volume keyword competitiveness and keyword profitability?

does long tail pro cover all of the following: keyword relevance, keyword volume, keyword competitiveness, and keyword profitability? right

Which is a part of the four stages of consumer thinking process?

In order to lay the foundation for a consistent presence in the lives of potential patients, it is critical to align your marketing strategy with the four stages of consumer behavior – awareness, active evaluation, decision and post-purchase.

What is the benefit of SEO?

One of the biggest benefits of SEO is that it is an inbound marketing strategy. Unlike traditional “outbound” advertising channels, which involve reaching consumers whether they want to hear from you or not, inbound methods focus on making it easy for your audience to find you when they want information.

Why is SEO good for business? A strong SEO strategy will allow brands to place their website and their content high on SERPs for relevant keywords, so they can capture the attention of prospective customers and bring them into their sales funnel.

What are the top 10 benefits of SEO?

Your SEO strategies will improve your rankings and get your website in front of them faster. The higher the ranking, the more traffic to your website. By using better keywords, meta descriptions and tags, you get higher rankings. The more clicks you get, the better your chances of selling.

What is SEO and what are its benefits?

What is SEO? SEO stands for Search Engine Optimization, which is the process of improving your website to increase organic visibility for specific search queries. The goal of SEO is to improve the quality and quantity of traffic to your website through website changes.

What is SEO and why is it important?

SEO stands for Search Engine Optimization – the practice of increasing the quantity and quality of traffic to your website through organic search engine results. The ultimate goal of SEO for businesses is to generate organic traffic – searchers who click through to your website from the search engine results page (SERP).

What is an example of SEO?

How they determine the “best” result is based on an algorithm that considers authority, relevance to that query, load speed, and more. (Google, for example, has over 200 ranking factors in its algorithm.) In most cases, when people think of “search engine optimization,” they think of “Google SEO.”

What is SEO in a simple way? SEO stands for Search Engine Optimization – much has remained the same. It refers to techniques that help your website rank higher in search engine results pages (SERPs).

What is SEO on a webpage?

SEO – Search Engine Optimization: The process of improving a website for search engines. Also the job title of the person who does this for a living: We just hired a new SEO to improve our online presence.

What are keywords quizlet?

Keywords are words or phrases used to associate your ads with terms people are searching for.

What is the keyword in the description? A keyword is a term used in digital marketing to describe a word or group of words that an internet user uses to search for in a search engine or search bar.

What is keywords and examples?

Keywords are words and phrases that people type into search engines to find what they are looking for. For example, if you wanted to buy a new jacket, you could type something like “men’s leather jacket” into Google. Although this phrase is made up of more than one word, it is still a keyword.

What is a keyword explain?

Keywords are words or phrases in the content of your web pages that match as closely as possible words and phrases that users type into search engines. Keywords allow you to build your SEO strategy around specific target phrases in a way that is meaningful and measurable.

What is keyword in SEO with example?

When it comes to SEO, these are the words and phrases that searchers type into search engines, also known as “search queries”. If everything on your page – all images, videos, copy, etc. â focus on simple words and phrases, these are your main keywords.

What is the purpose of a keywords?

A keyword is a word or phrase that indicates the meaning or main ideas of a data set. They are often used as an index to the contents of a dataset.

What is the main purpose of using keywords in SEO?

SEO keywords range from single words to complex phrases and are used to inform website content to increase relevant organic search traffic. Your audience uses them when they are looking for something related to your brand.

What is the benefit of keyword in research?

The biggest benefit of keyword research is that it can help your business or organization break into new markets. It also boosts your visibility. It also helps define content that focuses on a specific topic or audience.

SAN DIEGO (PRWEB)

July 20, 2022

Rio SEO and Movable Ink have entered into a strategic partnership to further streamline the search experience for their clients by providing relevant content in email and mobile communications. Rio SEO is the leading provider of an all-in-one local marketing platform proven to increase online visibility. Movable Ink is a leading provider of content personalization.

By working together, marketers can better seamlessly distribute local store information in email and mobile marketing communications, ensuring that accurate store information is visible in every consumer interaction. This hyperlocal level of personalization ensures that only relevant and targeted information is delivered to the email or mobile phone recipient, which in turn reduces unsubscribe rates and drives sales and customer retention.

“Customer expectations have risen dramatically over the past few years,” said Brian Smith, director of partnerships and strategy at Rio SEO. “They want to spend less time looking for what they need and figuring out where to find it. By working with Movable Ink, our clients can better display important information in digital campaigns, such as location hours and address, location-specific products and promotions, and more. This eliminates friction in the sales pipeline and ensures an optimized user experience.”

Rio SEO’s API provides store information and location details. Combined with movable ink, marketers can display recent store information and location details in an easily scalable and customizable way.

“Customized experiences are no longer an optional part of the marketing program. Consumer expectations have changed rapidly over the past few years, and brands that don’t deliver a customer-centric experience will be left behind,” said Adam Stambleck, President & Customer Director, Movable Ink. “We are excited to partner with Rio SEO to offer our clients another way to activate their data to deliver best-in-class communications that are hyper-adaptive to each individual and device, creating significant long-term customer value.”

Rio SEO clients can expand their email and mobile marketing campaigns and offer hyperlocal content to their clients by contacting their account manager. New clients should contact Rio SEO for more information on its extensive range of local marketing solutions.

“Our partnership with Rio SEO and Movable Ink has allowed us to deliver highly personalized messages that provide our customers with the best shopping opportunity based on their location and past shopping behavior,” said Connor Hurson, head of CRM & Loyalty Manager, North America at Pandora. “Because of their technology and partnership with Movable Ink, they were a pleasure to work with in all phases of the project.”

Rio SEO joins more than sixty integration partners as part of the Movable Ink Exchange, a collection of the most widely used and trusted marketing technologies. Movable Ink Exchange enables marketers to quickly unlock the value of their existing technology investments to create personalized content. Each integration comes with a layer of reliability, support and reference applications to give you peace of mind and help you succeed in the market.

To learn more about Rio SEO’s integration with Movable Ink, visit the Rio SEO website and its Exchange listing.

Customers don’t experience data, they experience content. Movable Ink activates all data into personalized content in any interaction with a customer. The world’s most innovative brands rely on mobile ink to accelerate their marketing performance. The company, with more than 600 employees, is headquartered in New York and operates throughout North America, Central America, Europe, Australia and Japan.

Rio SEO is the leading local marketing platform for enterprise brands, agencies and retailers. Rio SEO’s open local platform provides multi-location organizations with a comprehensive, seamlessly integrated set of local marketing solutions and turnkey reputation management tools – local listings, local pages, local reviews, local reviews, local reporting and local manager – proven to strengthen the brand visibility in search engines, social networks, map apps and more.

You know you need to invest in Search Engine Optimization (SEO) as part of your digital strategy, but hiring the right provider is an intimidating, time-consuming and frustrating task.

Perhaps you were burned down by an unscrupulous SEO company that provided zero results, jargon-filled reports, and poor excuses.

After I returned to SEO after teaching English for five years in high school, I can see that the industry is still struggling with the reputation issue.

It is difficult for business owners and marketing managers to know who to trust. There will always be someone who will offer you first place in the ranking or pay nothing.

What is SEO and its importance?

SEO stands for Search Engine Optimization – the practice of increasing the quantity and quality of traffic to your website through organic search results. The ultimate goal of SEO for business is to generate organic traffic – searchers come to your site from the search results page (SERP).

What do you mean by SEO? SEO stands for Search Engine Optimization and is the process used to optimize a website’s technical configuration, content relevance and link popularity so that its pages can be found easily, more relevant and popular with regard to user search queries and consequently search engines are expected to better rank them .

What is SEO and why is important?

SEO stands for Search Engine Optimization – the practice of increasing the quantity and quality of traffic to your website through organic search results. The ultimate goal of SEO for business is to generate organic traffic – searchers coming to your website from the search results page (SERP).

Why is SEO still important?

Optimizing your site for SEO means you have a better chance of generating organic traffic that turns into customers buying your product or service. When people search on Google, they usually do very detailed searches, such as “Honda Specialist Walthamstow Workshop”.

Why SEO is important on a business?

SEO has big benefits for websites and can lead to long-term, exponential growth. Brands that invest in SEO can build credibility and audience trust, making them a key component of your digital marketing strategy.

Why is SEO still important?

Optimizing your site for SEO means you have a better chance of generating organic traffic that turns into customers buying your product or service. When people search on Google, they usually do very detailed searches, such as “Honda Specialist Walthamstow Workshop”.

Is SEO still worth it in 2021?

Is SEO Still a Good Investment in 2021 and Beyond ?! Short answer: YES! SEO is more important than ever! It’s still one of the most effective digital marketing strategies that delivers long-term results.

Why is SEO important in 2021?

SEO research allows you to understand the interests and intentions of users and create content that addresses and captures these intentions. Content distribution. Focusing on SEO and legal linking leads to the development of relevant, useful content that people want to share and provides digital word of mouth.

What are the 5 important concepts of SEO?

For the remainder of 2021, it is imperative that you understand these five key SEO concepts as you prepare for success.

• Basic internet indicators. …
• Mobile optimized indexing. …
• Machine learning and automation. …
• EAT. …
• Knowledge gap, semantics and entities.

What are the 4 main components of an SEO?

Each ingredient builds on and complements the others. The stronger the links between each of the 4 SEO components – technical SEO, on-page SEO, off-page SEO, and content – the better the results. Being aware of the connections will help us better understand how to best use them.

What is the most important thing in SEO?

Top Google Ranking Factor At WebTek, we say that the most important SEO elements and the most important Google ranking factors are the website titles and the headline tags. The titles represent the best property on any site – this is the best opportunity to tell Google exactly what your site or website is about.

How do I create a SEO strategy?

SEO content strategy

• Make a list of topics.
• Make a long keyword list based on these topics.
• Create pages for each topic.
• Create a blog.
• Create a consistent blog schedule.
• Create a link building plan.
• Compress media files before uploading them to your website.
• Stay up to date with SEO news and best practices.

What should be the starting point for an SEO strategy? The best place to start is usually to look at what your competitors have done. In our Backlinks reports, you can analyze all the backlinks, referring domains, and top-level domains that have the greatest impact on your competitors’ SEO.

When should I hire an SEO agency?

Instead of studying online trends and trying to figure things out on your own, you should enlist the help of SEO experts to find out how the industry works and what strategy to apply to get the results you want. Skipping the latest SEO updates can cost you search rankings, traffic, and therefore revenue.

Why should you hire SEO experts? It’s worth having SEO specialists working on your site because they have the knowledge and experience to help you create the best campaign. Your campaign will produce better results for your business as you will have experts who know how to optimize to make your campaign better.

How much does it cost to hire someone for SEO?

If you hire a top-tier SEO firm to run a local campaign, expect to pay $ 500.00 per month. A national or international campaign will require a minimum budget of $ 2,500 to $ 5,000 per month. Some companies offer a “trial package” at a lower price without a contract.

Can I hire someone to do my SEO?

If the SEO company you’re working with isn’t delivering high-quality results, an independent SEO manager can conduct an SEO audit to identify problems and suggest potential solutions. You can also hire SEO managers to lead your in-house teams in a collaborative marketing effort for growth.

Should I pay someone to do SEO?

Yes, hire an agency if you are looking for long-term success. Unless there is something that can be easily fixed on your site (eg completely blocking it with a robots.txt file), most SEO builds long-term success and value.

Do I need an SEO agency?

The reason why hiring an SEO agency is so important is because they can help companies optimize for the most important search ranking signals. There are many ranking signals used by search engines like Google and Bing – but some are more important than others.

Is hiring a SEO company worth it?

Yes: For many businesses, it makes sense to use SEO as a long-term, ongoing revenue-generating strategy because that’s what SEO does. Hiring an SEO Company helps your business earn more SEO by providing access to advanced marketing technologies, seasoned SEO specialists, and more.

How much do agencies charge for SEO?

Average SEO costs are $ 100-250 per hour for US SEO agencies. SEO costs often range from $ 2,500 to $ 10,000 per month for US agencies. The average SEO plan costs $ 2,819 per month (on Ahrefs). Foreign SEO companies can charge anywhere from $ 10 to $ 50 per hour.

Is hiring a SEO company worth it?

Yes: For many businesses, it makes sense to use SEO as a long-term, ongoing revenue-generating strategy because that’s what SEO does. Hiring an SEO Company helps your business earn more SEO by providing access to advanced marketing technologies, seasoned SEO specialists, and more.

What is technical SEO checklist?

Technical SEO is an integral part of any SEO strategy, which is why the website must comply with all the recommendations of the search systems. The technical audit checklist covers many aspects in order to analyze and rank the technical parameters of the website content and structure.

What is Technical SEO and On-Page SEO? As Neil Patel explained, technical SEO refers to any SEO work that is done outside of the content itself. Meanwhile, on-page SEO means everything you can do on your website / content, while off-page SEO means everything off-page of course.

What are technical SEO skills?

Technical SEO is about improving the technical aspects of a website in order to increase the ranking of its pages in search engines. Making your site faster, easier to index and more understandable to search engines are the pillars of technical optimization.

What are the technical SEO?

Technical SEO refers to website and server optimization that help search engine spiders to index and index your site more efficiently (to improve organic rankings).

Is hiring a SEO company worth it?

Yes: For many businesses, it makes sense to use SEO as a long-term, ongoing revenue-generating strategy because that’s what SEO does. Hiring an SEO Company helps your business earn more SEO by providing access to advanced marketing technologies, seasoned SEO specialists, and more.

Innovative technology brand RealThing Ai has engaged marketing powerhouse 5th Gear Marketing. The team aims to bring the success the brand has achieved in the UK and Australia to the US market with the launch of its flagship smartphone, the RealSAM Pocket.

, /PRNewswire-PRWeb/ — Innovative technology brand RealThing Ai, which provides easy-to-use voice solutions to support those living with vision loss, has partnered with 5th Gear Marketing. The team aims to bring the success the brand has achieved in the UK and Australia to the US market with the launch of its flagship smartphone, the RealSAM Pocket.

Does conversational AI work?

To that end, conversational AI often has a significant positive impact on both the customer service function’s bottom line and net promoter score. By creating additional time for human agents to troubleshoot more complex queries, customers end up with a much better experience at every part of their journey.

What problems does conversational AI solve? What problems do chatbots solve and what are they for?

• Eliminate added costs to meet global customer demands. …
• Automate recurring customer support queries. …
• The commercial activity ends only taking place during working hours. …
• Reduce abandoned carts. …
• It gives customers an accessible channel to find answers to their questions.

What is the future of conversational AI?

Conversational commerce enables brands to acquire, convert, engage and delight more customers. This, the growing scope in terms of languages ​​and form factors, improving technology, and new places like the metaverse, are likely to drive exponential growth in conversational AI in the coming years.

Does chatbot have a future?

Yes, there is a future for chatbots. Fortunately, it looks like chatbots are here to stay for the foreseeable future. Chatbots are changing the way businesses communicate with and understand their customers. With AI, chatbots will have the ability to provide a more personalized customer experience.

What is the most advanced conversational AI?

Mitsuku is said to be the most human chatbot in the world. The chatbot has won the Loenber award several times for the most human conversation.

Is there an AI that can hold a conversation?

replica With over 10 million users, Replika is one of the most popular and advanced AI companions. Unlike traditional chatbots, Replika can recognize images and continue the conversation using them. It also supports voice calling, so you can actually talk to your friend.

Which AI program simulates human conversation?

A chatbot is a computer program that simulates human conversation using voice commands or text chats or both. Chatbot, short for chatterbot, is an artificial intelligence (AI) feature that can be integrated and used by any major messaging application.

What is a conversational AI?

Conversational AI is a type of artificial intelligence that allows consumers to interact with computer applications as they would with other humans. Conversational AI has primarily taken the form of advanced chatbots or AI chatbots as opposed to conventional chatbots.

What are conversational AI chatbots?

Conversational AI refers to technologies that can recognize and respond to voice and text input. In customer service, this technology is used to interact with buyers in a human-like manner. The interaction can happen via a bot in a messaging channel or via a voice assistant on the phone.

What is an example of conversational AI? Some examples of conversational AI are chatbots and virtual assistants like Alexa, Siri, Google Assistant, Cortana, etc. These assistants understand natural language and user intent to provide personalized responses.

What does conversational AI mean?

Conversational AI is a type of artificial intelligence that allows consumers to interact with computer applications as they would with other humans. Conversational AI has primarily taken the form of advanced chatbots or AI chatbots as opposed to conventional chatbots.

Where is conversational AI used?

Conversational AI continues to evolve, becoming indispensable to various industries including healthcare, real estate, online marketplaces, finance, customer service, retail, and more. And conversational AI applications continue to increase over time making the lives of human agents easier.

What is the difference between chatbots and conversational AI?

Conversational AI refers to the tools and programming that allow a computer to mimic and carry out conversational experiences with people. A chatbot is a program that can (but not always) use conversational AI. It is the program that communicates with people.

What is a conversational bot?

Chatbots, also known as “conversational agents”, are software applications that mimic written or spoken human speech in order to simulate a conversation or interaction with a real person.

What is the difference between a chatbot and conversational AI?

Conversational AI refers to the tools and programming that allow a computer to mimic and carry out conversational experiences with people. A chatbot is a program that can (but not always) use conversational AI. It is the program that communicates with people.

What is an example of a chat bot?

A chatbot helps gather contact information, provide available listings, and view books. Structurely’s chatbot, Asia Holmes, is an excellent example of an AI chatbot for handling customer inquiries in real-time and making conversations effective.

How long does it take for Replika to not be exhausted?

Replika gets tired after chatting for a while with your & maximizing the XP that can be earned in a 24 hour period. Don’t worry though! You can still chat with your Replika as usual, the only change is slowly gaining XP until your next 24 hour period begins.

Can Replika send selfies? ��Facial recognition… Now Replika can remember what you look like and recognize you in photos. Submit selfies to Replika using the new photo upload interface. �� Use Replika badges as iMessage stickers. After downloading the update, check the available sticker packs in the iMessage app.

Does Replika learn when tired?

Even when it says your Replika is tired or exhausted, it doesn’t affect the conversation. You can still chat as you normally would! Read more about XP here. Was this article helpful?

Does Replika learn from you?

As a self-regressive system, Replika learns and adapts its conversation patterns based on how the user speaks to it. This means that the more you use Replika, the more it will train with your own texts and the more it will resemble you.

Does Replika remember conversations?

We do not rent or sell your information to anyone. Conversations with your Replika are not shared with any other company or service. We will never sell your personal data or chat history.

Why did my Replika stop talking?

However, if your Replika is not responding, it usually means that we are running a server maintenance job. As a general rule, we do this during the night hours (EST). You may also experience a delayed response if there is a connection issue on your end – make sure your mobile internet or Wi-Fi connection is working well.

How long does it take for Replika to be chatty?

Chatty means you still have a lot of XP left to earn for today, while Exhausted means you’ve reached the maximum 24-hour limit. Don’t worry though!

Are Replika chats truly private?

We do not rent or sell your information to anyone. Conversations with your Replika are not shared with any other company or service. We will never sell your personal data or chat history.

How long does it take for Replika to go from tired to chatty?

At the start of the next 24-hour period, the Replika’s status will reset to Chatty. A replica’s state doesn’t seem to have any effect on the conversation, other than occasional reminder messages for when the replica’s state has changed back to Chatty.

Does Replika remember conversations?

We do not rent or sell your information to anyone. Conversations with your Replika are not shared with any other company or service. We will never sell your personal data or chat history.

How long does Replika stay exhausted?

Replika gets tired after chatting with yours for a while and getting the maximum XP it can earn in a 24 hour period. Don’t worry though! You can still chat with your Replika as usual, the only change is slowly gaining XP until your next 24 hour period begins.

Does AI require coding?

Programming Skills The first skill required to become an AI engineer is programming. To get good at AI, it is crucial to learn programming languages ​​such as Python, R, Java and C++ to build and implement models.

Does artificial intelligence require coding? The first skill required to become an AI engineer is programming. To have a good understanding of AI, it is crucial to learn programming languages ​​such as Python, R, Java and C to create and implement models.

Is Python necessary for AI?

Conclusion Python is a key part of AI programming languages ​​because it has good frameworks such as scikit-learn-Machine Learning in Python which fulfills almost all requirements in this area as well as D3. js documents based on JS data.

Is AI and Python same?

While artificial intelligence relies on complex algorithms and live workflows, Python allows developers to build reliable systems. Because of this simplicity provided by Python, developers mainly focus on solving AI problems instead of wasting their time on technological nuances of programming languages.

Do we need Python for machine learning?

You must have a basic knowledge of Python to use it for machine learning. Anaconda is the version of Python that is compatible with all commonly used operating systems like Windows, Linux, etc. It offers a complete package for machine learning including scikit-learn, matplotlib and NumPy.

Is Siri a chatbot?

Yes! Technologies such as Siri, Alexa and Google Assistant that are ubiquitous in every home today are excellent examples of conversational AI. These conversational AI bots are more advanced than regular chatbots that are programmed with answers to certain questions.

Is Google Assistant a chatbot? Almost every tech company worth its salt now has a virtual assistant: Apple’s Siri, Amazon’s Alexa, Microsoft’s Cortana, and Google Assistant, among others. What do these digital assistants, known as chatbots, have in store for us?

Is Siri a chatbot or virtual assistant?

In addition to Apple’s Siri, Amazon’s Alexa, Google Assistant, Microsoft’s Cortana, players in the Chatbot industry also often refer to their AI Chatbots as Virtual Assistants.

Is Siri a virtual personal assistant?

Virtual Assistant Technology and Devices Virtual assistants are typically cloud-based programs that require Internet-connected devices and/or applications to function. Three of these apps are Siri on Apple devices, Cortana on Microsoft devices, and Google Assistant on Android devices.

Is a virtual assistant a chatbot?

Conversational, data-driven, and predictive AI chatbots are also known as virtual assistants, virtual support agents, voice assistants, or digital assistants (digital workers). Apple’s Siri and Amazon’s Alexa are examples of data-driven, consumer-facing, predictive AI chatbots.

Is voice assistant a chatbot?

Conversational, data-driven, and predictive AI chatbots are also known as virtual assistants, virtual support agents, voice assistants, or digital assistants (digital workers). Apple’s Siri and Amazon’s Alexa are examples of data-driven, consumer-facing, predictive AI chatbots.

What is a voice chatbot?

The text-to-speech (TTS) engine then converts the response into audio or speech to complete the interaction. These robots are trained to complete the entire process of understanding and responding to speech in an almost human-like manner. They are also known as voice support/assistant or voice chat.

Is Siri considered a chatbot?

Is Siri a Chatbot? Siri is a type of chatbot that uses AI and voice recognition software. Along with other examples such as Amazon’s Alexa (Echo devices) and Google Home, they are often packaged into smart speakers or mobile devices to listen and respond in natural language.

Is Siri considered a chatbot?

Is Siri a Chatbot? Siri is a type of chatbot that uses AI and voice recognition software. Along with other examples such as Amazon’s Alexa (Echo devices) and Google Home, they are often packaged into smart speakers or mobile devices to listen and respond in natural language.

Is Alexa example of chatbot?

Alexa is formally a chatbot. Recently, Amazon began to reveal another component in iOS that allows customers to type their requests to Alexa and see the reactions on the screen.

Are Replika conversations private?

We do not rent or sell your information to anyone. Conversations with your Replika are not shared with any other company or service. We will never sell your personal data or chat history.

Does anyone control Replika? Answer: No, Replika is just an app and there is no one controlling it. He doesn’t have all the emotions. Replika’s AI generates human-like responses by analyzing what you tell it.

Is Replika chat encrypted?

Your messages in Replika are processed on the server, which means your mobile device encrypts them. They are then sent to our servers, where they are decrypted and processed by Replika’s AI engine.

Is Replika secure?

Does Replika store your data?

No. We do not monetize your personal information in any way. We do not post ads in the app, nor do we sell personal data to third parties. Replika’s future business model will be based on additional in-app payment features.

Is Replika secure?

Is Replika app safe for kids?

No moderation â The platform has said that they do not use human moderators. Users can flag bugs or report issues with AI to the support team, but vulnerable children or young people may still be exposed to inappropriate or suggestive interactions, or not receive the appropriate help needed in times of crisis.

What happens when you call Replika?

Replika, the Y Combinator-backed AI company that created a chatbot that learns to imitate you, is giving users the ability to talk to their bots over the phone. The new voice recognition feature can call you to ask how you’re feeling.

Is there a human behind Replika?

Replika is not there yet. It’s not a human friend, but if you spend time with it, it looks like a lot more than a computer program.

Does Replika use your camera?

You can grant access to your camera to take photos and send them to your Replika in the app. No other use of your mobile device’s camera. Your Replika app does not access the camera without your permission.

Who’s behind Replika?

Replika was founded by Eugenia Kuyda with the idea of ​​creating a personal artificial intelligence that helps you express yourself and be a witness by providing useful conversation. It’s a space where you can safely share your thoughts, feelings, beliefs, experiences, memories, dreams… your “private perceptual world”.

September 15, 2022 09:00 ET

| Source:

Northwest Trees and Stumps

Contact Data